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Epigenetic misregulation of gene expression is known to be an important feature in 
cancer. This has mainly been studied at the level of changes in DNA methylation and 
histone modifications at individual genes. In this thesis I have set out to investigate 
whether there are long-range changes in chromatin structure linked to altered gene 
expression in breast cancer. From large published datasets, I used a computational 
approach to identify large genomic regions which are coordinately misregulated in breast 
cancer independent of copy number aberrations (genomic effects). I found 26 regions of 
co-ordinate regulation of neighbouring genes that are consistent between breast tumours 
and breast cancer cell lines. These regions had different expression phenotypes 
(activation, repression, no change) compared to normal breast and also with tumour sub-
type (luminal vs basal and ER status). The regions of epigenetic regulation (RER) 
identified in breast cancer were mostly cancer type specific.  
 
I investigated the mechanism of long-range misregulation at one such region on 
chromosome 16p11.2 which is aberrantly activated in breast cancer. Interestingly, in 
estrogen-receptor positive (ER+ve) cells, genes in this region are upregulated relative to 
estrogen receptor negative (ER-ve) cells. Using fluorescence in situ hybridisation (FISH) 
I found that in ER+ve breast cancer cell lines and tumour tissue this region is in a more 
decondensed chromatin architecture than in ER-ve cell lines and tumour tissue. 
Furthermore this region was very compact in a normal breast epithelial cell line and 
breast tissue corresponding to what would be expected from the expression data. Estrogen 
was found to play a key role in maintaining the aberrant decondensation of chromatin at 
this locus on chr16p11.2, as shown by compaction of the region by starving ER+ve cells 
of estrogen and decompaction upon subsequent estrogen treatment. Interestingly there 
was also an estrogen mediated repositioning of the 16p11.2 RER domain away from the 
nuclear centre in hormone starved conditions and towards the centre upon estrogen 
stimulation. Together these results show that estrogen is key to regulating the changes in 
nuclear organisation and chromatin decompaction at this locus, which are associated with 
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 1.1 Breast Cancer 
  
The term breast cancer describes a group of complex and molecularly heterogeneous 
disorders with distinct clinical and pathological differences.  Cancer incidence and 
mortality data reveal that breast cancer is not only the most frequently occurring 
malignancy in women but also one of the top three causes of death due to malignancy in 
Europe (Ferlay et al., 2007). Within the UK >48,000 women are diagnosed with breast 
cancer each year and 1,000 women with breast cancer die (from 
www.breakthrough.org.uk). The number of women surviving breast cancer has been 
vastly improved by campaigns to increase awareness as well as advances in research to 
improve screening and treatment.  
 
1.1.1. Normal breast anatomy & physiology 
 
Glandular, fatty and fibrous tissues comprise the normal breast, which is situated over the 
pectoral muscles of the chest. Fatty tissues surround the glandular tissue containing 
lobules and lactiferous ducts responsible for producing milk (Figure 1.1). Each duct 
opens towards the nipple to form the ampulla. Connective fibrous tissue is interspersed 
between the lobules and ducts of the breast tissue. In the normal breast, lymph fluid is 
used to transport waste products around the lymphatic system. Breast cancer cells are 
able to spread via the lymphatic vessels and the more lymph nodes in which tumour cells 
are present the more likely the tumour cells are to spread to other organs as they are then 
able to invade the circulatory system. 
 
During embryonic development the mammary glands are initially visible as placode-like 
formations from the ventral epidermis which invade the mesenchymal cell layer known 
as the mammary fat pad. Mammary growth is then arrested until puberty when the 
mammary glands undergo elongation and secondary branching to form the tubular ducts 
and lobules that fill the fat pad (Watson and Khaled, 2008). In the fully developed breast 
these lobular/ductal structures are called terminal duct lobular units (TDLU) and are 
embedded amongst the stroma and fatty tissue (Figure 1.1).  The TDLU is composed of a 
bi-layer epithelium made of two distinct types of cells: the inner luminal cells that line 
the apical surface and the basally-positioned myoepithelial cells that surround them 
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(Figure 1.1 and Figure 1.2).  It is thought that basal cells and breast progenitor cells also 
exist in the TDLU (Smalley and Ashworth, 2003; Spike et al., 2012). Furthermore it has 
been found that the inner luminal cells are functionally heterogenous with a hierarchy of 
nonclonogenic luminal cells, differentiated and undifferentiated luminal progenitors 
identified in normal human breast tissue (Shehata et al., 2012). In vitro mammosphere 
formation has been used to assay for the presence of mammary stem/progenitor cells 
(Dong et al., 2013; Guo et al., 2012).  
 
During pregnancy further changes occur to the breast whereby the TDLU’s undergo 
tertiary branching terminating in alveolar buds, accompanied by a rapid proliferation of 
the luminal cells and their differentiation into alveolar secretory cells (Watson and 
Khaled, 2008). Whilst the luminal cells are involved in milk secretion it is the 
myoepithelial cells with their contractile properties that are involved in transporting the 






Figure 1.1: A cross-section through the breast showing ducts and lobules. Most breast 
cancer cases originate from the terminal duct-lobular unit (TDLU) which is comprised of outer 




1.1.2. Breast cancer classification 
 
Breast cancers derive from breast epithelial cells and can be classified according to the 
histopathological type, the grade of the tumour, the stage of the tumour, by the presence 
of specific proteins and by the gene expression profile of the tumour. This classification 
guides the assessment of the best possible course of clinical action and can be used as 
predictive factors to detect response to a specific treatment. Generally the initial 
classification is based on tumour histopathology - except in inflammatory breast cancer 
(IBC) where a physical exam is definitive of this type of ductal carcinoma by the 
inflammation of the breast (Giordano and Hortobagyi, 2003).  
 1.1.2.1. Histopathology of breast tumours 
 
The histological grading by hematoxylin-eosin (HE) staining combined with light 
microscopy is the simplest method of classifying tumours of the breast from biopsies. 
The majority of breast cancers arise from the ducts leading to the nipples and a smaller 
number from the lobules where the milk is produced. Tumours arising from these areas 
can be described as invasive (abnormal growth of cells that has invaded the surrounding 
tissue thereby increasing the risk of metastasis to lymph nodes) or non-invasive 
(abnormal growth of cells that is localised to the site it initiated having not invaded 
surrounding normal tissue) (Figure 1.2).   
 
    Normal cells   Non-invasive tumour cells     Invasive tumour cells 
 
 
Figure 1.2: Schematic representation of breast cancer progression. Normal cells in the 
TDLUs become tumorgenic due to genetic and epigenetic lesions. These tumour cells can remain 
localised (non-invasive) or metastasize by invasion of the basement membrane. Adapted from 




 The three most common types of breast tumour are:  
(1) Invasive ductal carcinomas (IDC) is the most common type of breast cancer 
representing 55% of all cases (Eheman et al., 2009). It originates in the milk duct initially 
spreading to the surrounding normal tissue.  
(2) Ductal Carcinoma in situ (DCIS) represents 13% of all breast cancer cases (Eheman 
et al., 2009) and is the most common type of non-invasive breast cancer. It is defined as 
tumour cells which do not invade the basement membrane of the lactiferous ducts and is 
usually seen as small deposits of calcium (microcalcifications).  
(3) Invasive Lobular Carcinoma's (ILC's) represent 5% of all cancer cases (Eheman et 
al., 2009) and arise from the terminal ducts of lobules. The malignant cells are generally 
arranged in single rows but can be difficult to distinguish from ductal carcinomas. Mostly 
they tend to be multicentric within a breast (approx 20% are bilateral).  
 1.1.2.2. Morphological grading and staging of breast tumours 
 
As part of the pathological assessment, breast tumours are graded according to the degree 
of differentiation using the Bloom-Richardson (BR) scoring system (Bloom and 
Richardson, 1957)  which assigns points dependent on whether or not each of the 
following features are present in a slight, moderate or marked degree: 
 (1) Differentiation or tubule formation:  the tendency of the cells to group into tubular 
arrangement indicating the degree of structural differentiation. The higher the degree of 
differentiation the more it is considered indicative of good prognosis. A score of 1 
indicates well-marked tubule formation, 2 - indicates moderate tubule formation and 
tumour sections showing little/no attempt at differentiation with cells growing in 
sheets/strands are scored at 3 points.  
(2) Pleomorphism: As assessed by uniformity of the nuclear size, shape and staining. 
The more irregular the nuclear grade the worse the prognosis. A score of 1 indicates a 
fairly uniform nucleus, 2 indicates there is variation and a score of 3 that there is a severe 
degree of pleomorphism.  
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(3) Hyperchromatic and mitotic nuclei: A score of 1 indicates the presence of 
occasional hyperchromatic or mitotic figures, a score of 2 the presence of two to three 
and a score of 3 is given for more than this and indicates a poor prognosis. 
Hyperchromatic staining of the nucleus would appear to suggest grossly abnormal 
chromatin organisation. 
Cumulative BR scores below 5 are considered Low, 6-7 is Intermediate and 8-9 is High 
grade. Traditionally Low scoring malignancies are known as Grade I tumours. They are 
usually slow growing, non-aggressive tumours with the best prognosis., High scoring 
Grade III tumours appear distinctly abnormal by light microscopy, are extremely 
aggressive, grow rapidly and tend to have the worst prognosis (Bloom and Richardson, 
1957) (Figure 1.3). 
 
Figure 1.3: Bloom-Richardson (BR) Grading of Tumours. Grading is achieved by awarding 
points (1-3) for key features of malignant cells as viewed by light microscopy. The resultant 
combined score determines the grade of the tumour and is indicative of the prognosis for the 
patient. (taken from Bloom & Richardson., 1957).  
Other systems of staging breast tumours include the American Joint Committee on 
Cancer (AJCC) TNM system that assesses the primary tumour size (T), lymph node 
involvement (N), and metastases (M) (Greene et al., 2002); and the Nottingham 
Prognostic Index (NPI) which adapts the BR system to include tumour size and node 
status (Haybittle et al., 1982).  
Although histological grading is of prognostic value, much of tumour grading relies on 
subjective analysis of nuclear morphology, which are not always reproducible (Frierson 
et al., 1995). There have been more objective attempts to score nuclear morphology and 
texture by computational image-analysis though these are not currently widely used in 
clinical practice as the changes that occur in the cancer nucleus are not well characterised 




 1.1.2.4. Receptor status 
 
Gross morphological grading of breast tumours is now being complemented by 
classification of breast tumours dependent on the expression of specific molecular 
markers. Breast tumours are routinely screened by immunohistochemical  (IHC) staining 
for expression of the estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal receptor 2 (HER2/ERBB2/neu).  
As discussed later in this thesis estrogen action is mediated via the estrogen receptors 
alpha (ERα) and beta (ERβ) (see section 1.2.4.6.). Unless otherwise stated, throughout 
this thesis ER shall refer to the ERα isoform, which has been well studied in breast 
cancer. 
ER positive (ER+ve) breast tumour cells differentiate and grow in the presence of 
estrogen and have a better prognosis (Nilsson and Gustafsson, 2002; Sørlie et al., 2001). 
Increased lifetime exposure to estrogen is one of the most important risk factors for breast 
cancer and drugs which can inhibit the synthesis of estrogen, or ER signalling attenuate 
disease progression (see section 1.1.4.3). The progesterone receptor (PR) can be used as a 
surrogate marker of ER activity and therefore as a prognostic factor (Mohsin et al., 2004).  
ERBB2/HER2 encodes a tyrosine-kinase transmembrane receptor whose activity is 
associated with cell differentiation and growth (Olayioye, 2001). It is overexpressed in 
20-40% of breast cancers and amplified in 20% of invasive breast tumours (Clark and 
McGuire, 1991; Paik et al., 1990). Generally, ERBB2/HER2 is amplified in the more 
aggressive types of breast cancer, in particular inflammatory breast cancer, and is 
associated with very poor prognosis, increased metastatic properties and invasive 
potential (Sawaki et al., 2006; Tan et al., 1997).   
As well as IHC, HER2 status is also assayed by fluorescence in situ hybridisation (FISH) 
where a FISH ratio (HER2 gene signals to chromosome 17 signals) of > 2.2 are required 
to classify the tumour as  HER2+ve (Bertos and Park, 2011; Wolff et al., 2007).   
Breast tumours with none of these receptors (ER-ve/PR-ve/HER2-ve) are known as triple 





 1.1.2.5. Molecular Profiling of breast tumours 
 
  
Breast cancers are heterogenous in nature both between and within tumours. This has 
presented the biggest challenge towards studying and treating breast tumours which have 
been historically classified by histopathology, staging, grading and receptor status. With 
the development of high throughput expression profiling it is now possible to classify 
tumours based on their gene expression profile (Chung et al., 2002; Ramaswamy and 
Perou, 2003; Sørlie et al., 2003, 2001) and this disease stratification is having a large 
impact on the understanding and treatment of breast tumours.  
Seminal work by Sorlie et al (2001), using hierarchical clustering of cDNA microarray 
data for 85 experimental samples including 78 breast tumours (71 ductal, five lobular and 
two ductal carcinomas in situ) led to the classification of distinct tumour subtypes based 
on their expression profiles (Figure 1.4) (Chung et al., 2002; Sørlie et al., 2001). The 
largest two groups are ER +ve and ER -ve, with at least three subtypes within the ER +ve 
group and three in the ER -ve group (one with normal-like gene expression, one with 
high HER2 gene expression and the last with basal epithelial cell gene expression 
features) (Sørlie et al., 2001).  
Basal-type tumours highly express keratins 5 and 17, laminin, and fatty acid binding 
protein 7 (Figure 1.4A, red & Figure 1.4E) whereas the ERBB2+ (HER2) type tumours 
had highly expressed genes from the ERBB2 amplicon on chr17q22.4 (Figure 1.4A, pink 
& Figure 1.4C) (Sørlie et al., 2001). The normal-like tumours showed high expression of 
genes normally expressed in adipose and non-epithelial cell types (Figure 1.4A, green & 
Figure 1.4F) (Sørlie et al., 2001). This entire branch of tumours (basal-type, ERBB+ type 
and normal-like type) all showed a relatively higher expression of genes characteristic of 





Figure 1.4. Gene expression profiling of breast tumours. Hierarchical clustering of microarray 
data for 85 experimental samples (including 78 carcinomas, three benign tumors, and four normal 
tissues) reveals distinct subtypes of tumour (A) Division of tumours into six subtypes based on 
differences in gene expression. Luminal subtype A (dark blue); luminal subtype B (yellow); 
luminal subtype C (light blue); normal breast-like (green); basal-like (red); and ERBB2+ (pink). 
(B) Full cluster diagram with heat map of gene expression (scaled down). The coloured bars on 
the right represent the heat map segments in C–G. (C) ERBB2 amplicon cluster. (D) Novel 
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unknown cluster. (E) Basal epithelial cell-enriched cluster. (F) Normal breast-like cluster. (G) 
Luminal epithelial gene cluster containing ER. (figure taken from Sørlie et al 2001, PNAS). 
 
 
Luminal A type tumours showed the highest expression of ERα, GATA binding protein 
3, X-box binding protein 1, trefoil factor 3 (TFF3), hepatocyte nuclear factor 3 α 
(HNF3a), and estrogen-regulated LIV-1 (Figure 1.4A, dark blue and Figure 1.4G) (Sørlie 
et al., 2001). Remaining ER +ve tumours which also express luminal-type genes can be 
subdivided into luminal types B (Figure 1.4A, yellow) and C (Figure 1.4A, light blue) 
(Sørlie et al., 2001). Both these two groups showed low to moderate expression of 
luminal-specific genes (including the ER) and luminal C type tumours also have a group 
of highly expressed novel genes of unknown function (as did the ERBB2+ type of 
tumours) (Sørlie et al., 2001).  
These molecular tumour subtypes were further investigated by examining their 
correlation with available clinical outcome data. Kaplain-Meier curves showed 
significant differences between the subtypes defined in Figure 1.4 for both overall 
survival and relapse-free patient survival (Figure 1.5) with the basal and ERBB2+ 
subtypes having the worst prognosis (Sørlie et al., 2001). As previously discussed, over-
expression of ERBB2 (HER2) has been associated with poor prognosis and this gene was 
also highly expressed in the ERRB2+ tumour subtype of tumours defined by Sørlie et al 
(2001). Similarly the basal type tumours showed poor survival and have been associated 
with TP53 mutations (Sørlie et al., 2001). TP53 encodes p53, an important tumour 
suppressor, which is most frequently inactivated by mutation in many cancers and is 
associated with poor clinical outcome in breast cancer (Pharoah et al., 1999; Vousden and 
Prives, 2005) (see section 1.1.3.1 on genetic risk factors).   
Overall, ER +ve luminal type tumours showed the best prognosis as highlighted by the 
luminal A type (highest ER expression) having the best overall survival as well as relapse 
free survival (Figure 1.5;(Sørlie et al., 2001). Survival analysis also showed a highly 
significant difference between luminal A  and luminal B+C type tumours (Figure 1.5) 
and it has been suggested that the luminal B+C type tumours represent a group that are 






Figure 1.5. Prognosis varies between molecular subtypes of breast tumours. Probability of 
overall survival (left panel) and relapse-free survival (right panel) analysis of the 49 breast cancer 
patients based on different gene expression classification by Sørlie et al 2001. (Taken from Sorlie 
et al 2001).  
This original molecular tumour classification was further refined in a larger number of 
tumours as well as independent breast tumour datasets (Sørlie et al., 2003). Clustering of 
115 tumours and 7 non-malignant tissues (including the 85 used in the previous study) 
led to the re-classification of five distinct tumour profiles: luminal A, luminal B, 
ERBB2+, basal-like and normal-like ((Sørlie et al., 2003). The biggest distinction was the 
branching off for luminal A type tumours which were highly ER expressing compared to 
the other subtypes (Figure 1.6).  
	  
	  
Figure 1.6: Refining the molecular subtypes of breast tumours. Dendogram showing 
hierarchical clustering of 115 tumour tissues and 7 nonmalignant tissues into five subgroups 
based on their “gene signature”. Branches for tumours with low correlation to a subtype are 




Survival analysis showed once again that luminal A type tumours had the best clinical 
prognosis, and the basal and ERBB2+ subtypes the worst (Figure 1.6; (Sørlie et al., 
2003). It also became apparent that BRCA1-associated tumours fell into the basal 
subtype and were associated with the worst prognosis and lowest expression group for 
ER (ESR1 gene) and HER2 (ERRB2 gene) (Sørlie et al., 2003). BRCA1 and BRCA2 are 
involved in repair of DNA damage and mutations in these genes are associated with 
severely increased risk of breast cancer (Fackenthal and Olopade, 2007) (see section 
1.1.3.4.).   
 
Figure 1.7. Kaplan Meier analysis of prognosis in molecular tumour subtypes is confirmed 
in independent datasets. (A) Time to distant metastasis development (months) in 97 cases from 
Veer et al data (B) Overall survival for 72 cases in an independent cohort (Norway). (Figure taken 




Breast cancer cell lines have also been subject to high-throughput expression profiling 
and hierarchical clustering to investigate whether they reflect the molecular portraits 
painted in tumours (Richard M. Neve et al., 2006). Breast cancer cell lines do indeed also 
cluster into basal-like (ER -ve, CAV-1 positive) and luminal-like (ER +ve, ERRB3 +ve) 
expression patterns recapitulating overall two of the major groups observed in tumours 
(Richard M. Neve et al., 2006). The luminal subgroup was homogenous whereas the 
basal-like subgroup consisted of a division into basal A and basal B type cell lines 
(Richard M. Neve et al., 2006).  Basal A is thought to recapitulate the gene expression 
profile described for the basal tumour subtype (Chung et al., 2002; Sørlie et al., 2003, 
2001). Overall it is suggested that the expression profiling of these 51 cell lines 
successfully portray the same molecular heterogeneity seen in tumours (Richard M. Neve 
et al., 2006).   
Agglomerative analysis of data collected from 12 different studies for 10,159 invasive 
breast cancer cases confirmed the existence of these molecular subtypes defined by their 
gene expression signature and that these can be used as clinical markers of prognosis 
(Blows et al., 2010). Furthermore, the ER-negative basal subclass of tumours has been 
further refined into at least four main subtypes with heterogeneous clinical outcome data 
(Teschendorff et al., 2007).  
A new molecular subtype of breast cancer - denoted claudin-low - has been more recently 
identified and is characterised by low/no expression of tight junction proteins claudin 3, 4 
and 7 and E-cadherin (Herschkowitz et al., 2007; Prat et al., 2010). This subtype is 
distinct from previously identified molecular subtypes as the tumours have very low 
levels of HER2 and luminal markers (e.g. ER, PR), a high enrichment of epithelial-to-
mesenchymal (EMT) transition markers, high expression of immune response genes (e.g. 
CD79b, CD14, Vav1), angiogenesis (e.g. vascular endothelial growth factor C,), cell 
communication, differentiation (e.g. KLF2, IL6) and migration genes (e.g. integrin a5, 
moesin) (Prat et al., 2010).  It has been suggested that these tumours have cancer stem 
cell -like properties as they highly express ALDH1, a marker of breast stem cells, 
compared to other tumour subtypes (Ginestier et al., 2007; Prat et al., 2010).  
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Most triple negative (ER-ve/PR-ve/HER2-ve) tumours with the worst prognosis are 
basal-like or claudin-low (Prat et al., 2010). By Kaplan-Meier survival analysis the 
claudin-low tumours are intermediate between luminal and basal-like tumours (Prat et al., 
2010) (Lu et al., 2012) Moreover, patients with claudin-low basal-like tumours show 
worse recurrence-free survival than those with claudin-high tumours indicating that the 
claudin-low status is a strong prognostic factor (Lu et al., 2012).  
 
 
1.1.2.6. Genome instability in breast tumours 
 
1.1.2.6.1 Genomic amplifications and deletions  
Genomic instability is a common feature of nearly all tumours and regions of genetic gain 
or loss are common in breast cancer. Comparative genomic hybridisation (CGH), using 
tumour DNA and normal reference DNA, in combination with array technology has 
allowed breast tumour amplifications and deletions to be assessed genome-wide (Chin et 
al., 2006; Fridlyand et al., 2006; Jönsson et al., 2010; Richard M. Neve et al., 2006). One 
study looking at the relationship between expression and genomic profiling classified 
breast tumours into three distinct categories (1a/16q, amplifier and complex subtype) 
based on their copy number profiles and this correlated with prognosis (Chin et al., 
2006). Remarkably, breast cancer cell lines mirror the recurrent copy number aberrations 
frequently found in primary tumours, indicating that they have maintained expression and 
genomic patterns characteristic of the breast tumours from which they were derived 
(Richard M. Neve et al., 2006).  
 
Higher resolution CGH analysis of 359 tumours revealed a detailed map of 31 frequent 
copy number alterations (Figure 1.8) with the most frequent aberrations found in 
chromosomes 1q, 8p, 8q, 11q and 16q (Jönsson et al., 2010). Overall 6 genomic subtypes 
of breast cancer  with different clinical outcome were identified by this study   (17q12, 
basal-complex, luminal-simple, luminal-complex, amplifier, and mixed subtype) that 
were similar to previously identified subtypes based on gene expression signatures 




Figure 1.8. Copy- number aberrations breast cancer. Frequency plot based on aCGH data for 
359 tumours where blue indicates a region of significant genomic alteration, red indicates a 
region of genetic gain and green a region of genetic loss. (Figure taken from (Jönsson et al., 
2010)).  
 
Integration of CGH profiles, single nucleotide polymorphisms (SNPs) and transcription 
profiles for 2,000 breast tumours, representing all tumour types, has allowed further 
refinement of these subtypes and the elucidation of 45 regions of misregulation of genes 
by amplification or deletion sequence changes (Curtis et al., 2012). It was therefore 
possible to identify 10 novel subtypes of breast cancer that were associated with different 
clinical prognoses (Curtis et al., 2012).  
 
1.1.2.6.2 Deep sequencing and integrative genome analysis 
The advent of array technology allowed the development of molecular signatures in 
tumours through analysis of differential gene expression and copy number profiles. The 
evolution of deep sequencing and integrative genome analysis means that there are 
increasing numbers of studies working towards characterising these changes on a 
genome-wide level and investigating the underlying mechanism(s).  For example 
genome-wide integrative analysis of triple negative breast tumour/matched-normal tissue 
sequencing data has revealed a number of loci with monoallelic expression due to loss of 
heterozygosity, resulting in the disruption of key pathways such as the cell cycle (Ha et 
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al., 2012).  A number of other studies have also highlighted the genetic heterogeneity of 
breast cancer both within and between different subtypes: 
Whole-genome sequencing of 100 breast tumours has revealed strong mutational 
heterogeneity with 40 genes identified containing either copy number changes or/and 
driver point mutations (Stephens et al., 2012). The incidence of these mutations was 
highly variable with a maximum of 6 tumourigenic mutations per sample. Moreover 
some of the mutations were shown to be associated with age in ER-ve tumour samples 
but not ER+ve patients (Stephens et al., 2012). Deep-sequencing and transcriptome 
analysis of 104 primary triple-negative breast cancer genomes revealed  the presence of 
mutations and copy number aberrations which fluctuate greatly between (and within) 
tumour samples, indicating that these changes occur during different stages of tumour 
progression (Shah et al., 2012). Three of the genes identified (TP53, PIK3CA and PTEN) 
were associated with early breast tumour development (Shah et al., 2012).  
Exome sequencing of 103 tumour/matched-normal paired samples from patients revealed 
a number of heterogeneous subtypes due to somatic non-silent mutations (Banerji et al., 
2012). This study also implicated the MAGI3–AKT3 translocation and mutations in the 
transcription factor CBFB and its partner  RUNX1 in breast cancer for the first time 
(Banerji et al., 2012). The MAGI3-AKT3 gene fusion was specific to triple negative breast 
cancer and caused constitutive activation of AKT kinase (Banerji et al., 2012).  
The mutational heterogeneity of breast tumours was also highlighted by whole-genome 
sequencing of the ER+ve breast cancer genome in patients undergoing treatment with 
aromatase inhibitors (see  section 1.1.4.3) (Ellis et al., 2012). Patients with high 
expression of Ki67, a marker of proliferation and implicated in resistance, had a higher 
frequency of somatic mutations compared to those with low Ki67 expression (Ellis et al., 
2012).  
Integrative analysis of six different technology platforms, including genomic copy 
number arrays and exome sequencing, did not reveal any previously unknown molecular 
subgroups based on expression profiling  (as originally defined by Sørlie et al., 2003 and 
confirmed in subsequent studies by Blows et at., 2010 amongst others). However the 
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mutational heterogeneity of the breast cancer genome was once again highlighted with 
numerous subtype-specific novel gene mutations identified (Koboldt et al., 2012).   
 
1.1.3. Breast cancer risk factors 
 
 
The exact etiology of breast tumourignesis is unknown but a number of factors can 
increase the risk of developing breast cancer. These risk factors can be biological, genetic 
or environmental. Age is the most significant risk factor after gender.  
 Lifetime risk of developing breast tumours increases significantly with age, with the 
estimated risk for a 29-year of 1 in 2000, compared with 1:50 for a 49-year old and 1:13 
at age 69 (Sasieni et al., 2011). Childbearing and breast feeding are associated with 
reduced risk of developing breast cancer, with a 4.3% decrease in risk for every 12 
months spent breast feeding and 7% decrease for every childbirth (“Breast cancer and 
breastfeeding,” 2002). Hormone replacement therapy (HRT) for five or more years 
increases the risk of developing breast cancer by 35% but this disappears 5 years after 
stopping HRT use (Collaborative Group on Hormonal Factors in Breast Cancer, (“Breast 
cancer and hormone replacement therapy,” 1997). Increased risk has been observed in 
both estrogen-only as well as estrogen-progestin therapy with highest risk for the latter 
(Stahlberg et al., 2004).  
A high breast density (ratio of tissue to fat) has been highly correlated with development 
of tumours in a number of population studies and meta-analyses making it one of the 
strongest risk factors for breast cancer (Boyd et al., 2010; McCormack and dos Santos 
Silva, 2006).  
Breast cancer risk increases by 11 in 1000 per additional alcoholic beverage per day 
(Allen et al., 2009). Many epidemiological studies have also shown a dosage dependent 
increase in the risk of developing breast cancer upon alcohol intake, the mechanism of 
which is unknown, although alcohol consumption increases estrogen levels which is also 
an important risk factor (reviewed in (Coronado et al., 2011). Low fat diets are thought to 
decrease risk of breast cancer development as well as reducing the risk of recurrence 





1.1.3.1. Genetic risk factors 
Constitutional mutations in key genes required for normal cell function, especially the 
response to DNA damage, cell signalling and cell adhesion, can predispose an individual 
to developing cancer. These mutations show autosomal dominant inheritance but 
incomplete penetrance. According to Knudson’s two-hit hypothesis this is because 
although there is an inherited mutation (first “hit”), a secondary somatic mutation (second 
“hit”) is required in the target tissue for tumourigenesis to occur due to complete loss of 
function. This can occur through a second independent mutation or due to loss of 
heterozygosity. Genetic testing can be used to screen individuals for risk mutations (first 
“hit”) especially where there is a family history of breast cancer. 
BRCA1 and BRCA2: Hereditary breast cancer accounts for 5-10% of breast cancer cases 
in Europe and ~80-90% of these are due to mutations in BRCA1 and BRCA2 (Ford et al., 
1998; Gage et al., 2012).  Lifetime risk for carriers of mutations in BRCA1 and BRCA2 
genes is 50-80% (Fackenthal and Olopade, 2007). Tumours with triple negative receptor 
status tend occur in BRCA1 mutation carriers rather than  BRCA2 and tend to be higher 
grade with the worst prognosis (Mavaddat et al., 2012; Reis-Filho and Tutt, 2008). 
Receptor status amongst BRCA1/2 tumours is highly variable with ER+ve/PR-ve tumours 
less likely to be BRCA2 mutated than ER+ve/PR+ve tumours, and ER-ve/PR+ve 
tumours were more likely to be BRCA2 mutated than ER-ve/PR-ve tumours (Mavaddat 
et al., 2012). BRCA1 and BRCA2 are both involved in repair of double-stranded breaks 
in DNA by homologous recombination (HR) where they function at different stages 
(Figure 1.9). BRCA1 is involved at the early stages when it is phosphorylated in response 
to DNA damage and becomes involved in checkpoint activation of signalling pathways 
(Turner et al., 2005). BRCA1 is a RING finger protein that associates with another RING 
domain protein BARD to form a heterodimeric E3 ubiquitin ligase.  C-terminal BRCT 
repeats can bind phosphorylated proteins and it is this function, but not E3 ligase activity, 
that is required for tumour suppression (Shakya et al., 2011). BRCA2 mediates HR by 
binding to, stimulating the oligomerisation of, and localizing the recombinase RAD51 to 
sites of DNA damage (Turner et al., 2005).  
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ATM encodes a kinase involved in DNA damage repair that initiates a signalling cascade 
which includes phosphorylation of p53, BRCA1 and CHK2 (Figure 1.9). Autosomal 
recessive mutations in ATM cause Ataxia telangiectasia which is characterised by 
immune problems.  Mutations in ATM are also more prevalent in families with a history 
of breast cancer (Thorstenson et al., 2003). There is a moderate increase in the risk for 
developing breast cancer in individuals with heterozygous mutations in ATM (Thompson 
et al., 2005). 
TP53: This tumour suppressor gene encodes a p53 which has many cellular roles 
including activation of DNA repair, cell cycle arrest and apoptosis. Constitutional 
mutations in TP53 are responsible for Li Fraumeni Syndrome and breast cancer accounts 
for 24% of the cancer incidence in these families (Gage et al., 2012; Kleihues et al., 
1997).  There is a high incidence of TP53 mutations in BRCA1 breast tumour cases 
compared to non-BRCA1 tumours (Holstege et al., 2009).  
CHEK2: This cell cycle checkpoint kinase is activated by ATM and is involved in the 
DNA damage response (Figure 1.9) (Matsuoka et al., 1998). Premenopausal women with 
breast cancer with CHEK2 mutations have been shown to be at high risk of tumour 
recurrence and poorer prognosis compared with non-carriers (Schmidt et al., 2007). 








Figure 1.9. The role of breast cancer risk genes in the DNA damage response. (A) In 
response to DNA damage in normal cells, ATM phosphorylates BRCA1, leading to formation of a 
complex with BRCA2 which relocates to DNA damage sites to initiate repair by homologous 




PTEN: Mutations in PTEN cause Cowden & Bannayan-Zonana syndromes which, 
though rare, have been associated with severely increased breast cancer risk (Marsh et al., 
1998; Schrager et al., 1998). PTEN encodes a lipid phosphatase involved in inhibiting the 
PI3K/Akt/mtor signalling pathway which regulates proliferation, apoptosis and 
metabolism (Figure 1.10). Mutations in PTEN cause hyper-activation of the 
PI3K/Akt/mtor signaling pathway in breast cancer (and other malignancies) where is 
contributes to survival of tumour cells and these patients suffer from poor prognosis 
(Ghayad and Cohen, 2010).  
 
 
Figure 1.10. Schematic representation of the PI3K/Akt/mTOR signalling pathway. PTEN 
functions to inhibit the PI3K/AKT pathway progression preventing activation of AKT and mTOR 
which would result in upregulation of cellular processes which are important to tumourigenesis. 
STK11 mutations inhibit signalling through the AMPK pathway therefore preventing activation of 




STK11: Patients with Peutz-Jeghers syndrome, characterised by oral pigmentation and 
gastrointestinal polyps, have mutations in STK11 and increased risk of developing breast 
cancer (Hearle et al., 2006). STK11 encodes a serine/threonine kinase that – like PTEN - 
is involved in PI3K/Akt/mtor pathway inhibition (Figure 1.10).  
CDH1 encodes E-cadherin which is important for cell-to-cell adhesion and is commonly 
mutated in hereditary diffuse gastric cancer (Becker et al., 1994). Patients with familial 
CDH1 mutations are highly predisposed to developing invasive lobular breast cancer 
(Schrader et al., 2008).  
A number of studies based on consortium data have led to the discovery of low 
penetrance susceptibility loci with heterogenous associations with breast cancer subtype 
(Broeks et al., 2011; Garcia-Closas and Chanock, 2008; Garcia-Closas et al., 2008; 
Reeves et al., 2010). Recently an investigation of  genome-wide association study 
(GWAS) susceptibility loci in a pool of 31 studies showed that 6/8 were associated with 
ER+ve tumours; 4/8 with triple negative tumours; and two loci, CASP8  and TGFB1, 
were high risk loci for PR-ve tumours (Broeks et al., 2011).  This heterogeneity was 
similar to previous findings using GWAS risk loci in FGFR2, TNRC9, MAP3K1, 8q24 
and LSP1, which showed heterogeneity with regard to ER  status (Garcia-Closas et al., 
2008).  
 
1.1.4. Current therapies for breast cancer 
 
Multiple therapeutic strategies exist for breast cancer depending on the tumour 
classification. This is an evolving field with increasingly targeted therapies thanks to the 
advent of molecular profiling/genetic markers and new models for predicting response to 
the different treatment options. It is an exemplar for the advantages of stratified medicine. 
 1.1.4.1. Surgery and radiotherapy 
 
Removal of a breast tumour by surgical excision is known as a lumpectomy, but the 
margin of surrounding tissue removed is hotly debated with 20-30 % of patients requiring 
secondary re-excision surgery (Morrow et al., 2012). Radiotherapy usually follows a 
lumpectomy to kill any remaining tumour cells in the breast (radioadjuvant therapy) or 
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prior to surgical intervention to shrink the tumour to a size suitable for excision 
(neoadjuvant radiotherapy) (Kirova, 2010).  Another treatment option is mastectomy - 
removal of the whole breast by either a simple mastectomy (removal of breast tissue) or 
more rarely a radical mastectomy (removal of all breast tissue and underlying chest 
muscle). This can also be followed by radiotherapy, particularly if there has been lymph 
node involvement and it was not possible to remove all nodes surgically (Kirova, 2010).  
Individuals with strong family histories of breast cancer, in particular BRCA1/BRCA2 
mutation carriers, often undergo mastectomies as a preventative measure.  
 1.1.4.2. Chemotherapy 
 
Chemotherapy with different combinations of cytotoxic drugs can be used to kill tumour 
cells in either a neoadjuvant setting to shrink the tumour or adjuvant setting to kill 
remaining tumourigenic cells. The drugs (anthracyclins, taxanes, anti-metabolites, DNA 
replication inhibitors, alkylating agents, topoisomerase inhibitors etc) can have a number 
of side effects (infections, hair loss, nausea and vomitting). Frequently used treatment  
combinations are CMF (cyclophosphamide, methotrexate and 5-fluorouracil), FAC/CAF 
(5-fluorouracil, doxorubicin and cyclophosphamide) and FEC (5-flurouracil, epirubicin 
and cyclophosphamide) (Klaassen and Seeber, 1997).  
 1.1.4.3. Endocrine therapy 
Reducing the level of circulating estrogen or blocking its action using drugs is widely 
used to target ER +ve tumours. Selective estrogen receptor modulators (SERMs) function 
by competitively occupying the estrogen binding site on estrogen receptors and these 
include Tamoxifen, Toremifene, Raloxifene, Idoxifene and Droloxifen (Goldhirsch et al., 
2002). Multiple clinical trials have provided evidence that treatment with SERMs 
significantly reduces the risk of developing ER+ve invasive breast cancer and that 
Tamoxifen can reduce the risk by 50% (Cazzaniga and Bonanni, 2012; Visvanathan et 
al., 2009).	   Alternatively, estrogen hormone synthesis can be blocked by aromatase 
inhibitors which preventing the conversion of androstenedione and testosterone to 
oestrone and oestradiol by this enzyme (Figure 1.11). Aromatase inhibitors can be 
steroidal (Type I) or non-steroidal (Type II) and include aminoglutethimide, anastrozole, 
letrozole, 4-OH-androstendione and exemestane. A number of studies have shown that 
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use of aromatase inhibitors can even be more effective than standard treatment with 
SERMs for shrinking tumours prior surgery (Dixon et al., 2000, 1999) with improved 
disease-free survival and fewer side effects (Cazzaniga and Bonanni, 2012). Pituitary 
downregulators can also be used to inhibit the release of gonadotrophin from the pituitary 
thereby preventing the release of estrogen from the ovaries (Goldhirsch et al., 2002; Tan 




Figure 1.11. Summary of estrogen synthesis and antiestrogen therapy. Estrogen is 
synthesized by aromatase enzyme from androgens. Estrogen binds to the estrogen receptors 
(ERb and ERa), where they recruit  coactivators/repressors  leading to dimerization, 
conformational change and allow the binding of estrogen response elements (EREs) upstream of 
estrogen responsive genes. Endocrine therapy by treating with inhibitors of aromatase can be 
used to prevent estrogen synthesis or by SERMs which bind to the ERs inducing conformational 
changes that inhibit transcription of estrogen  regulated genes. Image from PharGKB.org (Whirl-





 1.1.4.4. Molecular targeted therapies 
 
Tumours overexpressing HER2 can be treated with drugs which inhibit this receptor 
including monoclonal antibodies against HER2 such as Tratuzumab (Herceptin) and 
Pertuzamab (Omnitarg), or tyrosine kinase inhibitors (Lapatinib /Tyverb) (Chu and Lu, 
2008). Moreover combined treatment of Lapatinib and Tratuzuab with aromatase 
inhibitors have proved more effective in hormone receptor positive cases of HER2 
amplified metastatic tumours (Fleeman et al., 2011) 
Patients with cancer due to BRCA1/2 mutations can be treated with inhibitors against 
Poly(ADP-ribose) polymerase (PARP). PARP is essential for the base excision repair 
(BER) pathway that is responsible for repairing single-stranded breaks in DNA 
(Ashworth, 2008; Baute and Depicker, 2008; Rouleau et al., 2010). Inhibition of PARP 
prevents repair by BER leading to double-stranded breaks which then cannot be repaired 
by HR in BRCA1/2 deficient cells as they are key to that pathway (see section 1.1.3.1 and 
figure 1.9). PARP inhibition in BRCA1/2 mutant cells leads to an accumulation of DNA 
damage and cell death due to synthetic lethality (Ashworth, 2008; Carroll et al., 2011). 
Olaparib/AZD2281 is a PARP inhibitor that is currently undergoing phase I clinical trials 
(Bundred et al., 2013). Interestingly, in olaparib-resistant metastastic tumours secondary 
mutations in BRCA2 have been identified which are able to restore full-length functional 
BRCA2 and are thought to contribute to the mechanism of resistance to this PARP 
inhibitor (Barber et al., 2013).  
Angiogenesis is a requisite for tumour growth and therefore targeting tumour vasculature 
can be used to treat tumours. Vascular endothelial growth factor (VEGF) which is needed 
for angiogenesis can be blocked by the tyrosine kinase inhibitor Sunitinib (Sutent) or by 




1.2. Chromatin function and organisation  
 
  
The human genome comprises 3.2 billion base pairs (bp) of DNA wound around proteins 
and packaged into the cell’s nucleus. Together the combination of DNA wound around 
proteins is known as chromatin. Packaging of chromatin in the nucleus is not random but 
infact highly organized with important roles in the regulation of gene expression.  
1.2.1. DNA methylation  
Methylation of DNA at CpG dinucleotides (5mC) is a heritable epigenetic mark catalysed 
by DNA methyltransferases (DNMT) and often associated with repression of 
transcription (Figure 1.12). Methylation occurs frequently in the human genome at 70-
80% of CpGs (Ehrlich et al., 1982). CpG dinucleotides are not evenly distributed in the 
genome and cluster together to form ‘CpG islands (CGIs)’ which span 0.5 to 5kb and are 
generally unmethylated in normal cells (Weber et al., 2007). CpG islands occur at the 
promoters of 60-70% of all human genes (Weber et al., 2007) and in particular 
constitutively expressed genes (e.g. housekeeping genes) but just 40% of tissue specific 
genes (Larsen et al., 1992). Although most CGIs coincide with transcription start sites 
(TSS) of genes a number of “orphan” CGIs exist that are not associated with known 
promoters and undergo DNA methylation during development (Illingworth et al., 2010). 
In general it is thought that unmethylated CGIs are permissive of  transcription due to 
their association with RNA polymerase II recruitment, active chromatin structure and 
transcription factor binding which becomes inhibited directly by DNA methylation or 
indirectly through recruitment of proteins and co-repressors (reviewed in (Deaton and 
Bird, 2011)).  
Another major modification to the DNA itself is the hydroxylation  of 5mCto form 
hydroxy-methyl-cytosine (5hmC) catalysed by ten-eleven-translocation (TET) enzymes 
(Figure 1.12) (Iyer et al., 2009).  It has long been known that this epigenetic mark is 
present in bacteriophages and trypanosomes but it was only recently found to be an 
abundant modification in mammalian genomes (Kriaucionis and Heintz, 2009). 
Bisulphite sequencing, which has been traditionally used to detect DNA methylation, 
does not distinguish between hydroxyl-methylation and methylation of DNA (Jin et al., 
2010; Nestor et al., 2010). Methods that distinguish between 5mC and 5hmC include end-
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labeling with thin-layer chromatograph, enzymatic radio-labeling by glycosylation, real 
time sequencing,  and sensitive mass spectrophotmetry  (reviewed  in (Kinney and 
Pradhan, 2013)).  
 
 
 Figure 1.12: Summary of the major modifications to Cytosine at position 5.  Cytosine (C) is 
converted to methyl-cytosine (5-mC) by DNA methyltransferase (DNMT) enzymes using the co-
factor S-adenosyl methionine (SAM). Methyl-cytosine can then be converted by Ten-eleven 
translocation (TET) enzymes with α-keto glutarate (αKG) and oxygen to hydroxy-methyl-cytosine 
(5-hmC). Hydroxy-methyl-cytosine can then be converted back to Cytosine by a combination of 
TET enzymes and thymine DNA glycosidase (TDG).  
 
 
The exact function of 5hmC is currently not known though it is known to be on the 
pathway to DNA demethylation. 5hmC has a much reduced affinity for binding to methyl 
binding proteins (MBDs) compared to 5mC (Jin et al., 2010), but their might be other 
proteins/protein motifs with specific affinity for 5hmC. The abundance of 5hmC amongst 
human tissues is highly variable compared with 5mC, with the highest levels in the brain 
(Li and Liu, 2011; Nestor et al., 2012) and the levels rapidly decrease as cells are 
cultured. Moreover 5hmC is enriched in gene bodies of active genes and the level of 





1.2.2. Chromatin Structure & Remodeling  
 
Histones fall into two broad classes: linker (H1 and H5) and core (H2A, H2B, H3 and 
H4). Approximately 146 bp of DNA is wound around 8 core histone proteins (2 of each 
type) to form a nucleosome with linker histones at DNA exit/entry sites (Hamiche et al., 
1996; Luger et al., 1997; Zhang and Reinberg, 2001). Nucleosomes form the 10nm 
chromatin fiber, which is visible as “beads-on-a-string’’ in low salt cellular extracts by 
electron microscopy  (Olins and Olins, 1974). Under physiological salt conditions in vitro 
the 10nm fiber is packed sequentially into 30nm fibers with 6 nucleosomes per turn and 
700nm structures which might represent heterochromatin (Hansen et al., 1989; Zhang and 
Reinberg, 2001). Evidence for the existence of the 30nm chromatin fiber in vivo has been 
demonstrated in starfish sperm nuclei although its presence in most interphase cell types 
remains very contentious (as reviewed in (Bian and Belmont, 2012; Fussner et al., 
2011)).  
 
There is a nucleosome free region (NFR) at the transcription start sites (TSS) of active 
genes which is thought to allow polymerase and transcriptional machinery access to the 
gene (Yuan et al., 2005).  To allow transcription to take place, there is a constant removal 
of histones ahead of the polymerase and replacement after it has passed. This process is 
known as chromatin remodeling (or “histone exchange”) and is regulated by ATP-
dependent chromatin remodeling complexes and covalent modifications to histones. A 
number of these remodeling complexes have been implicated in the regulation of the 
transcription activation mediated by nuclear receptors (Belandia and Parker, 2003). The 
SWI/SNF complex was one of the first ATP-dependent remodelling complexes to be 
identified and has been implicated in the regulation of ER- and BRCA1- dependent 
transcription (García-Pedrero et al., 2006; Harte et al., 2010).  
 
Nucleosome organisation can also be mediated by the FACT (facilitates chromatin 
transcription) complex which acts as a histone chaperone promoting the accessibility of 
DNA possibly by eviction of a H2A-H2B dimer (Winkler and Luger, 2011). The FACT 
complex is also physically and functionally associated with the PAF (polymerase 
associated factor) complex during transcriptional elongation by RNA polymerase II 
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(Squazzo et al., 2002). The PAF complex recruits the chromatin remodelling factor 
CHD1 where it interacts with other factors involved in transcriptional elongation 
including components of the FACT complex, though the specific function of CHD1 is 
unknown (Simic et al., 2003).  PAF-1, a component of the PAF complex in humans, is 
also associated with modifications to histones as well as chromatin remodelling 
complexes (Dey et al., 2011).  
 
 
1.2.3  Histone modifications  
 
Post-translational modifications can occur on the globular domain of the histones 
themselves but they predominantly occur at the N- and C- terminal tails that extend from 
the nucleosome . Histone-modifying enzymes catalyze the addition or removal of 
acetylation, methylation, phosphorylation, ubiquitination and ADP-ribosylation, amongst 
other chemical changes. These changes can affect the charge on histone tails but also 
provide the binding sites for chromatin proteins that recognise specific histone 
modifications.  Histone tail modifications can be assayed genome-wide by chromatin 
immunoprecipitation (ChIP) with specific antibodies combined with arrays (ChIP-chip) 
or high through-put sequencing (ChIP-seq) (Barski et al., 2007).  
 
 1.2.3.1. Histone Acetylation 
 
Addition of negatively-charged acetyl groups to positively-charged lysine residues, which 
are abundant in histone tails, neutralises the charge on histone tails and is known to relax 
DNA-histone interactions making chromatin permissive to transcriptional machinery 
(Hebbes et al., 1988; Hong et al., 1993). Acetyl group addition is carried out by the 
histone acetyl transferase (HAT) enzymes and is reversed by histone deacetylases 
(HDACs). Acetylation of histones H3 and H4 occurs at the TSS of active genes 
(Bernstein et al., 2005; Pokholok et al., 2005) and acetylation ‘islands’ distant from the 
TSS can be used to predict the presence and activity of long-range regulatory elements 
(e.g. enhancers of gene expression) (Roh et al., 2007), (Visel et al., 2009), (Creyghton et 




 1.2.3.2. Histone Methylation 
 
Histones can be mono-, di- or tri-methylated by the addition of methyl group(s) to 
arginine (R) or lysine (K) residues by histone methyltransferases (HMT). Demethylation 
is carried out by LSD1 and the jumonji (JMJ) family of proteins. Histone methylation of 
R residues are little studied compared to lysine methylation residues but are thought to be 
important for cell proliferation and differentiation (as reviewed in (Wysocka et al., 
2006a). These modifications include: methylation histones of H3R2, H3R17 and H3R26 
by coactivator associated arginine methyl transfer 1 (CARM1); histone H3R8 by protein 
arginine methyl transferase 5 (PRMT5); and histone H4R3 by either PRMT1 or PRMT2. 
Arginine methylation is linked to the mechanism of transcriptional activation by nuclear 
hormone receptors (Barrero and Malik, 2006; Ma et al., 2001; Wang et al., 2001; Xu et 
al., 2004, 2001) and is not just limited to methylation of histones (Ceschin et al., 2011; Le 
Romancer et al., 2008; Naeem et al., 2007). 
 
 Tri-methylation of H3K27 (H3K27me3) is an important repressive histone mark that is 
catalysed by the EZH2 (enhancer of zeste 2) component of the polycomb group 
repressive complex 2 (PRC2).	   There are two main classes of polycomb repressive 
complexes (PRC): the PRC1 complex (PC, PH, PSC and RING1B) which can 
ubiquitinate H2AK119 and the PRC2 complex (EZH2, SUZ12 and EED) which can tri-
methylate H3K27 (Otte and Kwaks, 2003). H3K27me3 is associated with repression of 
gene expression through interactions with, or recruitment of, the PRC1 to DNA(Simon 
and Kingston, 2009). The PRC system plays a critical role in regulating gene expression 
during normal development. PRC1 has a key role in compacting chromatin in vitro and in 
vivo (Ragnhild Eskeland et al., 2010; Francis et al., 2004) in association with gene 
silencing.  This is antagonised by histone acetylation – which partially reverses 
polycomb-mediated chromatin compaction and gene repression (R Eskeland et al., 2010). 
Furthermore, H3K27me3 deposition and binding of polycomb components in mouse ES 
cells has been linked to DNA methylation through the action of Tet1 enzyme which is 
thought to recruit polycomb group proteins to CpG-rich promoters in mouse ES cells 




H3K27me3 has also been shown to mark genes that become hypermethylated in tumour 
cells and it is thought that PRC2 normally maintains the mark in differentiated cell types 
but that in tumour cells this complex recruits DNMT enzymes for de novo methylation 
(Schlesinger et al., 2007; Widschwendter et al., 2007). This has given rise to the idea that 
a “stem cell chromatin signature” may exist where loss of H3K27me3 can predispose 
genes to acquire aberrant DNA methylation and repressive histone marks in adult cancers 
(Ohm et al., 2007).  Genome-wide studies have indicated that there is a mutually 
exclusive switch between DNA methylation and H3K27me3 repressive marks (Gal-Yam 
et al., 2008; Hahn et al., 2008) though subsets of genes have also been identified with 
both these repressive marks (Coolen et al., 2010; Gal-Yam et al., 2008; Hawkins et al., 
2010; Meissner et al., 2008). The latter finding is supported by the advent of 
Bisulphite/ChIP sequencing which showed that H3K27me3-marked histones were able to 
bind to both methylated and unmethylated DNA at specific regions of the genome and 
that are repressed in cancer (Statham et al., 2012).  
 
Histone methylation is not uniformally associated with repression of genes. H3K4me3 is 
deposited by members of the COMPASS family of HMTases (Shilatifard, 2012) at the 
TSS of genes where it is associated with transcriptional activity (Barski et al., 2007; 
Milne et al., 2002; Noma K et al., 2001; Wysocka et al., 2006b; Yokoyama et al., 2004). 
H3K36 is methylated by the Set2 HMTase that associates with the elongating (serine 2-
phosphorylated) RNA polymerase II. Whereas H3K4me3 peaks at the 5’ end of genes, 
H3K36me3 is enriched toward the 3’ end and is particularly associated with exons (Bell 
et al., 2008; Hon et al., 2009; Santos-Rosa et al., 2002). The presence of H3K4me3 and 
also di/tri-methylated  H3K36 (H3K36me2/3) directly inhibits PRC2 therefore preventing 
methylation of H3K27 on genes that are being actively transcribed (Schmitges et al., 
2011). 
 
 1.2.3.3. Histone Phosphorylation 
 
Histone phosphorylation is associated with transcriptional regulation, cell cycle 
progression, chromosome condensation, DNA repair and regulation of developmental 
genes (Cheung et al., 2000; Cruickshank et al., 2010; Johansen and Johansen, 2006; 
Rogakou et al., 1998). Phosphorylation of serines 10 and 28 in histone H3 (by Aurora B 
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kinase) correlate with transcriptionally active loci and is associated with mitotic 
condensation (Nowak and Corces, 2000). Phosphorylation of H3S28 mediated by 
mitogen- and stress-activated kinases (MSK) leads to a displacement of polycomb protein 
complexes from H3K27me3 marked promoters forming a double mark 
(H3K27me3S28p) and leading to transcriptional activation (Gehani et al., 2010). Most 
recently, phosphorylation of tyrosine 41 of H3 (by JAK2 tyrosine kinase) has been shown 
at active promoters where it correlates with H3K4me3 as well as over the transcribed 
regions of tissue-specific active hematopoetic genes (Dawson et al., 2012). 
 
 1.2.3.4. Other histone modifications 
 
Mono-ubiquitylation of H2B has been correlated with both transcriptional activation and 
repression of genes (Wright et al., 2012). Ubiquitylation of H2A (H2Aub) is involved in 
polycomb-mediated repression (Endoh et al., 2012). The RING1B component of the 
PRC1 complex can mediate chromatin compaction and gene silencing independently of 
histone ubiquitylation activity (Endoh et al., 2012; Eskeland et al., 2010a).  Other 
modifications not discussed here include biotinylation, citrullination, carbonylation, 
poly(ADP-ribosyl)ation, and sumoylation, amongst others.  
 
 
1.2.4. Chromatin Organization in the nucleus 
 
Rather than being randomly organized chromatin in the nucleus is spatially organised and 
is thought to affect gene function. Nuclear components have specific localisations within 
the nucleus and movement of chromatin into environments that are conducive for 
transcription and post-transcriptional processing to take place is key for normal gene 
function.  
 1.2.4.1. Chromosome Territories  
 
Chromosomes occupy specific positions within the nucleus known as chromosome 
territories (Cremer et al., 2006; Heard and Bickmore, 2007). Gene-rich chromosomes and 
chromatin regions are generally located towards the interior and gene-poor chromosomes 
towards the nuclear periphery (Figure 1.14 and section 1.2.2.4) (S Boyle et al., 2001; 
Croft et al., 1999). Chromosome territories are not completely spatially separated as 
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intermingling of chromosomes occurs at the territory periphery (Branco and Pombo, 
2006). Furthermore, within these territories gene rich  and poor regions can be spatially 
separated (Shopland et al., 2006; Simonis et al., 2006). Translocations that join together 
chromosomes that normally are found in different nuclear environments result in altered 
nuclear organisation and gene expression (Harewood et al., 2010). There are some reports 
that this can alter cancer risk and the full impact of this area of nuclear organisation on 
tumours with complex karyotypic rearrangements is yet to be assessed. 
The human major histocompatibility complex (MHC) was the first example of genes 
looping out of their chromosome territory when active (Volpi et al., 2000). The 
interferon-γ induced looping out of MHC genes is mediated through the transcriptional 
activator P-STAT1 and the chromatin remodeller BRG1 (Christova et al., 2007). The Hox 
genes have also been shown to loop out of their chromosome territories when active 
during differentiation (Chambeyron and Bickmore, 2004). Therefore it is possible to 
increase the surface of chromosome territories by looping out into the intrachromosomal 
compartment or conversely by infoldings into these territories (Cremer et al., 2006; Heard 
and Bickmore, 2007).  The scale of looping out of gene-rich genomic regions from 
chromosome territories has been recently revealed by FISH (Boyle et al., 2011). Regions 
looped out from chromosome territories have an enhanced probability of interacting with 
sequences from other chromosomes  - as measured by chromosome conformation capture 
(3C) methods (Kalhor et al., 2012; Würtele and Chartrand, 2006). It is thought that the 
relocalisation of genomic regions in their chromosome territories allows access to 
different nuclear environments containing transcriptional machinery components (Brown 
et al., 2006; Moen et al., 2004; Morey et al., 2009; Osborne et al., 2004).   
 
1.2.4.2. Chromatin folding 
Fluorescence in situ hybridisation (FISH) is a molecular cytogenetic technique which has 
been used by the Bickmore lab (and others) to detect whole chromosomes as well specific 
DNA loci in the nucleus. FISH can be used to measure the compaction of chromatin over 
a specified genomic region. A random walk model of the behaviour of higher order 
chromatin has been identified using FISH data with pairs of probes at different genomic 
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intervals along the linear DNA molecule (van den Engh et al., 1992). With probe 
separations of 100kb to 1.5 Mb there is a linear relationship between the mean inter-
probe distances (squared) and the genomic distance that fits a “random walk” model with 
the chromatin behaving like a flexible polymer (van den Engh et al., 1992). This model 
was also suggested in subsequent work using probes for 150kb to 190Mb intervals on 
chromosomes 4, 5 and 19 and modelling of the large-scale chromatin geometry (Sachs et 
al., 1995; Yokota et al., 1995). This analysis produced a “random walk/giant loop” model 
of large-scale chromatin organisation whereby at megabase intervals the chromatin is 
organised in giant loop structures which are fixed (or “tethered”) on a flexible backbone 
that shows random walk behaviour (Sachs et al., 1995).  In this model interprobe distance 
conform to a Rayleigh distribution and are characterised by a standard deviation/mean 
ratio of ~0.52 and a median/mean ratio of ~0.94.  
Chromatin compaction using pairs of FISH probes has been well studied using this 
method during differentiation of embryonic stem cells, (Chambeyron and Bickmore, 
2004), in the developing embryo (Chambeyron et al., 2005; Morey et al., 2007), 
comparing wildtype and mutant cells (Ragnhild Eskeland et al., 2010) and also for the 
study of multiple loci in the same cells (Gilbert et al., 2004). Similar data distributions are 
observed for multiple regions of the mouse and human genomes in a wide variety of cell 
types and in tissue sections (Chambeyron and Bickmore, 2004; Gilbert et al., 2004; 
Williamson et al., 2012). Furthermore data from 2D FISH analysis of fixed cells has been 
shown to recapitulate the chromatin compaction observed with 3D FISH though distances 
are typically larger (Ragnhild Eskeland et al., 2010; Morey et al., 2007).  
The degree to which chromatin in compacted is not constant over the genome. Regions 
with low gene densities (as in G-bands) are significantly highly compacted compared 
with high gene density regions (as in R-bands) (Gilbert et al., 2004). However, “open” 
and “closed” chromatin status does not absolutely distinguish between regions that are 
actively transcribed or being repressed - as active genes can be found in compact regions 
and silent genes in open regions (Gilbert et al., 2004). It is thought that the decompact 
“open” chromatin structure facilitates active transcription as it is permissive to access by 
transcriptional machinery but does not necessitate that genes will be expressed (Gilbert et 
al., 2004).   
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1.2.4.3. Transcription factories  
 
Active genes co-localise at sites of transcription measuring approximately 80nm in 
diameter which are known as “transcription factories” (Osborne et al., 2004; Sutherland 
and Bickmore, 2009). These foci can be visualised by incorporation of bromouridine 
(BrdU) into newly synthesized RNA (Jackson et al., 1993). Between 4 and 20 RNA 
polymerase II molecules have been shown to cluster together in these transcription 
factories at a time (Iborra et al., 1996). Co-regulated genes have been shown to cluster in 
space, beyond their observed linear organisation by gene order in the genome and that 
this spatial co-localisation of genes leads to higher expression (Ben-Elazar et al., 2013; 
Rieder et al., 2012; Sutherland and Bickmore, 2009). The co-localisation of active genes 
at the transcription factories has been suggested to be important in the generation of 
specific cancer-associated translocations (Osborne et al., 2007). 
Genes within their chromosome territory have been shown to relocate to the edges and 
outside of their territories to associate with transcription factories (Morey et al., 2009). 
Furthermore nuclear hormone receptors are found to concentrate at transcription factories 
when hormone ligand is bound (Sutherland and Bickmore, 2009). Recent evidence has 
also suggested that transcription factories are the result of the spontaneous concentration 
of active chromatin modifications like histone H4 acetylated at Lysine 16 (H4K16ac) 
which induce the formation of stiff microdomains (Canals-Hamann et al., 2013).  
 
1.2.4.4. The Nuclear Periphery  
Gene density is a major factor in the localisation of chromosomes in nuclear space. 
Chromosomes with a high gene density (“gene-rich” chromosomes) occupy a central 
position in the nucleus and conversely those that have a low gene-density (“gene-poor” 
chromosomes) are located at the periphery (S Boyle et al., 2001; Croft et al., 1999) 
(Figure 1.13).  This radial distribution of gene-rich and gene-poor chromosomes is also 
present in tumour nuclei though is it less pronounced compared to normal nuclei (Cremer 
et al., 2003) which could be due to the presence of  chromosomal rearrangements such as 
translocations  in tumour cells (Harewood et al., 2010). Proximity to the nuclear 
periphery is also associated with the level of transcription, with repressed genes located 
closer to the periphery than more centrally located active gene clusters.  Moreover, 
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tethering chromosomes to the nuclear periphery using a E.coli lac operator system (lacO) 
can reduce the expression of some endogenous genes located near the lacO sites (Finlan 
et al., 2008). A  notable exception to this dogma of nuclear periphery as a repressive-
compartment is in mouse  retinal rod cells where this is inverted: gene-poor 
heterochromatin is packed in the centre of the nucleus and gene-rich euchromatin at the 
periphery (Solovei et al., 2009). However, overall chromatin at the nuclear periphery 
represents inactive, compact and gene-poor chromatin.  
 
Figure 1.13:  Chromosome territories in interphase nuclei for human chromosomes 18 and 
19. Human lymphoblastoid cell nucleus hybridized by FISH with paints for the gene-rich 
chromosome 19 (red) and gene-poor chromosome 18 (green) showing the radial organization of 
these chromosomes in the nucleus. (Figure taken from Croft et al., 1999)  
 
Tethering of the E. coli DNA adenine methyltransferase (Dam) to a chromatin protein, 
allows in vivo targeting of Dam to binding sites of the protein, which become marked by 
DNA A methylation (Steensel and Henikoff, 2000).  Dam ID technology has been used to 
target Dam to proteins in the nuclear lamina providing a map of chromatin domains that 
associate with the nuclear periphery.  These lamina-associated domains (LADs) span 
mega-base sized regions in humans and mice, where they generally correlate with gene-
poor regions that are transcriptionally inactive and late replicating (Guelen et al., 2008; 
Peric-Hupkes et al., 2010). A role for the nuclear lamina in control of gene expression is 
further demonstrated by dissociation of genes from the lamina which results in either 




1.2.4.5. Chromatin interactions and topology 
 
There is increasing evidence of elements of the genome physically interacting over large 
genomic distances with one another, indicating that a three-dimensional network of 
genomic organisation exists which is defined by these physical interactions (Dostie and 
Dekker, 2007; Dostie et al., 2006). Development of techniques such as Chromosome 
Conformation Capture (3C), which cross-link together chromatin regions in proximity in 
the genome has allowed a number of long range cis and trans associations to be 
identified. For 3C chromatin interactions are fixed using formaldehyde before being 
digested with a restriction enzyme (Dekker et al., 2002). The digested fragments retain 
the cross-links created by formaldehyde and the sticky ends are ligated before the cross-
links are reversed (Dekker et al., 2002). The ligation products are detected by qPCR 
(quantitative polymerase chain reaction) amplification of selected ligation junctions using 
primers for the genes of interest designed towards the end of the restriction fragments 
(Dekker et al., 2002). Since the advent of 3C a number of techniques have also evolved 
based on this method for identifying chromatin associations (Figure 1.14).  
 
Using the 3C technique a number of cis interactions connecting promoters and regulatory 
regions have been identified including at both the mouse and human β-globin locus 
(Deng et al., 2012; Tolhuis et al., 2011), the α-globin locus (Vernimmen et al., 2007) and 
the TH2 cytokine locus (Spilianakis et al., 2005). The importance of the enhancer-
promoter chromatin loop has been demonstrated by forcing the formation of a loop 
between the locus control region (LCR) and promoter of the β-globin locus, which 
resulted in recruitment of RNA polymerase II and activation of transcription (Deng et al., 
2012).  The effect of enhancers of gene activity can be attenuated by insulator sequences 
that are often bound by CCCTC-binding factor (CTCF) (Phillips and Corces, 2009).  
 
CTCF is a ubiquitously expressed, highly conserved,  zinc-finger DNA-binding protein 
with many roles including transcriptional activation, transcriptional repression,  as a 
transcription factor involved in hormone-responsive gene silencing, as an insulator 
protein, as a protein involved in imprinting/X-chromosome inactivation, as a boundary 
element and as an aid to long-range chromatin interaction within and between 
chromosomes (Phillips and Corces, 2009). CTCF has been shown to bind sites around the 
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mouse β-globin locus that spatially cluster in the erythroid cell nucleus and mediate 
long-range DNA looping at this locus with maintenance of local histone modifications 
(Splinter et al., 2006). It is well reported that cohesin, a protein complex that holds sister 
chromatids together, localises to CTCF binding sites and that association of this complex 
is essential for the insulator properties of CTCF (Parelho et al., 2008; Rubio et al., 2008; 
Stedman et al., 2008; Wendt et al., 2008). However, cohesin and the transcriptional-
coactivator mediator can also co-occupy enhancer and active promoter sites 
independently of CTCF where they are thought to maintain DNA loops by the formation 
of ring structures connecting the two sites (Kagey et al., 2010) 
 
Circular 3C (4C) is a development of the 3C method, which is used to identify 
interactions between a region of interest with any other genomic region. As shown in 
Figure 1.14 the 3C ligated fragment is digested, then re-ligated to form circularised 
fragments and any interacting regions can be identified by hybridisation to microarrays 
(Simonis et al., 2006) or next generation sequencing (Splinter et al., 2011). 4C interaction 
profiles of genes located in inactive (β-globin) and active (Rad23a) chromatin domains 
are very different from one another with many contacts identified for Rad23a with active 
regions but expression-dependent active/inactive contacts for β-globin in different tissues 
(Simonis et al., 2006). 4C has also been used to identify contacts in response to 
glucocorticoid receptor (GR) stimulation where no large-scale movement was observed 
(Hakim et al., 2011) and cis contacts between genes repressed in association with 





Figure 1.14: Schematic overview of 3C-derived methods. The horizontal panel of the “C” 
methods. The vertical panels indicate the steps that are specific to separate methods. Figure 
taken from (de Wit and de Laat, 2012) 
 
 5C (3C carbon copy) is a high-throughput adaptation of 3C used  to detect long-range 
interactions between multiple genomic loci. 5C  uses pools of reverse (T3 tagged) and 
forward (T7 tagged) primers that are designed to detect all possible junctions in a 3C 
library of cross-linked restriction fragments, which are then ligated to form a carbon-copy 
library which is amplified with primers (to T7 and T3) and sequenced or hybridised to 
microarrays (Dostie et al., 2006).  Analysis of the HOXA gene cluster showed long-range 
interactions between the active components of the gene cluster in cell lines (Wang et al., 
2011) and the formation of active/inactive contact domains along the developing body 
axis in vivo (Noordermeer et al., 2011). This does not however marry up with the 
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observations by FISH that active HOX loci are in a decondensed chromatin conformation 
and therefore not clustered together (Dostie and Bickmore, 2012). 
 
5C and super-resolution microscopy  have been  used to analyse the spatial organisation 
of a  4.5 Mb domain (containing Xist) and  led to the discovery of 200 kb -  1 Mb 
topologically associating domains (TADs) that correlate with H3K27me3 or H3K9me2 
blocks, lamina-associated domains and coordinately regulated gene clusters (Nora et al., 
2012). Furthermore the TADs were able to spatially segregate active/inactive chromatin 
regions  and disruption of the TAD boundaries led to long-range misregulation of 
transcription (Nora et al., 2012) 
 
Hi-C (Lieberman-Aiden et al., 2009) can identify long-range interactions which occur 
across the genome. After formaldehyde crosslinking of interacting DNA and restriction 
digestion the fragment ends are biotin-labelled before ligation creating a library of 
products with biotin at the junction. This library is sheared and the biotin labelled 
junctions pulled down by streptavidin beads and subjected to high-throughput sequencing 
to identify the interacting regions. Similarly to Nora et al (2012), partitioning of the 
genome into large topological domains (~1 Mb) that are highly conserved and stable 
across cell types has been identified using Hi-C detection of chromatin interactions 
(Dixon et al., 2012).  Furthermore the boundaries of the TADs identified by Dixon and 
colleagues were enriched with CTCF , transcription start sites (TSS), transfer RNAs, 
housekeeping genes and short interspersed element (SINE) retrotransposons, which are 
thought to be involved in TAD structure (Dixon et al., 2012).  
 
The ChIP-loop assay combines 3C and ChIP to identify genomic interactions that are 
associated with a particular protein (Horike et al., 2005). This technique uses the purified 
cross-linked chromatin after digestion with restriction enzymes (3C library) for 
precipitation with protein A/G beads bound with antibodies for the protein of interest. 
This fraction of protein-bound cross-linked fragments are ligated and analyzed by qPCR. 
ChIP-loop was used to study interactions of a methyl-binding protein (MECP2) which 
mediates  a silent chromatin structure (11kb DNA loop)  that is lost in Rett syndrome 
where MECP2 is mutated (Horike et al., 2005). Combined 3C-ChIP-cloning (6C) uses a 
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3C  library to identify fragments enriched in a protein of interest using a specific antibody 
(as with ChIP-loop) by reversing cross-links in enriched fragments cloning them into a 
vector which can be screened by digestion and sequencing to identify interaction partners 
(Tiwari et al., 2008). This has been used to identify a number of long-range inter/intra-
chromosomal contacts mediated by the polycomb group protein EZH2, which correlated 
with transcriptional repression (Tiwari et al., 2008).  
 
Chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) also allows the 
detection of chromatin interactions associated with a protein of interest and allowed a 
genome-wide interactome to be identified for the ER (Fullwood et al., 2009) and CTCF 
(Handoko et al., 2011). For ChIA-PET cross-linked DNA fragments are enriched by 
ChIP and tethered by covalent linkers before extraction (by restriction 
digestion/streptavidin-magnetic beads) of paired-end tags (PETs) for sequencing 
(Fullwood et al., 2009; Goh et al., 2012). The interactome map  identified for  the ER in 
breast cancer cells (MCF7s) suggested a mechanism for coordinated expression of genes 
by the formation of intrachromosome loops  (consisting of “anchor” and “loop” genes) 
that are maintained by the ER  (Fullwood et al., 2009). Similarly the CTCF interactome 
in mouse embryonic stem cells (ESCs) showed a network of cross-linking between 
regulatory elements and promoters anchored by CTCF (Handoko et al., 2011).  
 
1.2.4.6. The Estrogen Receptor  
 
Estrogen action is mediated via the estrogen receptors alpha (ERα) and beta (ERβ), which 
are part of the nuclear receptor superfamily. ERα and ERβ are both expressed in normal 
mammary epithelial cells but can also be differentially expressed in different cell types, 
for example ERβ is expressed in the prostate epithelium and ERα in stroma (Heldring et 
al., 2007; Nilsson and Gustafsson, 2002) where it promotes carcinogenesis (Ricke et al., 
2008). Knockout studies in mice showed that ERα is crucial for formation of ducts during 
mammary development (Hewitt et al., 2005) whereas ERβ knockout leads to much 
milder mammary phenotypes and an increase in Ki-67 expression in the luminal 
epithelial cells of the mammary gland (Förster et al., 2002). ERβ is also thought to have a 
protective role and is often silenced in malignant breast and prostate cancer (Järvinen et 
al., 2000; Zhu et al., 2004).   
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The ERs regulate gene expression via a sequence of events initiated by ligand binding to 
ERα or ERβ to induce dimerization as either homodimers (ERα/ERα or ERβ/ERβ) or 
heterodimers (ERα/ERβ). These then translocate to the nucleus where they bind to 
specific estrogen response elements (EREs) in the promoters of target genes and trigger 
the recruitment of cofactors and RNA polymerase II. ERα and ERβ have different 
biological functions, the ERα homodimer promotes cell growth and proliferation whereas 
ERβ activation is anti-proliferative and promotes apoptosis (Helguero et al., 2005). 
Forced expression of ERα/ERβ heterodimers in breast and prostate cancer cells leads to 
growth inhibition (Powell et al., 2012) however evidence for the existence of such 
heterodimers in vivo  is lacking. The anti-tumourigenic protective effect of ERβ is also 
demonstrated in ER+ve breast tumours where ERβ expressing patients show better 
prognosis and rate of disease-free survival (Omoto et al., 2001). ERα and ERβ show 
distinct binding profiles in the genome and are thought to regulate different genes 
(Leitman et al., 2010).  
Transcriptional activity of genes through recruitment of coregulator complexes has 
mainly been studied with ERα and may be different in ERβ mediated transcription. 
Ligand binding to ER leads to conformational changes in the receptor, binding to 
estrogen response elements (EREs) at promoters and extensive recruitment of 
coregulatory proteins involved in transcription and chromatin remodelling. The 
coregulatory proteins recruited to ERα and transcriptional activity of target genes are 
determined by the ligand bound to the receptor (Figure 1.15 (Teyssier et al., 2010)). 
Coactivators are able to modify chromatin and facilitate transcription upon estrogen 
stimulation.  The SRC (p160) family of coactivators are recruited in response to estrogen 
binding to ERα and include SRC1 (NCOA1), SRC2 (NCOA2/TIF2) and SRC3 
(NCOA3/AIB1) (Heldring et al., 2007; Zwart et al., 2011). The SRC coactivators also 
recruit histone methyl transferases (PRMT1 and CARM1/PRMT4) to ERα (Teyssier et 
al., 2010). PRMT1 methylates arginine 3 on histone H4 (H4R3) and facilitates 
deacetylation of H4 tails by p300 and active transcription (Wang et al., 2001). The 
coactivators CBP and p300 are histone acetyltransferases (HATs) which interact with 
SRC family members to enhance transcription mediated by estrogen bound ERα (Green 
and Carroll, 2007). Furthermore the expression of SRC3 and CBP bound genes can be 
used for prediction of patient response to endocrine therapy (Zwart et al., 2011) The 
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ATP-dependent remodelling complex SWI/SNF also acts as a coactivator through spatial 
reorganisation of nucleosomes which allows the Mediator complex and transcriptional 
machinery to be recruited to the initiation start point (Kassabov et al., 2003; Teyssier et 
al., 2010).  
 
Figure 1.15: The ERα Coregulator Complexes. The recruitment of corepressor or coactivator 
complexes depends on the type of ligand bound to ERα. (taken from (Teyssier et al., 2010)) 
By contrast, upon antiestrogen ligand binding corepressor complexes are recruited that 
modify chromatin making it less accessible transcriptional machinery and block 
transcription.  NCOR1 and SMRT (NCOR2) are corepressor complexes which are 
involved in the recruitment of histone deacetylases (HDACs) which are key to modifying 
the chromatin so that access to the promoters is inhibited (Dobrzycka et al., 2003; 
Teyssier et al., 2010). In response to estrogen the ER can bind with RIP140 which 
interacts with HDACs and acts as a corepressor (Teyssier et al., 2010).  
As discussed in section 1.2.4.5. identification of the ERα interactome in estrogen-
responsive cells showed that a number of complex intrachromosomal interactions exist 
that are mediated by estrogen for active transcription  (Fullwood et al., 2009). Further 
evidence for large-scale changes in chromatin architecture comes from  tethering the ER 
to DNA resulting in large scale decondensation of chromatin   (Nye et al., 2002; Sharp et 
44	  
	  
al., 2006).  It has also been reported that estrogen stimulation of breast cancer cells leads 
to the recruitment of PAD2 enzyme which targets ERα bound promoters and citrullinates 
H3R26 leading to chromatin decondensation and activation of transcription (Zhang et al., 
2012).  
Through genome-wide binding studies it is apparent that the ER can regulate gene 
expression from a distance (Carroll et al., 2006; Hurtado et al., 2011). FoxA1 binding is 
highly enriched at distal gene promoters and it is hypothesized that interactions between 
distal binding sites and elements like FoxA1 could potentiate DNA looping (Carroll et 
al., 2005). FoxA1 is a pioneer factor that binds to compact chromatin and creates an open 
chromatin state by displacing linker histone H1 and disrupting the H3/H4 tetramer 
(Cirillo et al., 2002, 1998).  Moreover FoxA1 binding has been found to correlate with 
regions rich in H3K4me1/2 and poor in H3K9me2 (Lupien et al., 2008).  A number of 
other pioneer factors have been associated with hormone-dependent cancer including 
PBX1, TLE and GATA3 (Jozwik and Carroll, 2012).  
 
Figure 1.16: The function of pioneer factors. By binding with condensed chromatin pioneer 
factors are able to increase accessibility to estrogen response elements (EREs) facilitating ERα-
chromatin interactions (Jozwik and Carroll, 2012). 
 
Almost  all ER-chromatin interactions which effect gene expression are dependent on 
FoxA1 and are negatively regulated by CTCF  (Hurtado et al., 2011). Comparison of 
CTCF and ER binding data has shown that CTCF binding can divide the genome into 
blocks of estrogen-regulated genes with ER binding sites (Chan and Song, 2008). 
Moreover CTCF binding upstream of FoxA1 has been shown to demarcate the estrogen 
regulated genes by acting as boundary to the spread of heterochromatin (Zhang et al., 
2010).   
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Estrogen or tamoxifen treatment has no effect of the genome-wide CTCF binding events 
in breast cancer cell lines (Ross-Innes et al., 2011). In fact CTCF was co-bound with key 
transcription factors some of these CTCF binding events are cell-line specific and are 
associated with highly expressed genes. However numerous binding sites exist that share 
ER- and cohesin-binding events but lack CTCF and are regulated by estrogen (Schmidt et 
al., 2010).  
In the absence of estrogen, breast cancer cells are growth arrested and can only 
proliferate and re-enter the cell cycle after estrogen stimulation (Prall et al., 1997), and 
this is cohesin-dependent (Schmidt et al., 2010).  The fact that cohesin has a role to play 
in ER-mediated gene expression was also highlighted by a genome-wide functional 
screen in which silencing of NIBL, RAD21, SMC3 (components of the cohesin complex) 
conferred tamoxifen resistence in ER+ve breast cancer cells (Mendes-Pereira et al., 
2012). Another key regulator of the cell cycle is FoxM1 which was recently shown to co-
bind with the ER (like FoxA1) in breast cancer cells where it interacts with  co-activator 
associated arginine methyltransferase (CARM1) and is involved in transcriptional 




1.3 Cancer and Epigenetics  
 
 
The term “epigenetics” is used loosely in the literature with a various different meanings 
(as discussed in (Bird, 2007)). The term was first used by Conrad Waddington to describe 
the relationship between genotype and phenotype during development (Waddington, 
n.d.). Later definitions that are commonly quoted include those by Robin Holliday and 
Arthur Riggs, where epigenetics is used to describe heritable changes that cannot be 
explained by the DNA sequence itself (Holliday, 1990; Riggs, 1996). The current use of 
the term “epigenetics” however deviates from these historical definitions in that it is used 
to describe changes that are not necessarily heritable but give rise to “altered activity 
states” (Bird, 2007). At a Cold Spring Harbour meeting in 2008 a consensus definition 
for an epigenetic trait was defined as a "stably heritable phenotype resulting from 
changes in a chromosome without alterations in the DNA sequence” (Berger et al., 2009) 
. In this thesis I have used the term “epigenetics” to describe changes in gene expression 
that are not associated with changes to the DNA sequence but to changes in chromatin 
structure, organization and modifications to the DNA that do not affect the sequence.  
Here I talk about the role of epigenetics in tumourigenesis with particular regard to breast 
cancer.  
 
1.3.1. DNA methylation in breast cancer  
 
Aberrant patterns of DNA methylation have been reported in cancer cells with both gains 
(hypermethylation) and losses (hypomethylation) of methylation. Global DNA 
hypomethylation is a consistent characteristic of tumours (Bernardino et al., 1997) and 
occurs at repetitive elements and at satellite DNAs, which are heavily methylated in 
normal cells.  Many hypomethylated genes are normally expressed exclusively in 
germline cells and have been denoted as “cancer-germline” (CG) genes i.e. genes that 
rely primarily on DNA methylation for their tissue-specific expression (De Smet and 
Loriot, 2013). Discrete blocks of hypomethylation identified across the genome in 
tumours associate with highly variable expression profiles that are thought to contribute 
to tumour heterogeneity (Hansen et al., 2011). They also correspond to domains which 
show patterns of partial methylation in normal tissues (Hon et al., 2011; Berman et al., 
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2011) A number of cancer-specific differentially methylated regions (DMRs) - highly 
variable between tumour types – have been attributed to the loss of defined boundaries to 
DNA methylation around CpG islands (Hansen et al., 2011)..  
As well as large domains of hypomethylation, focal DNA hypermethylation has been 
reported at CGIs in tumours. For example, this has been implicated in the loss of 
expression of critical genes ultimately leading to the progression of breast tumours and 
includes the genes encoding the estrogen and progesterone receptors in approximately 
half of breast cancer cases (Lapidus et al., 1996; Ottaviano et al., 1994). 
Hypermethylation of the genes involved in cell cycle regulation, p16 and 14-3-3-sigma, 
has also been demonstrated in breast cancer (Ferguson et al., 2000; Herman et al., 1995). 
In cases of sporadic breast cancer, where BRCA1 mutations are not observed, loss of 
BRCA1 expression has been correlated to DNA methylation at the promoter of this gene 
(Bal et al., 2012; Dobrovic and Simpfendorfer, 1997). Inactivation of BRCA1 associated 
with promoter hypermethylation has also been seen in ovarian cancer and lung 
adenocarcinoma (Botana-Rial et al., 2012; Wang et al., 2012). Other genes frequently 
hypermethylated in breast can include Glutathione S-transferase (GSTP1) which protects 
against cytotoxic and carcinogenic agents (Esteller et al., 1998); E-cadherin which 
suppresses tumour invasion and metastasis (Graff et al., 1995); and Tissue inhibitor of 
metalloproteinase-3 (TIMP-3) which antagonizes matrix metalloproteinase activity and 
can suppress tumour growth, angiogenesis, invasion, and metastasis  (Bachman et al., 
1999).   
 
The assumption implicit in these studies is that the DNA hypermethylation is directly 
causative of the gene silencing and that it is a driver of tumourigenesis through the 
silencing of tumour suppressor genes. However a careful analysis of tumour ontology and 
analysis of the ‘normal’ cells from which tumours arise has suggested that this idea needs 
to be revised. In breast (Sproul et al., 2011) and other cancers (Sproul et al., 2012) 
hypermethylated genes were found to be already silent in the normal tissues from which 
the tumours arose, so that DNA methylation was acquired subsequent to gene repression 
rather than being a cause of it. The acquisition of DNA methylation as a consequence, 
rather than a cause, of gene silencing is also evident from the recent ENCODE data 
release where transcriptor factor binding is thought to block the acquisition of DNA 




 1.3.2. Histone Acetylation and Methylation in breast cancer  
 
In breast cancer, ‘aberrant’ histone modifications have also frequently been associated 
with silencing of tumour suppressor genes and genomic instability. The regions of partial 
(hypo)methylation discussed above show a correlation with both H3K9me3 and 
H3K27me3 and, interestingly, DNA methylation and these repressive histone 
modifications were allele specific and mutually exclusive to form domains of gene 
silencing (Hon et al., 2012).  Similarly, it has also been shown that genes subject to DNA 
hypermethylation in tumours tend to be repressed by the polycomb system (H3K27me3) 
in the normal cells from which the tumours arose (Sproul et al., 2012).   
 
H3K27me3 is associated with increased risk of cancer in colon cancer models as well as 
stem and progentitor cells (Ohm et al., 2007; Schlesinger et al., 2007). Overexpression of 
EZH2 (the H3K27 HMTase) occurs in a number of  malignancies, especially in those that 
are steroid dependent like breast cancer (Kleer et al., 2003). In normal breast, levels of 
EZH2 and H3K27me3 in luminal cells change dramatically during pregnancy, and Ezh2 
is required for alveologenesis, and progenitor cell proliferation (Pal et al., 2013). In 
human mammary epithelial cells, overexpression of EZH2 leads to an increase in 
anchorage-independent growth and cell invasion (Bracken et al., 2003; Kleer et al., 2003) 
and in basal-like tumours EZH2 promotes a gene expression programme in which both 
basal- and luminal-lineage genes are co-expressed (Granit et al., 2012). EZH2 is also 
involved in regulating estrogen-dependent transcription through a novel binding partner 
REA (repressor of estrogen receptor activity) which acts as a corepressor of the ER 
(Hwang et al., 2008).  
 
HDAC inhibitors can alter chromatin structure to allow re-expression of key genes that 
have been silenced in tumours in association with apoptosis/growth inhibition of the 
tumour cells (Khan and La Thangue, 2008; Marson, 2009). In ER –ve breast tumours, the 
HDAC inhibitors Scriptaid and Trichostatin A (TSA) promote increased of H3 and H4 
acetylation and re-expression of ER, leading to	   growth inhibition (Keen et al., 2003). 
Combination treatments with HDAC and DNA methyltransferase (DNMT) inhibitors 
have shown better clinical responses than either type of drugs alone. HDAC/DNMT 
inhibitor combinations have shown better re-expression of aberrantly silenced genes in a 
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number of cancer cell lines including breast as well as increased apoptosis of tumour cells 
(Belinsky et al., 2003; Cameron et al., 1999).  
 
A model of the role of histone methylation and the enzymes involved is shown in Figure 
1.17 (From review (Huang et al., 2011)).	  	  
	  
	  
Figure 1.17: Model of dynamic interplay of enzymes mediating methylation of histone 
lysines. Methylases are shown in pink and demethylases are shown in brown. (From Huang et al 
2011 review). 
 
The long non-coding RNA (lincRNA) HOTAIR is highly expressed in primary tumours 
and metastases where it has been linked to PRC2 recruitment and subsequent deposition 
of the H3K27me3 repressive mark (Chisholm et al., 2012; Gupta et al., 2010). 
Moreover it is possible to inhibit cancer invasiveness by depletion of HOTAIR and this 
effect was most prominent in cells with high PRC2 activity (Gupta et al., 2010). 
HOTAIR transcription is estrogen-mediated in breast cancer where it is thought to 
contribute to tumour progression (Bhan et al., 2013).  
Histone lysine-specific demethylase 1 (LSD1) is involved in demethylating lysine 4 of 
histone H3 (H3K4me1 and H3K4me2) in association with transcriptional activation (Shi 
et al., 2004). LSD1 is highly overexpressed in ER-ve breast tumours and its inhibition 
prevents tumour cell growth, making it a therapeutic target for this aggressive subtype of 
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breast cancer (Lim et al., 2010).  There is also mechanistic evidence for gene activation 
by interplay between ligand-bound nuclear receptors and histone methylation. In the ER-
positive breast cancer cell line (MCF7) genes with promoters co-bound by both LSD1 
and ERα could be stimulated by treatment with estrogen (Garcia-Bassets et al., 2007).  
LSD1 has also been demonstrated to have a complex relationship with HDAC inhibitors 
in human breast cancer cells. HDAC treatment actually causes increased H3K4me2 (the 
substrate of LSD1) whereas inhibition of LSD1 with Pargyline or siRNA causes 
increased acetylation of H3K9 (Huang et al., 2012). When combined these HDAC/LSD1 
inhibitor treatments cause increased H3K4me2 and H3K9Ac with growth inhibition of 
breast tumour cells, indicating a cooperative strategy for regulating gene expression 
(Huang et al., 2012).  
1.3.3. The nuclear periphery and cancer  
The nuclear periphery (see section 1.1.2.4.4). is generally associated with transcriptional 
silencing. Importantly the domains of DNA hypomethylation identified in colorectal 
tumors correlate with late replication and nuclear lamina attachment (LADs) (Berman et 
al., 2012). This has also been seen in breast cancer (Hon et al., 2012) (Figure 1.18) This 
suggests that the genome-wide changes in DNA methylation observed in cancer are 
linked to silencing mechanisms regulated by chromatin organization and the nuclear 
periphery, but the direct involvement of the nuclear periphery in tumourigenesis has not 
been investigated directly.   
 
Figure 1.18: Domains of hypomethylation correlate with late replication and the nuclear 
lamina in breast cancer. (A) Distribution of HCC1954 %mCG for 10-kb regions that are 
consistently early-, middle-, and late-replicating in four cell types, compared to the background 
genome (green). (B) Distribution of HCC1954 %mCG for 10-kb regions that are found in Tig3 
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lamina-associated domains (blue), compared to the background genome (gray).  (Figure taken 
from Hon et al., 2012) 
 
1.3.4.  Long-range epigenetic silencing (LRES) in cancer   
 
Misregulation of gene expression correlating with genetic and epigenetic lesions in 
tumourigenesis has been largely explored at the single gene level. However, there are 
increasing reports of contiguous genes being co-ordinately repressed in association with 
tumour progression - a phenomena which has become known as Long Range Epigenetic 
Silencing (LRES). One of the first examples of this was a 100kb region containing the 
HoxA gene cluster which was silenced in association with loss of active histone 
modifications and aberrant DNA methylation in breast cancer (Novak et al., 2006).  
In colorectal cancer, concordant gene silencing of a 4Mb region on chromosome 2q14.2, 
accompanied by DNA hypermethylation of a subset of CGIs in that region, was 
associated with repression of genes within the entire chromosome band despite CGIs at 
the promoters of many of these neighbouring genes remaining unmethylated (Frigola et 
al., 2006). LRES at this locus was also associated with the repressive histone 
modification H3K9me2 (Frigola et al., 2006).  Recently this same genomic region has 
also been shown to be repressed by LRES in prostate cancer in association with 
hypoacetylation of H3K9, H3K9me2, H3K27me3 and localised DNA hypermethylation 
(Devaney et al., 2011).  
 
Since this first seminal example of concordant silencing of a large chromosomal region in 
association with DNA hypermethylation in cancer, other genomic regions or 
“agglomerates” of  hypermethylated regions have been described. Analysis of  DNA 
methylation in breast cancer specimens and normal breast tissue identified large 
chromosomal regions (up to ~700 kb) of cancer-specific LRES which occurred 
frequently at gene clusters including the protocadherin family cluster (PCDH) on 
chromosome 5q31 (Novak et al., 2008). This region has also been identified as an LRES 
hypermethylated domain in colorectal adenomas and carcinomas where methylation of 
specific genes in the region mark progression along the adenoma-carcinoma transition 
(Dallosso et al., 2009). This region was also found to be hypermethylated in Wilms’ 
52	  
	  
tumour (Dallosso et al., 2012). Additionally, LRES associated with DNA 
hypermethylation at a 2.7 Mb region on chromosome 12q14 has been identified in gastric 
cancer (Park et al., 2011).  Cancer-associated hypermethylation of Ikaros, which belongs 
to a family of genes encoding transcription factors involved in regulating cell 
differentiation,  has also been shown to be embedded within a region described as LRES 
due to association with DNA hypermethylation and loss of H3K4me3 (Javierre et al., 
2011).  
Computational biology has been successfully employed to systematically identify LRES 
through the integration of trancriptomic and epigenomic data for different types of 
tumours. In bladder carcinoma a sliding window approach was used to generate scores 
for how well as gene’s expression correlated with that of its neighbours (Stransky et al., 
2006). This allowed regions of co-ordinately down-regulated genes to be identified and 
regions where this reduced expression was due to genomic copy number aberrations were 
eliminated allowing the identification of potential LRES domains (Stransky et al., 2006) 
(Figure 1.19).  Importantly this was the first (and only) study to incorporate a CGH 
analysis of copy number aberrations into the search for LRES. In all, 28 copy-number 
independent regions of deregulation were identified and these have been associated with 
increased histone methylation, both H3K9me3 and H3K27me3, and histone 
hypoacetylation, without any necessary change in DNA methylation (Stransky et al., 
2006; Vallot et al., 2010). Further work showed that regions of LRES can exist in subsets 
of bladder cancer and that this phenotype correlates with the higher stage and 
aggressiveness of the cancer (Vallot et al., 2010).  
Using a similar computational approach 47 LRES domains were identified in prostate 
cancer using a sliding window that seeks out windows of “lowly expressed genes”’ which 
were associated with gain of repressive histone and methylation marks (Coolen et al., 
2010). Although both of these studies describe the systematic identification of large 
regions of epigenetic repression in cancer there is no consensus as to how these regions 





Figure 1.19: Identifying LRES domains in Bladder Carcinoma. Transcriptome Correlation 
Maps (TCMs) showing scores of how well a gene’s expression correlates with seven 
neighbouring genes before (A) and after (B) removal of genes that are affected by a copy number 
aberration. Left panel – a copy-number independent region of co-ordinately misregulated genes 
(circled). Right panel – a copy-number dependent region of co-ordinately misregulated genes 
(circled) (From Stransky et al., 2006) 
 
By integrative analysis of coordinate gene expression and ER binding data, 11 regions of 
LRES in breast cancer were identified in association with estrogen signalling and altered 
chromatin topology as assessed by chromosome conformation capture (3C) (Hsu et al., 
2010).  It was shown that at one such locus on chromosome 16p11.2 the repression was 
estrogen-inducible in normal cells and was associated with the formation of a large DNA 
loop structure that brought together the promoters of the 14 silenced genes in the region 
(Hsu et al., 2010). Moreover it was found that in breast tumour cells this loop structure 
was not transient but a permanent feature of the cells indicating a novel mechanism of 
LRES involving alteration of the chromatin structure itself (Hsu et al., 2010). The 
existence of a permanent loop structure is contentious given that chromatin fibers are 
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constantly moving and undergoing nucleosomal rearrangements,  however it is possible 
that the  effects seen by Hsu et al due to persistent signalling stimulation of the ER leads 
to contacts between the gene promoters more frequently than would be expected under 
normal circumstances.    
Prior to my PhD, research in the field of long-range regulation was focussed on aberrant 
silencing (LRES) in cancer, as discussed in the examples above. At the time of writing 
this thesis the first example of long-range epigenetic activation (LREA) was published 
(January 2013). Bert et al (2013) show in prostate cancer, using an integrated genomic 
approach to uncover regions of multiple upregulated neighbouring genes, that these 
regions undergo epigenetic activation by chromatin remodelling and DNA methylation 
changes across the LREA domains. Furthermore the prostate cancer associated LREA 
regions contained the biomarker genes, oncogenes and microRNAs which were activated 








1.4 Aims of Thesis  
 
Identifying domains of coordinate misregulation in breast cancer with a 
view towards investigating the mechanism in terms of chromatin 
architecture  
 
The core aim of this thesis is to use publically available datasets to identify regions of 
misregulation in the breast cancer genome that are independent of genomic 
amplifications/deletions and could therefore be potential regions of epigenetic regulation 
(RER). This was to be achieved using expression microarray and CGH array datasets for 
breast tumours and cell lines to look for genes that fit the following criteria: 
1) The genes are positioned local to one another  
2) The genes in the region would be co-ordinately expressed   
3) The changes in gene expression would be independent of genomic changes that 
could account for the coordinate gene expression pattern 
LRES has become a common phenomenon in the cancer literature and has been attributed 
to a whole medley of gains/losses of various histone modifications and DNA methylation 
changes. Given that there is no consensus as to the cause of LRES my hypothesis was 
that nuclear organization, in particular chromatin architecture has a role in the 
misregulation of gene expression over such large regions of contiguous genes. Therefore, 
having identified co-ordinately misregulated regions in breast cancer tumours and cell 
lines, my aim was to investigate how compact the chromatin at these regions were, how 




















During my PhD I was fortunate to benefit from the excellent Core Scientific Services at 
the MRC Human Genetics Unit (HGU). Solutions and ingredients provided by these 
facilities are described below: 
 
 
 L-Broth: Tryptone 10 g, Yeast extract 5 g, NaCl 10 g, Glucose 1 g. Made up to 1 litre 
with water and autoclaved. 
 
L-Agar: 15 g agar was added to 1 litre L-broth to prepare solid media. 
 
Tris-HCl: Tris[hydroxymethyl]aminomethane (Tris base) was dissolved in sterile water 
and pH adjusted using HCl. 
 
EDTA: Ethyldiaminetetra-acetic acid di-sodium salt was dissolved in sterile water, solid 
NaOH added to bring pH to 8.0. 
 
TE buffer: 10 mM Tris.HCl (pH 8.0), 1mM EDTA 
 
PBS (Phosphate buffered saline): NaCl 8g, KCl 0.2g, Na2HPO4 1.44g, KH2PO4 0.24g , 
all  in a final volume of 1 litre of distilled water with the pH adjusted to 7.4. 
 
SSC (Saline Sodium Citrate) (20X): NaCl 175.3g; Sodium citrate 88.2g – in a final 




2.2. Cell Culture 
 
 2.2.1. Cell lines  
	  
Normal breast epithelial and cancer cell lines utilised for the experimental part of this 
thesis are listed in table 2.1. Culture conditions for all cell lines were 37°C with 5% CO2. 
Cell lines were stored at -80°C in fetal calf serum (FCS) supplemented with 10% DMSO 
(dimethyl sulfoxide) before transfer to liquid nitrogen storage tanks. Cells from liquid 
nitrogen storage were thawed at 37°C, transferred to their respective culture media and 
spun down by centrifugation (1000g for 4 mins). The cell pellet was then resuspended in 
the culture media and plated into either t25cm² or t75cm² tissue culture flasks depending 
on the number of cells thawed (GIBCO).  
 




Gene Cluster                     
(Neve et al., 2006) ER status Culture media  
MCF7 Luminal  positive  DMEM, 10% FCS, 1% P/S 
LY2 Luminal  positive  DMEM, 10% FCS, 1% P/S 
MDAMB231 Basal B negative DMEM, 10% FCS, 1% P/S 
MDAMB468 Basal A negative L-15, 10%, 1% P/S 
MDAMB361 Luminal positive  DMEM, 10% FCS, 1% P/S 
HMLE NA                            NA MEBM, 1% P/S 
FCS, fetal calf serum; P/S, Penicillin (10,000 units/ml)/Streptomycin (650µg/ml), DMEM, 
Dulbecco’s modified Eagle’s medium  (GIBCO #11965-092); RPMI, RPMI medium 1640 (GIBCO 
#27016-021); Ham’s F12, F-12 nutrient mixture (Ham) (GIBCO #11039-021); L15, Leibovitz’s L-
15 medium (GIBCO #11415-064); MEGM, Mammary Epithelial Growth Media (Lonza #CC-3151). 
 
 
Cells were grown to a semi-confluent state (as assessed by light microscropy at 40x 
magnification) before being harvested and transferred into new culture flasks to ensure 
their continued growth. To passage adherent cells, all culture media was removed by 
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careful aspiration and then the cells washed with PBS (phosphate buffered saline 
solution). Trypsin-EDTA (Sigma) (10%) was added and the flask incubated at 37°C for 
3-5 minutes depending on the cell line. Cells were dislodged by agitation of the flask and 
combined with culture medium (90%) to inactivate the trypsin-EDTA. Cells were 
pelleted by centrifugation (1000g for 4 minutes) and resuspended in culture media for 
plating in new culture flasks. A confluent flask of cells was typically split 1:3.  
	  
 2.2.2. Synthesis of Stripped Fetal Calf Serum 
	  
For hormone deprivation experiments FCS was stripped of all endogenous steroids using 
the following protocol obtained from Ben Skerry (Edinburgh Cancer Research Centre). 
Fetal calf serum (1 litre) was heat inactivated in a waterbath set at 56°C for 30 minutes 
before adding 2000U/l of sulphatase (stock 22400U/g therefore 0.089g/litre needed). The 
serum was incubated with the sulphatase for a further 2 hours at 37°C and then the pH 
adjusted to 4.2 using HCl. A charcoal mix (for 1 litre: 5g charcoal, 25mg dextran T70, 
50ml water) was then added and incubated overnight at 4°C with a magnetic pellet 
stirring the mixture. The following day the charcoal was removed by centrifugation at 
500x g for 30mins at 4°C. The pH was then re-adjusted to 4.2 and a second charcoal mix 
(as above) added. This was incubated as before at 4°C overnight with magnetic stirring. 
The next day this second charcoal mix was removed by centrifugation at 10,000 rpm for 
30mins at 4°C. This centrifugation step was repeated to remove any residual charcoal and 
the pH adjusted to 7.2 with NaOH. Stripped FCS was filter sterilised, aliquoted into 50ml 
falcon tubes and stored at -20°C. 
2.2.3. Estrogen treatment of cells in culture 
	  
 
Semi-confluent cell cultures were transferred into phenol-free DMEM (Gibco) 
supplemented with 5% L-Glutamine, 5% P/S and 10% stripped FCS. Cell cultures were 
kept under “starvation” conditions in this media for 72 hours in a cell culture incubator at 
37°C and 5% CO2. Cultures were then induced with 100nM of 17ß-estradiol (Sigma) for 




2.3. Fluorescence in-situ hybridization (FISH) 
 
2.3.1. Preparing FISH probes 
Genomic clones used for FISH 
The UCSC browser was used to identify genomic clones flanking regions of interest for 
FISH experiments. Fosmids were obtained from the BACPAC Resources Centre at the 
Children’s Hospital Oakland Research Institute (http://bacpac.chori.org/). All fosmid 
clones were provided as bacterial stab cultures in agar. A full list of all fosmids used in 
this thesis are listed in Table 2.2 and the regions for which probe pairs were used in Table 
2.3.  
 
Table 2.2 Names and Genomic Positions of Fosmids used in this thesis.  All 
coordinates are based on hg19/Feb 2009 release of the UCSC genome browser 






Table 2.3  Fosmids used as probes for each FISH locus with coverage (kb).  
 
Bacterial culture and stocks 
Fosmids were streaked out onto LB-agar plates containing chloramphenicol (25µg/ml - 
made up in Ethanol) and incubated overnight at 37°C. Single colonies were picked using 
a sterile pipette tip which was added to a 5ml L-Broth supplemented with 
chloramphenicol (25µg/ml ). These were grown overnight in a 37°C incubator with 
shaking. Bacterial stocks were made of all fosmid clones taking a 1:1 mixture of the 
overnight culture of L-Broth:Glycerol. This mixture was stored at -70°C.  
 
Fosmid minipreps 
L-Broth cultures were pelleted by centrifugation at 16,000g for 30 seconds and 
resuspended in 200 µl GTE buffer (50mM glucose, 25 mM Tris pH 8, 10 mM EDTA) 
containing freshly added lyzozyme (Sigma) for 5 minutes at room temperature. To this 
400µl of ice-cold lysis buffer (0.2 M NaOH, 1% SDS) were added and mixed by 
inversion before a further 5 minute incubation on ice. This was followed by the addition 
of 300µl acetate buffer (5M potassium acetate, 11.5% glacial acetic acid) to precipitate 
out cell debris by 5 minute incubation on ice (white flocculent precipitate formed in 
tube). The precipitate was pelleted by centriguation at 16,000g for 5 minute at 4°C and 
the supernatant was combined with an equal volume of phenol:chloroform. Following 
centrifugation at 4°C for 2min at 16,000g the aqueous top layer was removed to a fresh 
tube and mixed with an equal volume of isopropanol and incubated at -20°C for at least 
one hour. The DNA was pelleted by 15min centrifugation at 16,000g at 4oC, washed in 
70% ethanol and air-dried before resuspension in 20-30µl of TE (depending on the pellet 
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size). Rnase A (1mg) was added to the resuspended DNA and incubated for 5 minutes at 
37°C. All fosmid DNA preparations were stored at -20°C. 
 
 
Labelling of probes by nick translation 
DNA probes for FISH were labeled by nick translation to incorporate either biotin-16-
dUTP or digoxigenin-11-dUTP (Roche). To do this 1-1.5 µg DNA were added to 4µl 
nick translation salts (0.5 M Tris-HCl pH 7.5, 0.1M MgSO4, 1mM DT, 500 µg/ml BSA) 
with 5 µl of each of 0.5 mM dATP, dCTP and dGTP. Then either 5 µl of 1mM biotin-16-
dUTP or 3 µl of 1mM digoxigenin-11-dUTP with 2 µl of 0.5mM dTTP were added to the 
mixture. DNaseI (Invitrogen) was diluted 1:500 and added to the reaction to a final 
concentration of 1U/ml. The reaction was made up to 40 µl with water and 1 µl of DNA 
polymerase I was added (10U/µl). After mixing the nick translation reaction ws left to 
proceed at 16°C for 90 minutes. Nick translation was stopped by the addition of 3µl of 
EDTA and 2µl of 20% SDS. Unincorporated nucleotides and enzymes were removed 
using Quick Spin Columns (Roche) as per the manufacturer’s instructions and eluting the 
labeled probes with TE pH7.5. Labelled probes were quantified (as below) and stored at -
20°C.  
Quantitation of labeled FISH probes 
Labelled DNA probes for FISH were spotted onto a nitrocellulose membrane which had 
been prepared by soaking in water, followed by 20xSSC for 10 minutes and allowed to 
dry. Probes were spotted in dilutions of 1:500, 1:1000, 1:5000 and 1:10000 and allowed 
to dry on the membrane. Standards of known concentration for biotin and digoxigenin 
(Roche) were also spotted on the membrane at 20, 10, 2 and 1pg. Once dry, the DNA was 
cross-linked to the membrane by exposure to UV irradiation (150mJ). The membrane 
was then soaked briefly in buffer 1 (0.1M Tris-HCl pH 7.5, 0.15M NaCl) at room 
temperature before being immersed in block solution (buffer 1 supplemented with 3% 
BSA) at 60°C for 60 mins. The blocked membrane was then incubated at room 
temperature (with gentle agitation) with strepavidin-alkaline phosphatase and anti-
digoxigenin-alkaline phosphatase (diluted 1:1000, Roche). The membrane was then 
washed twice in buffer for 15 mins at room temperature with agitation, then incubated in 
a sealed polythene bag with 5ml of buffer 3 (0.1M Tris-HCl, pH 9.5) and 2 drops from 
63	  
	  
each solution in the alkaline phosphatase substrate kit VI (Vector laboratories). A blue 
reaction product is formed by 5-bromo-4-chloro-3-idolyl phosphate and nitoblue 
tetrazoilium and allows estimation of the concentration of labeled DNA by comparison 
with the standards of known concentration.  
 
2.3.2. Preparing cells for 2D FISH 
KaryoMAX Colcemid (0.1 µg/ml) was added to cell culture 30mins prior to harvest to 
arrest the cells in metaphase through inactivation of spindle microtubules. This is 
important to increase the number of metaphase chromosome spreads in the preparation 
for karyotyping the cells (when confirming probe localization see section 2.4.8). Cells 
were then rinsed in PBS and resuspended in hypotonic solution (75mM KCl). Hypotonic 
solution was added gradually (drop-wise) with constant vortex agitation to avoid the 
formation of clumps keeping a single cell suspension. Cells were left to swell in 
hypotonic solution for 10 minutes at room temperature before centrifugation for 5 
minutes at 400g and aspirating off the hypotonic solution. The nuclear pellet was then 
resuspended in MAA fix (3:1 methanol:acetic acid) in a drop-wise manner with constant 
agitation. Fix was then removed by centrifugation and the pellet resuspended in fresh 
MAA fix to be stored at -20°C or used immediately for preparation of FISH slides. 
 
 2.3.3. Preparation of slides for 2D FISH 
Glass slides that had been soaked in ethanol (with a few drops of concentrated HCl) for at 
least an hour were cleaned and dried for use. The fixed cell preparations were centrifuged 
for 5 minutes at 1000g and fresh fixing solution added (a few drops or until the 
suspension was slightly “milky” in appearance). From a height of approximately 30 cm 
(“arm’s-length”) a drop of this suspension was dropped using a fine-tipped pastette onto 
the glass slide. Quality of the spread was improved by humidities of around 50% and if 
the cells were moist (by breathing on the slide prior to dropping). Slides were kept for 2-7 
days before being used for hybridization or artificially aged by baking the slides at 60°C 




 2.3.4. Preparation of tissue sections for 3D FISH 
Parrafin-embedded tissue sections were obtained with help from Jeremy Thomas 
(Consultant Pathologist, The Western General Hospital). Usage of tumour material was 
approved by the Lothian Research Ethics Committee (08/S1101/41) and obtained under 
the auspices of Experimental Cancer Medicine Centre programme (Edinburgh). Tissue 
sections for FISH were cut by Lynne Johnstone (Welcome Trust Clinical Research 
Facility)  at 6µm and laid on Superfrost+ slides.  
The slides were baked at 65°C for 30 minutes to melt the wax, washed four times in 
200ml xylene for 10 minutes, rehydrated through an ethanol series (4x 10 minute washes 
in each of 100%, 95% and 70% ethanol) before being microwaved for a further 30 
minutes in 0.1M citrate buffer (pH 6). The slides were then allowed to cool for 20 
minutes in the citrate buffer solution before being washed and stored in water. Slides 
were rinsed in 2x SCC before use.  
 
 2.3.5. Hybridisation of labeled FISH probes 
For 2D FISH, slides were incubated for 1 hour at 37°C with RNaseA (120 µg/ml) in 2 x 
SSC, rinsed in 2 x SSC at room temperature and then dehydrated through a series of 2 
minute ethanol washes (70%, 90% then 100%) and left to air dry. Slides were then heated 
in a 60°C oven for 5 minutes before being transferred to denature solution (70% 
formamide in 2 x SCC pH7.5) at 70°C for 1 minute. After denaturation slides were then 
transferred to 70% ethanol on ice for 2 minutes before further dehydration in 90% and 
100% ethanol at room temperature.  
For 3D FISH slides were washed in 2 x SSC at 75°C for 5 minutes  then denatured for 
3minutes at 75°C in 70% formamide/2xSCC pH7.5. Slides were then placed in ice cold 
100% ethanol for 3 minutes before further dehydration in 90% and 100% ethanol at room 
temperature (as for 2D FISH).  
The FISH probes were prepared for hybridization by combining 100-150ng of labeled 
DNA with 5 µg salmon sperm DNA per slide and 12µg of human Cot1 (supplier) DNA 
per probe. To this 2 x volume ethanol was added and the probes spun under high heat (in 
65	  
	  
a lyopholiser) to produce a white pellet of DNA which was resuspended in 25µl of 
freshly prepared hybridization mix (50% deionised formamide, 10% dextran sulphate and 
1%Tween 20 in 2 X SSC). Probes were incubated at 70°C for 5 minutes to allow 
denaturation and then 37°C for 15 minutes so they could reanneal before being pipetted 
onto 22 x 22mm coverslips (on a hot plate) and picked up using the slides. The slides 
were sealed using TipTop rubber solution around the coverslip and incubated in a 37°C 
waterbath in a covered tray overnight (or 16 hours). 
 
 
 2.3.6. Washing and detection of FISH probes 
After overnight hybridization, the rubber solution sealing the slides was removed and the 
slides were washed 4 x in 2 x SSC for 3 minutes at 45°C.  Coverslips fell off in the 
solution during the first wash and if they did not were gently agitated in the solution until 
they did. Slides were then washed 4x in 0.1 x SSC for 3 minutes at 60°C and transferred 
to 4 x SSC/0.1% Tween 20 at room temperature.  
 
Slides were incubated for 5 minutes with blocking buffer (4X SSC, 5% Marvel) before 
antibody detection.  All FISH antibodies were diluted in 5% Marvel in 4 X SSC.  
Digoxigenin-labelled probes were detected using sequential layers of Fluorescein 
isothiocyanate (FITC)-conjugated anti-digoxygenin (200ug/ml stock diluted  1:20) and 
FITC-conjugated anti-sheep IgG (1.5mg/ml diluted 1:100). Biotin-labelled probes were 
detected with sequential layers of Texas Red (TR)-conjugated avidin (1mg/ml stock 
diluted 1:500), biotinylated anti-avidin (BAA) (0.5mg/ul diluted 1:100) and TR-
conjugated avidin (1mg/ul diluted 1:500) (Suppliers for all of these reagents). All 
antibodies were obtained from Vector Laboratories with the exception of FITC-
conjugated anti-digoxygenin which was obtained from Roche. Detection was carried out 
in a humidity chamber for 30 minutes which was kept at 37°C. Slides were washed 3x 
after each antibody-incubation for 2 mins (with agitation) in 4 X SSC/0.1% Tween at 
37°C before addition for the next antibody layer.  
 
Slides for 2D FISH were mounted in Vectashield (Vector) with 0.5µg/ml DAPI. Slides 
for 3D FISH were incubated in 4 X SSC/1% Tween with 50ng/ml DAPI for 5 minutes 
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before mounting in Vectashield (Vector). Coverslips on all slides were sealed in place 
with rubber solution.  
 
 2.3.7. Image capture  
Examination of nuclei after 2D FISH was carried out using a Hamamatsu Orca AG CCD 
camera (Hamamatsu Photonics (UK) Ltd, Welwyn Garden City, UK) fitted to a Zeiss 
Axioplan II microscope with Plan-neofluar oil-immersion objectives, a 100 W Hg source 
and Chroma #8300 triple band pass filter set. Image capture and analysis of nuclear size 
and distance between the hybridization signals was performed with scripts written for 
IPLab Spectrum (Scanalytics Copr, Fairfax, VA) as described in section 2.4.10. 
Examination of nuclei from tissue sections by 3D FISH was carried out using a 
Hamamatsu Orca AG CCD camera (Hamamatsu Photonics (UK) Ltd, Welwyn Garden 
City, UK), Zeiss Axioplan II fluorescence microscope with Plan-neofluar or Plan 
apochromat objectives, a Lumen 200W metal halide light source (Prior Scientific 
Instruments, Cambridge, UK) and Chroma #89014ET single excitation and emission 
filters (Chroma Technology Corp., Rockingham, VT) with the excitation and emission 
filters installed in Prior motorised filter wheels. A piezoelectrically driven objective 
mount (PIFOC model P-721, Physik Instrumente GmbH & Co, Karlsruhe) was used to 
control movement in the z dimension. Hardware control, image capture and analysis were 
performed using Volocity (Perkinelmer Inc, Waltham, MA). Images were captured at 200 
nm intervals in the z axis and were deconvolved using a calculated PSF with the 
constrained iterative algorithm of Volocity. Image analysis was carried out using the 




2.3.8. Confirmation of probe localisation by FISH on 
metaphase preparations 
 The genomic localisation of all probes was verified by 2D FISH of metaphase spread 
preparations from cells with normal karyotype. All MAA fixed cell preparations for this 
analysis were obtained from Shelagh Boyle. Karyotyping and confirmation of probe 
localisation to the correct chromosome was carried out with the aid of expertise in this 
area from Shelagh Boyle and Elizabeth Kerr. An example of this, for RER locus 2,  is 
shown in figure 2.1.  
 
 
Figure 2.1. Confirmation of FISH probe localisation. Metaphase spreads from human blood 
fibroblast cells (obtained from Shelagh Boyle) were hybridised with digoxigenin- and biotin- labelled 
probes by FISH to verify their chromosomal localisation. Shown are the probes for RER locus 2 with 




2.3.9.  Scripts for image analysis 
All scripts for image analysis of 2D FISH images were written for IPLab by Paul Perry 
(Microscopy & Imaging Department).  Scripts for analysis of 3D FISH images in 
Velocity were written by Shelagh Boyle (Research Assistant, Bickmore Lab) using 
packages set up for Velocity by Matthew Pearson (Microscopy & Imaging Department).  
 
To calculate inter-probe distances in 2D, between 50-60 of the most evenly shaped nuclei 
with clear pairs of hybridisation signals were selected by systematic scanning of slides by 
eye. For each probe the IPLab script calculated the pixel in the image with the highest 
intensity. The highest intensity pixel in the centroid for each probe in a pair were selected 
and the distance between them calculated. For analysis of flattened 3D images from 
tissue section FISH the inter-probe distances were calculated by taking the centroid of 
each probe in the pair and calculating the distances between them. All inter-probe 
distances from 2D and 3D FISH were converted from pixels to microns by 
multiplification by 0.134µm. The 2D images were also segmented by DAPI staining to 
calculate the nuclear area (pixels). This measurement was used to calculate the nuclear 
radius which was also converted to µm units of measurement.  This analysis is illustrated 
in Figure 2.2.   
 
For 2D FISH data, inter-probe distances (d) and radii (r) were then squared and 
normalised to account for differences in nuclear size. Therefore all normalised inter-
probe distances described in this thesis are ratios of d2/r2. The difference between the 
distribution of squared inter-probe distances between datasets was assessed statistically 






Figure 2.2: Measuring the inter-probe distance  and nuclear area from FISH analysis. The 
script for image analysis was written for IPLab by Paul Perry. Shown is an example of a DAPI 
stained nucleus (blue channel) with FISH signals (red and green channels) representing the locus 
of interest (A). The image was segmented by the intensity of DAPI staining and the nuclear area 
estimated by the number of pixels within the segment (B). The image was then split to show the 
red (TxRd) and green (FITC) channels only and a paint tool was used to manually select the pairs 
of probes (C). The signal intensities for the red and green probes were calculated. The pixel with 
the highest signal intensity for each probe was to calculate the distance between the two probes 
(D).  The script generated a data table for each image giving the nuclear area and interprobe 









To determine the radial positioning of probe pairs a nuclear erosion script was used in 
IPLab for analysis of 2D FISH images. This script eroded the nuclei into five concentric 
shells of equal area as illustrated in Figure 2.3. It was then possible to count the 
distribution of probe hybridisation signals across the erosion shells in 50-60 nuclei. The 
number of hybridisation signals in each shell in the dataset were calculated as a 
percentage of the total number of signals and plotted as a histogram. Significance of 
changes in radial positioning of probes between cell lines was assessed using the fisher 
test with a cut off of p<0.05.    
 
This analysis was not carried on imaging data from 3D FISH of tissue sections as the 
nuclear erosion script is limited to analysis of single nuclei of regular shape that are not 








Figure 2.3: Measuring the probe localisation by nuclear erosion of FISH images. The script 
for image analysis was written for IPLab by Paul Perry. Shown is an example of a DAPI stained 
nucleus (blue channel) with FISH signals (green and red). The DAPI segment of the image was 
eroded into five consecutive shells of equal nuclear area (as calculated by the number of pixels in 





2.4. Computational Biology 
A number of websites were used for computational components of the work compiled in 
this thesis: 
Ensembl   http://www.ensembl.org/ 
R-Project   http://www.r-project.org/ 
Bioconductor  http://www.bioconductor.org/ 
Gorilla   http://cbl-gorilla.cs.technion.ac.il/ 
UCSC Browser http://ucsc.genome.edu/ 
OMIM   http://ww.ncbi.nlm.nih.gov/omim 
GEO    http://ww.ncbi.nlm.nih.gov/geo 
Circos   http://www.circos.ca/ 
Tinn R   http://www.sciviews.org/Tinn-R/index.html 
 
Basic quantitative analysis of data was carried out in Excel spreadsheets (Microsoft) 
using default settings.  
 
All statistical analysis was carried out in R open source statistical language (mainly 
version 2.15.1 and 2.15.2). 
 
Bar charts were drawn in Excel (Microsoft). Circular visualization of data was carried out 
in Circos. Boxplots were drawn in R where the median of the data was expressed as a 
heavy line and the boxed area representing the interquartile range (outliers were 
removed). Heat maps were plotted using the image function in R. TCS maps were plotted 
in R with a heatmap image representing the chromosome ideogram (coordinates obtained 
from Duncan Sproul).  
 
A large component of the work compiled in this thesis (chapters 3 & 6) was based on 
computational analysis of publically available datasets in R. The methods used for these 












Identifying Regions of Epigenetic Regulation 





Large scale gene expression profiling studies have helped our understanding of the 
clinical and pathological differences in breast cancer, leading to the conclusion that it is 
not a single disease but a collection of molecularly heterogeneous disorders (Sørlie, 2004; 
Sotiriou and Pusztai, 2009). Whilst genetic aberrations which cause misregulation of 
genes and genomic stability are a hallmark of cancer, epigenetic changes also have 
crucial influences on tumourigenesis and cancer treatment and could therefore be 
expected to contribute to breast tumour heterogeneity (Jones and Baylin, 2007; 
Kristensen et al., 2009).  
  
Long range epigenetic silencing (LRES) has become a common term to help explain 
some of the aberrant gene expression seen in cancer (Coolen et al., 2010; Dallosso et al., 
2012, 2009; Frigola et al., 2006; Hsu et al., 2010; Javierre et al., 2011; Novak et al., 2008, 
2006; Park et al., 2011; Stransky et al., 2006; Vallot et al., 2010). Importantly the LRES 
status has been correlated with aggressiveness of tumours and therefore has implications 
for patient prognoses (Dallosso et al., 2009; Vallot et al., 2010). Therefore, where 
previous classification of tumours has been based on traditional methods like 
histopathological grading and staging with newer prognostic predictions based on 
molecular signatures, finally an epigenetic classification is emerging which describes the 
link between the misregulation of genes in cancer and disease pathways.  
 
I set out to systematically identify large contiguous regions of the breast cancer genome 
that were misregulated, potentially by epigenetic mechanisms. I used a computational 
approach akin to that used previously in the study of breast and bladder cancer (Reyal et 
al., 2005; Stransky et al., 2006). My intention was to mine publically available breast 
cancer datasets for which both gene expression and copy number data were available. 
The latter was important to eliminate copy number gain or loss as causative of increased 





3.2.1: Datasets used  
Stransky et al. 2006. Affymetrix Human GenomeU95A & U95Av2 arrays consisting of 
12,500 probes were used for analysis of gene expression on 57 bladder carcinomas. 
DNAs were also analyzed on CGH microarrays (HumArray 2.0) containing 2,385 BAC 
clones at 1.3 Mb intervals.  Normalized expression data was obtained from ArrayExpress 
(E-TABM-147) and normalised CGH from  http://microarrays.curie.fr/publications/ 
oncologie_moleculaire/bladder_TCM/. (Stransky et al., 2006) 
 
Jöhnsson et al., 2010. Oligonucleotide arrays (Gene Expression Omnibus, GEO, 
platform GPL5345) and BAC microarrays (GEO platform GPL4723) consisting of 
32,000 clones were used for global analysis of gene expression and copy number in 359 
breast tumours (Jönsson et al., 2010). I used expression and copy number data for 356 
tumours common to both datasets.  All gene identifiers were mapped to Ensembl 
annotations using Ensembl BioMart. Where multiple probes were mapped to a gene the 
probe with the highest median expression was retained and the remaining multiple probes 
discarded.  
 
Chin et al., 2006. Copy number profiles for 145 primary breast tumours using Scanning 
(2464 BACs at 1Mb intervals) and OncoBAC arrays (960 P1, PAC, or BAC clones). 
Gene expression profiling was available for 130 breast tumours (Affymetrix U133A 
arrays) (Chin et al., 2006).  Expression and copy number data for 96 tumours common to 
both datasets were used for analysis here.  
 
Chen et al., 2010.  Expression data for 42 invasive ductal carcinoma (IDCs) samples and 
143 breast tissue samples with normal histopathology were obtained using Affymetrix 
U133Plus 2.0 GeneChips (Chen et al., 2009). Raw data was processed using standardized 





Neve et al., 2006.  Expression profiles for 51 breast cancer cell lines were obtained using 
Affymetrix U133A arrays and copy number data using Scanning (2464 BACs at 1Mb 
intervals) and OncoBAC (1860 P1, PAC, or BAC clones) arrays(Richard M Neve et al., 
2006). All expression and CGH data were obtained from the Lawrence Berkeley 
Laboratories website (http://cancer.lbl. gov/breastcancer/data.php). Expression and copy 
number data for 48 cell lines common to both datasets were used for analysis here. Raw 
data was processed using RMA normalisation (Bioconductor Affy package) and mapped 
to Ensembl gene annotation.  
	  
3.2.2: Removing genes affected by copy number aberrations  
In order to detect chromosomal copy number aberrations at high resolution, array 
comparative genomic hybridisation (aCGH) is used. The test DNA sample is hybridised 
with normal DNA (two copies of autosomal chromosomes) on arrays producing "clones" 
at base pair positions along the chromosomes. This produces log2 ratios which can be 
converted to "calls" for copy number gain (e.g. +1, +2, etc), loss (-1, -2, etc) or no change 
(0). I used the ‘R’ package CGHcall (van de Wiel et al., 2007) which is available via 
Bioconductor. This algorithm combines features of previously developed methods (e.g. 
chromosome breakpoint and segmentation information) to obtain accurate "calls" for the 
copy number status of each clone.  
 
Genome coordinates for aCGH data clones were mapped to UCSC Human Genome 
browser (http://genome.ucsc.edu/) build GRCh37/hg19 assembly. Clones were then 
mapped to their nearest Ensembl gene in the expression data for the respective tumours or 
cell lines. Copy-number affected genes (gain/loss) in the respective samples were 
removed from the corresponding expression data for those samples to produce a copy-
number independent gene expression file. This data file was used for all subsequent 
analysis.  
 
Example CGH profiles (plotted as log2 ratios) with the copy number status determined 
by CGHcall denoted by colour, are shown in Figure 3.1 for three breast cancer cell lines 
from Neve et al., (2006) and three breast tumours from Jönsson et al., (2010). CGH 
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profiles for all 48 breast cancer cell lines and 356 tumours are available in supplementary 
data (Appendices I & II, respectively). 
	  
Figure 3.1: DNA Copy Number Profiles in Breast Cancer Cell Lines & Tumours. The log2 
(sample:ref) ratios of the clones were plotted against chromosomal position. Regions of loss 







3.3.1: A sliding window approach to identify genomic regions 
with coordinate gene expression signatures  
 
 
An approach for visualising “Transcriptome Correlation Maps” (TCM) which highlight 
regions of coordinate gene expression patterns across the genome has previously been 
developed for invasive ductal breast carcinomas (Reyal et al., 2005). This involved 
calculating, for each gene, the correlation between its expression with that of its 
neighbours and identified a number of clusters of genes that were coordinately regulated 
in the tumours. The most significant of these coordinated clusters matched well-
established sites of frequently occurring genomic aberrations in breast cancer (e.g. 1q, 8p, 
8q, 16p, 16q, 17q and 20q) (Reyal et al., 2005). By later disqualifying regions where the 
coordinated expression was attributed to a copy number variation, this approach was 
adapted to identify 28 regions in the genome that are coordinately regulated by long 
range epigenetic silencing (LRES) in bladder carcinoma (Stransky et al., 2006). LRES 
regions have also been identified in the prostate cancer genome using a similar approach 
(Coolen et al., 2010). Whereas this latter method took into account the distance between 
neighbouring genes, it also selected specifically for regions of low gene expression.  
 
As I was primarily interested in coordinate regulation of neighbouring genes by higher 
order chromatin structure, regardless of whether it be repressive or activating in nature, I 
decided the former approach developed by the Radvanyi lab was more appropriate as it 
accounted for both and was more feasible to assess statistically with a set number of 
genes in the sliding window.   
 
I adopted a running score method equivalent to that used to find LRES regions in bladder 
cancer, and applied it to breast cancer. For each gene a transcriptional correlation score 
(TCS) was calculated which was the sum of the Spearman Rank correlation scores 
between the RNA levels of each gene with that of each of its neighbouring (2n) genes. I 
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developed an algorithm that would then calculate the TCS for all the genes in the dataset 
using a sliding window of 2n+1 genes (where n is the number of genes either side of the 
gene of interest). A schematic representation of this sliding window approach is shown in 




Figure 3.2: Sliding Window Approach to Identifying Regions of Coordinate Expression. For 
each  gene  the  Spearman Rank Correlation Score is calculated for the expression level of  that  
gene  with  each  of  its  neighbours  across  all  the  samples in a  dataset. The scores  for  these  
genes  are  then  summed  together  to get the overall score for each gene. A sliding window 




3.3.2 Assessing Significance & delineation of regions 
 
Having developed a method for assigning TCSs to genes in cancer expression datasets, I 
next wanted to use these scores to identify regions of co-ordinate gene expression in 
breast cancer. These would be expected to be composed of multiple contiguous genes 
with high TCS scores. As shown in the example in Figure 3.3 visual inspection of the 
TCS data using positional maps of the chromosomes shows that there are regions 
containing clusters of genes with high TCS scores, which form distinct peaks in the maps.   
	  
Figure 3.3: Map of transcription correlation for chromosome 17 for 356 breast tumours. 
Plotted are the transcription correlation scores (TCSs) for each gene, representing the degree of 
correlation between the expression profile or each gene with its neighbouring genes.  	  
	  
Next I examined the distribution of the TCSs using a histogram which showed that the 
data resembled a normal distribution with a long positive tail (Figure 3.4A). This 
suggests that there is random variation in the TCSs but that there are some genes which 
have elevated scores. To further examine the distribution of the TCS data I plotted a 
normal Quantile-Quantile (Q-Q)  plot (Figure 3.4B). This showed a strong concordance 
between the TCS scores and a normal distribution but had a tail of outliers at the high 
end. This confirmed my visual observation from the histogram (Figure 3.4A) and 







Figure 3.4: TCS data distribution. (A) histogram showing the distribution of all the calculated 
transcription correlation scores (TCS) across samples  (B) Normal Q-Q plot of the calculated 
TCSs across samples The Q-Q plot was used to plot the quantiles of calculated correlation 
coefficient against that derived from a normal distribution. Points deviating from the red line 




As a quantitative assessment I tested the normality of the data using the Kolmogorov-
Smirnov test which confirmed this deviation (p-value < 2.2e-16).  
 
I therefore identified regions of interest by using z-scores to identify outliers and 
positional information to delineate regions containing multiple outliers. To do this I used 
the mean and standard deviations of the TCS score distribution to calculate a z-score for 
each gene. This was then used to calculate a p-value for each gene based on the 
probability of observing this z-score in a normal distribution. A  p-value threshold was 
set at p<0.05 to determine which genes showed significantly high TCS indicative of 
coordinated gene expression signatures.  
 
Regions were then delineated by extracting n number of genes either side of the 
significant TCS genes (to get all the genes in the sliding window). Regions containing < 
2 significant TCS genes were discarded and overlapping regions were merged together. 
The regions were then further refined by calculating the median value of gene expression 
for each gene across all samples in the dataset and working out the correlation between 
this median for each gene with the rest of the region. It was then possible to assign p-
values (Spearman Rank test) for how well correlated each gene was with the rest of the 
region. The regions were thereby “trimmed” to the first and last gene that had a p value 
<0.05.  
 
3.3.3: Verifying Method with Published Literature.  
 
I validated my algorithm for detecting regions of coordinate regulation by comparison to 
the published bladder carcinoma study (Stransky et al., 2006). I used my sliding window 
algorithm with n=7 (2n+1=15 gene window) neighbouring genes as in Stransky et al. 
(2006). Figure 3.5 compares the transcriptional correlation map of chromosome 16 from 
the Stransky et al (2006) supplementary online material (Figure 3.5A: upper panel) and a 
map generated by my algorithm (Figure 3.5A:  lower panel). These data show that my 




As I was primarily interested in copy number independent coordinate misregulation I 
used copy-number independent gene expression data to determine where the regions of 
coordinate expression/repression were located (file created as described in section 3.2.2.). 
A significance threshold was established using z scores (cut off p-value <0.05).  Stransky 
et al (2006) do not describe all the genes in the sliding window but only the significant 
genes in the 28 regions of LRES. Figure 3.5B shows that using the scores generated with 
my TCS algorithm the genes described in Stransky et al (2006) as having correlated 
expression with their neighbouring genes also show significantly high scores in the data I 
generated compared with the rest of the genes on the array (Wilcox p <2.2e-16) .  
 
However, I also found a number of "extra" regions that were not described in Stransky et 
al (2006). It is possible that additional criteria were used to exclude these regions 
which are not described in the publication. One contributing factor could be that in their 
analysis they first identified copy-number dependent regions of coordinate expression 
and then from these regions eliminated those containing a copy number aberrations, 
whereas I used the z score approach (rather than permutations) on data that was copy 
number independent to begin with and therefore had more regions from the start. Also 
Stransky et al (2006) describe only genes with significant scores and not all the genes in 
each region. Given that it is seldom possible to reproduce analysis on published 
microarray data 100% of the time (Ioannidis et al., 2010) I was confident that as I have 
recapitulated a significant proportion of their data (Fisher p<2.2e-16) and produced TCS 
maps akin to those in their supplementary materials online, I had successfully verified the 





Figure 3.5: Published data on bladder carcinoma is reproducible using an algorithm for 
identifying regions of coordinate expression. (A) Transcription Correlation Map (TCM) for  
chromosome  16 produced  by Stransky et al (2006)  (upper panel) matches  the TCM pattern I 
produced for this chromosome  (bottom  panel).  (B)  Genes from  Stransky et al.,  (2006) show 
significantly  higher  Transcription  Correlation  (TC)  scores  in  the  data  I  generated  compared 




3.3.4: The Effect of Varying the Window Size  
 
The number of genes with significant scores (p<0.05) was calculated for 2n = 1 to 22 
neighbouring genes (Figure 3.6). As the number of neighbours increases beyond n=10 the 
number of significant genes I detected plateaued. Therefore I chose a window size of 
n=10 for all of my breast tumour analysis. Having selected n=10 for my sliding window 
algorithm I wanted to confirm that the regions derived at this window size were true 
regions of transcriptional correlation and therefore assessed whether they appeared in 
analyses when varying the window size.  To do this I made a heat map of all the genes on 
the array and marked genes with significant correlation scores whilst varying the number 
of genes in the sliding window (Figure 3.7, black). At smaller window sizes, for example 
n=1, there are lots of significant TCS genes where 3 genes are co-ordinately being 
expressed which are not observed at larger window sizes. By comparison, at n=10 the 
regions are much more consistent (wider horizontal black blocks) where significant TCS 




Figure 3.6: The Number of Significant Genes with varying Window sizes. Data for 356 breast 
tumours showed that varying the window size varies the number of significant genes in the 





Figure 3.7: Genes with significant TCS (black) when varying the number of neighbours. 
Plotted is a heat map representation of all genes tested for transcriptional correlation (y axis) at 
all window sizes (x axis). Genes with significant transcription correlation scores are highlighted 
black (horizontal bars). Many of the genes are significant across multiple window sizes (black 
bars). At n=10 many of the genes that have a significant TCS at other window sizes are also 
significant in this gene window. 
	  
As I was investigating the effects of high order chromatin structure on gene expression I 
was expecting the regions to consist of large co-ordinately regulated clusters of genes. 
Given that the Radvanyi group investigated the same phenomena (Stransky et al., 2006) I 
examined the size of the regions described in their paper against those that I derived 
(Figure 3.8). They describe using n=7 in the sliding window approach, i.e. 14 neighbours. 
Therefore initially I did the same, comparing the region sizes for breast tumour data at 
n=7 with the published data (Figure 3.8A). The range of sizes appeared similar. I then 
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examined n=10 for the breast tumour data and the Reyal et al 2005 tumour dataset 
(Figure 3.8B). This showed a significant difference at n=10 between these breast tumour 
datasets. A number of contributing factors could have caused this but I expect it is 
because the regions I analysed were copy-number independent whereas Reyal et al 
(2005) regions will have included any large gain or losses of genetic material that led to 
coordinate gene expression signatures.  
	  
	  
Figure 3.8: Comparison of Regions Sizes to  published Coordinately Expressed Regions. 
(A) Analysis of Bladder Carcinoma  Data  (Stransky et al., 2006)  using a total window size of 15 
genes (n=7) yields similar size range of RER regions to those  published for this window size (B) 
Analysis of breast tumours  (Jonsson et al., 2010) at  a  total  window  size  of  21  (n=10)  yields  
much  smaller  RER region sizes than published  coordinately  expressed  regions  in  breast  
cancer  (Reyal et al., 2005) 
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3.3.5: RER in Breast Tumours 
	  
I then used the approach described above to identify regions which showed coordinate 
changes in gene expression independent of copy number changes  in 356 breast tumours 
(RERs) (Jönsson et al., 2010). Maps of the TCS data for chromosomes 3 and 16 are 
shown in Figure 3.9 as examples (see Appendix III for all chromosomes). Overall I 
identified 406 genes with significantly correlated expression to their neighbours (p<0.05, 
threshold score 5.081).  
	  
Figure 3.9: Breast tumour Transcription Correlation Maps (TCM’s). Transcriptome correlation 
maps for chromosomes 3 & 16 generated by plotting all TCS values against chromosome 
position in megabases (Mb), using  data for 356 tumours (Jönsson et al., 2010). The dotted line 
represents the significance threshold. Genes above this line are considered to have expression 
profiles that are considerably correlated with their neighbours.  
 
This number was reduced to 382 significant genes after removing regions which contain 
only 1 correlated gene. After merging overlapping regions this finally led to the 
identification of 45 regions of potential long-range regulation (Table 3.1). The sizes of 
these regions varied from 0.12 Mb to 43 Mb (median 1.86 Mb). My algorithm for 
generating transcriptional correlation scores does not take into the distance between 
genes (and therefore the presence of centromeres or gene desserts). Indeed three of the 
regions I identified (6, 33 and 39) span centromeres.  
Table 3.1: RER domains generated from breast tumour data. The cytogenetic band where the 
RER's are located, the RER size (measured as the first to last significant TCS in the region) and 
also the gene ID's for all the significant TCS gene's in the region are shown.  
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Significant TCS Genes in Region 
1 2p25.1 - 2p24.2 2.35 2 ADAM17, PDIA6 
2 2q14.2 - 2q22.1 2.91 4 IWS1, SAP130, UGGT1, IMP4 
3 3p21.31 - 3p14.3 4.45 26 
ZNF589, CCDC51, UQCRC1, IP6K2, P4HTM, WDR6, 
DALRD3, IMPDH2, QARS, USP19, LAMB2, TCTA, 
DAG1, APEH, RNF123, IP6K1, RBM5, HYAL2, 
TUSC4, CYB561D2, TMEM115, MAPKAPK3, TEX264, 
ABHD14A, BAP1, SPCS1 
4 4q28.2 - 4q31.22 0.29 2 SCOC, ELMOD2 
5 6p22.3 - 6p22.1 1.39 3 C6orf62, GMNN, HIST1H4C 
6 6p11.2 - 6q21 27 14 
SLC17A5, TMEM30A, ZNF292, RARS2, MDN1, 
CASP8AP2, MAP3K7, KIAA0776, NDUFAF4,C6orf167, 
FBXL4, USP45, CCNC, ASCC3 
7 6q23.2 - 6q25.3 14.27 12 
IFNGR1, HEBP2, C6orf115, HECA, VTA1, PEX3, 
FUCA2, LTV1, SHPRH, PPIL4, RMND1, C6orf211  
8 7q11.23 - 7q21.2 12.23 4 STYXL1, MDH2, DMTF1, SRI 
9 7q33 - 7q36.2 10.94 11 
SLC37A3,NDUFB2, MRPS33, SSBP1, CASP2, CUL1, 
EZH2, ZNF746, ABCB8, TMUB1, CHPF2 
10 8p21.2 - 8p12 0.54 2 ZNF395, INTS9 
11 8p11.23 - 8q11.23 3.56 6 TM2D2, GOLGA7, MYST3, AP3M2, IKBKB, C8orf40 
12 8q21.13 - 8q24.3 42.91 32 
NBN, OTUD6B, RAD54B, KIAA1429, ESRP1, INTS8, 
PLEKHF2, MTERFD1, PTDSS1, MTDH, HRSP12, 
AP003355.2, VPS13B, ANKRD46, UBR5, AZIN1, 
ATP6V1C1, SLC25A32, TTC35, TAF2, MRPL13, 
DERL1, ATAD2, WDYHV1, TRMT12, RNF139 
13 8q24.3 0.99 13 
TSTA3, SCRIB, PUF60, NRBP2, PARP10, GRINA, 
GPAA1, CYC1, SHARPIN, FBXL6, GPR172A, VPS28, 
CYHR1 
14 9p21.3 - 9p13.3 1.17 2 NOL6, SIGMAR1 
15 9q34.11 - 9q34.12 0.78 4 TRUB2, ODF2, WDR34, DOLPP1 
16 10p15.1 - 10p12.1 5.79 5 UPF2, CDC123, HSPA14, RPP38, STAM 
17 10q25.3 - 10q26.2 3.11 3 SEC23IP, PLEKHA1, IKZF5 
18 11q12.2 - 11q13.1 1.709 5 C11orf48, WDR74, OTUB1, NUDT22, RPS6KA4 
19 11q13.1 - 11q13.2 0.577 6 KAT5, FIBP, CCDC85B, SART1, SF3B2, YIF1A 
20 12q15 - 12q21.33 8.18 2 RAB21, PPP1R12A 
21 13q14.11 - 13q14.2 1.32 2 ESD, MED4 
22 14q23.3 - 14q32.11 4.81 3 COMMD6, UCHL3, SPRY2 
23 13q33.1 - 13q34 0.42 2 ANKRD10, ARHGEF7 
24 14q11.2 - 14q12 2.83 7 
CHD8, RBM23, PCK2, DCAF11, RNF31, IPO4, 
CHMP4A 
25 14q23.3 - 14q32.11 8.36 8 




26 16p13.3 1.86 23 
TMEM8A, NME4, RAB11FIP3, PIGQ, RAB40C, LA16c-
398G5.2, WDR90, RHOT2, WDR24, METRN, 
FAM173A, CCDC78, NARFL, IFT140, NME3, 
MRPS34, HAGH, NDUFB10, GFER, NTHL1, TRAF7, 
MLST8, E4F1  
27 16p13.3 - 16p13.13 0.45 4 DNAJA3, ANKS3, ROGDI, UBN1 
28 16p12.3 - 16p12.1 0.12 3 EARS2, NDUFAB1, PALB2 
29 16p11.2 0.53 6 TBC1D10B, ZNF48, PRR14, FBRS, PHKG2, BCL7C 
30 16q12.2 - 16q24.1 23.58 22 
COQ9, C16orf57, C16orf80, CMTM1, DYNC1LI2, 
CES2, TMEM208, ACD, CENPT, SLC7A6OS, CIRH1A, 
WWP2, AARS, DDX19A, COG4, SF3B3, FTSJD1, 
DHX38, PSMD7, TMEM170A, ADAT1, CENPN 
31 16q24.1 - 16q24.3 0.51 6 CYBA, MVD, CTU2, FAM38A, CDT1, ACSF3 
32 17p13.3 - 17p13.2 0.16 2 MYBBP1A, PELP1 
33 17p12 - 17q11.2 10.47 17 
COPS3, MED9, SMCR8, AKAP10, IFT20, POLDIP2, 
UNC119, PIGS, SPAG5, KIAA0100, SDF2, SUPT6H, 
TLCD1, ERAL1, FLOT2, DHRS13, NUFIP2 
34 17q12 - 17q21.2 2.44 17 
TADA2A, MRPL45, MLLT6, PIP5K2B, CWC25, 
FBXL20, MED1, CRKRS, STARD3, PGAP3, ERBB2, 
C17orf37, GRB7, GSDMB, ORMDL3, PSMD3, MED24 
35 17q21.2 - 17q21.31 0.79 7 
GHDC, COASY, FAM134C, VPS25, CCDC56, PSME3, 
AARSD1 
36 17q21.32 - 17q24.1 13.73 33 
PDK2, PPP1R9B, MRPL27, LRRC59, RSAD1, TOB1, 
MSI2, MRPS23, CUEDC1, SFRS1, DYNLL2, RNF43, 
MTMR4, RAD51C, TRIM37, C17orf71, DHX40, CLTC, 
PTRH2, TMEM49, TUBD1, HEATR6, USP32, APPBP2, 
BCAS3, BRIP1, MED13, DCAF7, STRADA, CCDC47, 
DDX42, FTSJ3, PSMC5 
37 17q25.1 - 17q25.3 2.72 24 
TMEM104, ICT1, KCTD2, ARMC7, NT5C, HN1, 
NUP85, MIF4GD, SLC25A19, GRB2, KIAA0195, 
SAP30BP, GALK1, WBP2, TRIM47, TRIM65, FBF1, 
C17orf106, EVPL, SRP68, PRPSAP1, UBE2O, 
RHBDF2, SEPT9 
38 17q25.3 1 13 
AZI1, FSCN2, C17orf70, NPLOC4, HGS, MRPL12, 
ASPSCR1, STRA13, LRRC45, DCXR, RFNG, GPS1, 
CCDC57 
39 18p11.22 - 18q11.2 1.06 5 PSMG2, PTPN2, CEP192, C18orf19, RNMT 
40 18q12.3 - 18q21.32 7.14 3 IER3IP1, SMAD4, POLI 
41 20q13.2 - 20q13.33 3.82 5 RAB22A, VAPB, GNAS, TH1L, LSM14B 
42 22q11.23 - 22q12.1 1.18 5 C22orf13, SNRPD3, C22orf36, KIAA1671, ADRBK2 
43 22q12.2 - 22q12.3 3.03 3 C22orf28, FBXO7, MCM5 
44 22q13.1 - 22q13.2 0.31 2 ZC3H7B, PPPDE2 






To validate my results I also calculated copy-number-independent TCS’s for a second 
independent breast tumour dataset (Chin et al., 2006) and confirmed that the genes with 
significant TCS’s in one tumour dataset (Jönsson et al., 2010) also produced significantly 
high TCS’s in the second tumour dataset  (p<0.05). Figure 3.10 depicts this analysis as 
boxplot distributions of all TCS’s generated from each dataset and then the distribution of 




Figure 3.10: Validation of tumour RER genes in a independent datasets. Significant genes 
generated from Jönsson et al., 2010 tumour data also show significantly high scores in 







Having established that these RER domains were true regions of co-ordinately expressed 
genes I then set out to establish how they were behaving relative to normal breast tissue. 
Although the dataset I used to derive the 45 RER domains contained a vast number of 
tumour samples (356) with both expression and CGH data available (Jönsson et al., 2010) 
there were no normal samples in this dataset. Therefore I used another published dataset 
containing expression data for 42 breast tumours and 143 normal breast tissues (Chen et 
al., 2009). In order to compare expression in the 45 RER domains I generated mean-
centered z-scores for all genes and used the median z score per sample to plot the 
distribution as boxplots. The Wilcox test was used to determine whether or not there was 
a significant difference between tumour and normal samples. I found that not all my 
regions conformed to the LRES phenotype dominant in published studies. In fact of the 
45 regions I identified, 28 were aberrantly upregulated (shaded red in Table 3.1) in 
tumours compared to normal breast tissue, 6 were aberrantly down-regulated (shaded 
green in Table 3.1) and 11 showed no significant change in expression. Figure 3.11 
shows two examples of RERs with activated gene expression in tumours on 
chromosomes 3p21.31 and 16p11.2 (top panel) and two repressed regions on 





Figure 3.11: Analysis of gene expression changes in tumours relative to normal tissue. 
Mean centred z scores were calculated for all genes in the region. The median z score for each 
sample was used to plot the distribution of these scores as boxplots and to compare scores 
between samples. Regions 3 (3p21.31) and 29 (16p11.2) (top panel) are two examples of regions 
were genes are co-ordinately upregulated in tumours relative to normal. Regions 21 (13q14) and 




3.3.6: RER in Breast Cancer Cell Lines 
 
Although analysis of RER domains in tumours would be the ‘gold standard’, I wanted to 
move onto mechanistic studies which are not feasible in tumours, to determine how these 
RER domains are regulated. Therefore having identified 45 RER domains in breast 
tumours I next set out to identify them in breast cancer cell lines. Using the same 
approach as used for breast tumours, I analyzed expression and copy number data for 
breast cancer cell lines from Neve et al. (2006) (Figure 3.12).   
 
	  
Figure 3.12: Comparison of Transcription Correlation Maps (TCM’s) for Breast Cancer 
Tumours and cell lines. Transcriptome Correlation Maps generated for chromosomes 3 & 16 
using data generated for (A) 356 breast tumours (Jönsson et al., 2010) and (B) for 48 breast 





There were 557 genes that showed significant correlation scores (p<0.05, threshold score 
5.779) using the Spearman rank-sliding window approach. Figure 3.12 shows examples 
(chromosomes 3 & 16) of maps of the transcriptional correlation scores in both the 
tumour and cell line datasets.  Both the breast tumour and cell line maps show similar 
peaks of gene clusters with significantly high TCSs. This gives me confidence that breast 
cancer cell lines can be used to investigate the molecular mechanisms underlying RERs. 
Appendix V shows the TCS maps for all chromosomes derived from this cell line 
analysis.  
 
After excluding those regions containing only 1 correlated gene, 501 RERs remained in 
the cell line data. Merging of overlapping regions produced 71 regions with sizes ranging 
from 0.01 Mb to 15.8 Mb (median 0.9 Mb) (Table 3.2).  
 
Table 3.2: RER domains generated from breast cancer cell line data. The cytogenetic band 
where the RER's are located, the RER size (measured as the first to last significant TCS in the 
region) and also the gene ID's for all the significant TCS gene's in the region are shown. Blue 
shading indicates RER domains that overlapped with those derived from the tumour analysis. 
 




Significant TCS Genes in Cell Line Region 
1 1p36.13 0.532719 2 AKR7A3, RNF186 
2 1p34.3 0.332406 3 CDCA8,YRDC,UTP11L  
3 1p34.2 - 1p34.1 0.627772 3 ELOVL1,ATP6V0B,B4GALT2  







5 1q42.2 0.37173 2 TTC13, GNPAT 
6 1q43 0.392338 2 FH,EXO1 
7 2q32.3 - 2q33.1 9.658744 4 MYO1B, HSPE1, C2orf47, NIF3L1 
8 3p22.2 0.330516 2 VILL, SLC22A14 
9 3p22.1 - 3p21.31 3.457713 9 
ANO10, ZDHHC3, SLC6A20, FYCO1, CCR1, CCR2, CCR5, 
 CCRL2, PRSS50 
10 4p16.3 2.047026 11 
TACC3, WHSC1, WHSC2, HAUS3, RNF4, TNIP2, SH3BP2, 
ADD1,  
TETRAN, HTT, ADRA2C 
11 4q13.2 - 4q13.3 5.110343 11 
UGT2A3, SULT1B1, CSN1S1,CSN2, STATH, CSN3, SMR3B, 
 PROL1, IL8, CXCL5, CXCL3 
12 4q22.1 0.398405 2 MEPE, ABCG2 
13 4q26 - 4q27 2.091682 3 MYOZ2,PDE5A,TNIP3 
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14 5p13.2 2.465914 4 RAD1,BRIX1,SKP2,NUP155 








16 6p21.33 0.072086 4 LST1,NCR3,BAT2,APOM 
17 6p21.33 - 6p21.32 0.962297   
TNXB, CREBL1, PPT2, GPSM3, NOTCH4, C6orf10, HLA-DRB6, 
 HLA-DQB2, HLA-DMA 
18 6q23.2 0.146092 3 TAAR5,TAAR3,VNN3 
19 6q25.2 1.348873 3 RP3-468K3.1, RP3-527B10.1,OPRM1 
20 6q26 - 6q27 6.429087 7 PARK2,PDE10A,T,CCR6,GPR31,TCP10,C6orf123 
21 7p22.3 - 7p22.1 3.965987 6 MAD1L1,FTSJ2,CHST12,FOXK1,ACTB,RNF216 
22 7q22.1 0.146208 2 EPO,SLC12A9 
23 8p21.3 0.904261 6 BMP1,POLR3D,PIWIL2,SLC39A14,PPP3CC,SORBS3,BIN3, RHOBTB2,TNFRSF10B 
24 8p11.21 - 8q11.23 13.05061 6 AP3M2,POLB,VDAC3,SLC20A2,MCM4,MRPL15 
25 8q13.3 - 8q21.3 15.859747 6 KCNB2,STAU2,FAM164A,STMN2,FAM82B,MMP16 
26 8q22.2 - 8q22.3 5.291133 11 
RPL30,HRSP12,NIPAL2,VPS13B,COX6C,SPAG1,RNF19A, 
ANKRD46,UBR5,AZIN1,FZD6 
27 9p13.3 0.723551 6 KIAA1045,DNAJB5,RUSC2,CD72,SIT1,CA9 
28 9q34.3 2.096118 5 OLFM1,C9orf116,SNAPC4,ABCA2,GRIN1 
29 10p13 1.979364 3 HSPA14,NMT2,RSU1 
30 10q22.1 - 10q22.2 1.995287 4 PSAP,CBARA1,SEC24C,NDST2 





2.780985 5 BAG3,C10orf119,SEC23IP,BRWD2,PLEKHA1 
33 11q12.1 - 11q12.2 0.931709 6 MS4A2,MS4A5,MS4A12,GPR44,TMEM109,CD6 
34 11q13.1 0.191506 2 COX8A,MACROD1 
35 11q13.2 0.158078 2 SPTBN2,C11orf80 
36 11q23.3 - 11q24.3 11.105129 14 
FXYD6,CD3G,MLL,H2AFX,PDZD3,THY1,TECTA, 
SCN3B,ACRV1,DDX25,CDON,KCNJ1,KCNJ5,TP53AIP1 
37 12p13.32 0.157215 2 AKAP3,GALNT8 
38 12p13.31 0.952419 3 C3AR1,AICDA,KLRG1 





0.718107 3 ASB8,CACNB3,RND1 
41 12q13.2 1.293331 4 PDE1B,BLOC1S1,RDH5,MMP19 
42 12q21.31 - 12q22 7.055034 4 NTS,MGAT4C,DCN,EEA1 
43 14q32.13 0.228806 3 SERPINA2,SERPINA4,SERPINA5 





45 16p13.3 1.068754 5 OR1F1,OR2C1,NAT15,ADCY9,TFAP4 
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46 16p12.3 0.621226 2 C16orf88,GP2 





48 16q22.1 - 16q22.2 3.893046 11 
CDH16,NOL3,E2F4,ATP6V0D1,THAP11,PSKH1,DDX28 
,DUS2L,PRMT7,COG4,VAC14 
49 17p11.2 0.39805 3 TOM1L2,LRRC48,LLGL1 
50 17q11.2 0.155523 4 UNC119,KIAA0100,SDF2,SUPT6H 
51 17q21.2 0.363708 6 KRTAP1-3,KRTAP1-1,KRTAP2-4,KRTAP4-9,KRT34 ,KRT31 
52 17q21.31 0.659717 2 RUNDC3A,C1QL1 
53 17q25.1 0.358511 4 KCTD2,GGA3,MRPS7,GRB2 
54 17q25.3 0.315342 4 STRA13,RFNG,CSNK1D,SECTM1 
55 19p13.3 0.662667 4 PIAS4,ZBTB7A,SH3GL1,C19orf10 
56 19p13.2 0.030115 2 MAP2K7,SNAPC2 





58 19p13.11 1.329896 8 SLC5A5,PIK3R2,PGPEP1,ELL,FKBP8,DDX49,TMEM161A ,RFXANK 
59 19q13.12 0.55062 6 CD22,GAPDHS,ZBTB32,ARHGAP33,NPHS1,APLP1 











62 19q13.43 0.461506 5 ZNF550,ZNF134,ZNF211,ZNF586,ZNF606 
63 20p13 0.013104 2 OXT, AVP 
64 20p11.23 - 20p11.1 7.381602 14 
RBBP9,INSM1,FOXA2,CYB5P4,THBD,CD93,CST8,CST3, 
CST4,CST5,TMEM90B,CST7,C20orf3,FAM182B 
65 20q13.12 0.483177 4 ZSWIM1,MMP9,CDH22,SLC35C2 
66 20q13.33 0.820961 3 DIDO1,ARFGAP1,RTEL1 
67 21q22.3 0.669345 2 RRP1, LRRC3 
68 22q11.21 - 22q12.1 6.914663 13 
TRMT2A,P2RX6,TOP3B,PPIL2,IGLV1-40,ZNF280B,ZNF280A, 
ZDHHC8P,VPREB3,MMP11,UPB1,SEZ6L,CRYBB1 
69 22q12.2 0.169807 2 INPP5J, PIK3IP1 
70 22q12.3 - 22q13.1 0.751707 4 TMPRSS6,SSTR3,MFNG,GCAT 





3.3.7. Overlap of RER’s between cell line and tumours 
 
	  
I found that many of the RERs identified in breast tumours overlapped completely or in 
part with RERs from the breast cancer cell line datasets (Figure 3.12; Table 3.1; Table 3.2 
blue shading; Figure 3.13). There were also instances, for example RER 33 in the tumour 
data (which spans the centromere on chromosome 17), where the region could be divided 
into two smaller regions based on the two regions from the cell line data (regions 49 & 
50) which it overlapped with either side of the centromere. In addition, a region on 
chromosome 16p11.2 which appeared in both the tumour and cell line RER analyses 
encompasses the LRES domains previously identified in breast cancer cells (Hsu et al 
2010).  
	  
Figure 3.13: Comparison between RERs derived from tumour and cell line data. Ideogram 
representation of chromosomal locations of 71 RER’s in breast cancer cell lines (blue) and 45 
RER’s in tumours (red). 	  
	  
In total I was able to identify 26 copy number independent regions of coordinate 
expression that are in common between breast tumours and breast cancer cell lines based 
on their overlap (Figure 3.13; Table 3.1). The overall size range of these 26 regions was 
0.23-13.4 Mb (mean 3.67 Mb , median 1.40 Mb). Appendix VI contains tables of all 
genes within the 26 RER coordinates. Gene Ontology (GO) analysis for genes within the 
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overlapping regions showed a high enrichment a number of interesting GO terms 
including nucleosome assembly (GO:0006334), nucleosome organization (GO:0034728) 
and chromatin organization (GO:0006325). A full list of associated GO terms are 
included in Appendix IX.  
	  
Table 3.3: 26 RER domains derived from overlap between tumour and cell line RER’s. The 
cytogenetic band where the RER's are located, the RER size (measured as the first to last 
significant TCS in the region),  the total number of genes within each region according to 
Ensembl (including the entire gene window and those not included in the arrays), whether or not 
the regions are misregulated in tumours and the p-value associated with this analysis.   
Region Cytoband Size (Mb) 
All Genes 











1 6p22.2 0.89 66 UP 0.000000 
2 6q23.2 - 6q23.3 3.43 60 DOWN 0.003904 
3 6q25.1 - 6q25.3 6.71 86 DOWN 0.000023 
4 
8p11.21 - 
8q11.23 13.41 86 DOWN 0.000023 
5 8q21.13 - 8q21.3 10.54 118 No Sig. Change  0.8428 
6 8q22.1 - 8q23.1 11.99 212 No Sig. Change  0.1806 
7 9p13.3 1.13 51 No Sig. Change  0.1108 
8 10p13 - 10p12.31 6.71 105 DOWN 0.04647 
9 
10q26.11 - 
10q26.13 6.34 99 No Sig. Change  0.09559 
10 
11q12.3 - 
11q13.1 0.75 39 UP 0.000038 
11 11q13.2 0.36 28 UP 0.000015 
12 
12q21.31 - 
12q21.33 10.39 94 DOWN 0.007449 
13 16p13.3 2.16 182 UP 0.000000 
14 16p13.3 1.45 57 UP 0.000000 
15 16p12.3 0.38 10 No Sig. Change  0.8996 
16 16p11.2 1.36 124 UP 0.000000 
17 
16q22.1 - 
16q22.2 4.9 225 DOWN 0.03697 
18 17p11.2 1.69 58 DOWN 0.009758 
19 17q11.2 0.53 37 UP 0.000008 
20 17q21.2 0.28 12 No Sig. Change  0.4965 
21 17q25.1 0.9 41 UP 0.000006 
22 17q25.3 0.58 37 UP 0.000000 
23 
22q11.23 - 
22q12.1 5.93 164 DOWN 0.04232 
24 
22q12.2 - 
22q12.3 1.01 43 No Sig. Change  0.4402 
25 22q12.3 0.24 6 No Sig. Change  0.2172 
26 
22q13.1 - 







Taking these overlapping regions between tumour and cell lines as domains that are 
potential candidates for further mechanistic study I sought to determine how they were 
behaving in tumour vs normal tissue using data from (Chen et al., 2009). From this 
analysis I found once again that the regions did not conform to the LRES phenotype that 
is dominant in published studies.  
Of the 26 regions I found that, for nine of them gene expression was upregulated relative 
to normal breast and was downregulated in a further eight regions. There were also nine 
regions that showed no significant change in gene expression between tumour and normal 
tissues. Examples of aberrantly up/down-regulated regions are shown in Figure 3.14 and 
highlighted red/green respectively in Table 3.3 with Wilcox p-values shown for all 26 






Figure 3.14: Analysis of gene expression changes in tumours relative to normal tissue. 
Mean centred z scores were calculated for all genes in the region. The median z score for each 
sample was used to to plot the distribution of these scores as boxplots and enabling relative 
comparison of scores between samples. The top panel shown, regions 3 and 29, are two 
examples of regions that were relatively upregulated in tumours. The bottom panel shown, 







3.3.8. RER domains and tumour sub-type 
 
Breast cancers fall into a distinct sub-types dependent on their gene expression profiles 
and the expression of specific receptors (see Section 1.1.2.5 of Chapter 1). To determine 
if different RERs were characteristic of different tumour sub-types I performed 
unsupervised hierarchical clustering of gene expression data for all RER regions in both 
the breast cancer cell line and tumour data. This analysis showed that whilst there is a lot 
of heterogeneity with regards to the gene expression signature for a region there are also 
cases where there is a subtype-specific gene signature and in many cases this was 
sufficient to separate out the main luminal and basal-like subgroups in both the cell lines 
and tumour data sets. Where this signature exists in the region there is a relative 
up/down-regulation of the genes which is dependent on the molecular subtype. The data 
was transformed into mean centred z scores to enable relative comparison of gene 
expression changes between samples. Red/green indicates an increase/decrease in gene 
expression relative to the universal mean for each gene.  
 
Figure 3.15 shows an example for RER 13 on chromosome 16p13.3 where in both 
tumours and cell lines this region is relatively upregulated in the luminal (ER+ve) 
subtype compared to the basal (ER-ve) subtype tumours where it is relatively repressed. 
The heat map for the tumour tissue data (Figure 3.15A) showed a much more 
heterogeneous pattern in gene expression compared with the cell line data. This is likely 
to be a reflection of the cellularity of the tumour samples and generally the cell line data 
showed a much better segregation into luminal (ER+ve) Vs basal (ER-ve) gene 
signatures at RER domains than did the tumour data. Heat maps representing the 
clustering of gene expression data for all RER domains identified for breast tumours and 





A               Breast Tumour RER 13 
 
B     Breast cancer cell line RER 13 
 
Figure 3.15: Unsupervised cluster analysis of genes in RER 13 on chromosome 16p13.3.  
Heat maps for genes in RER number 13 to indicate the similarity of sample z scores for breast 
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tumour samples (A) and cell lines  (B). Each tumour or cell line is identified by a colour-coded 
matrix below the dendrogram representing the results of hierarchical clustering: basal (red), 
luminal (blue), ERBB2 (purple), normal-like (green). Red/green indicate an increase/decrease in 
gene expression relative to the universal mean for each gene.  The values were mean centred 




3.3.9: Other properties of RERs  
	  
	  
Given that the RERs were co-ordinately regulated and that the sizes of the regions highly 
variable, I investigated the gene density of the RER domains. This showed that RERs 
were occurring in regions of the genome that were significantly more gene dense than 
expected (Figure 3.16A, p=2.2e-16). This analysis was carried out initially for the data 
from the breast tumours, though data from the breast cancer cell lines and bladder 
carcinomas also showed significant enrichment in regions of high gene density (data not 
shown).  
 
As a result, I investigated whether the regions of coordinate expression that I observed in 
breast cancer corresponded to Regions of Increased Density of Gene Expression 
(RIDGE’s) previously identified in the human genome from the examination of gene 
expression data across 12 normal and pathological tissue types (Caron et al., 2001). 
RIDGEs are gene dense, have a high GC content and short introns, and anti-RIDGE’s 
have also been identified with opposite properties (Versteeg et al., 2003). Using genome 
coordinates for RIDGEs and antiRIDGEs obtained from the Versteeg lab I investigated 
whether or not the tumour tissue RERs correlated with these domains. Indeed many of 
my RER regions fell into RIDGE’s (48%) and also anti-RIDGE’s (15%), however not all 
RIDGEs/anti-RIDGES were regions of epigenetic regulation (RER) (Figure 3.16B). By 
generating a random set of regions (“fake” RERs) I was able to show that there was no 
co-occurrance of RER domains with RIDGE’s (Fishers p-value 0.395) or antiRIDGE’s 







Figure 3.16: Properties of RER regions. (A) Genes with a significant TCS occur in gene dense 
regions of the genome (calculated as genes/Mb) (p<0.05) (B) Ideogram representation of 
chromosomal locations for tumour RER’s (red), RIDGE’s (blue) and anti-RIDGEs (green) as 







In this chapter I developed an approach based principally on that used to identify LRES 
regions in bladder carcinoma (Stransky et al., 2006). My approach differed in that, 
whereas Stransky et al (2006) identified regions of coordinate repression and then 
eliminated regions where coordinate repression was due to copy number, I first removed 
all copy number affected parts of the dataset before going on to derive regions of 
coordinate regulation. From this analysis I was able to show that there are at least 26 
regions in the breast cancer genome that show coordinate gene expression that this is not 
due to copy number aberrations. This was shown by analysis of both breast tumour and 
cell line data and determining which genes had consistently high TCS across both 
analyses. 
 
Most interestingly the regions identified were not all subject to the LRES phenomena. 
Indeed a large proportion of these regions that were co-ordinately regulated were 
aberrantly activated in tumour tissues, and a large proportion showed no difference in 
their expression relative to normal tissues. At this stage it is also not possible to say that 
all the RER domains are epigenetically regulated. I have however identified regions 
which could potentially be regulated by epigenetic mechanisms and could be investigated 
further.  
 
Selection of a region to further investigate in vitro and ex vivo was based on the following 
criteria:  
 
(a) The region would be amongst the 26 overlapping regions between  tumour and 
cell line data analysis  
(b) The region would show a degree of subtype specificity in its gene expression 
signature (as assessed by heat map analysis) 
(c) Based on the analysis of tumour and normal samples, the region would show 
significant aberrant  repression or activation 
(d) The region selected would be of amenable size to work with 
(e) The region when examined on the UCSC browser contained most of the genes in 





The RER I identified as fitting these criteria the most was on chromosome 16p11.2. This 
region as identified in the breast tumour (region 26) and cell line data (region 47) was 
almost completely overlapping. Figure 3.17 shows a schematic of the RER from the 
UCSC browser with both the breast tumour and cell line RER marked.  
 
Figure 3.17: Schematic representation of RER on chromosome 16p11.2. Adapted from the 
UCSC genome browser (build hg19). Black bars represent RER domains in tumours (top) and 
cell lines (bottom). Ideogram above image indicates location of RER on chromosome 16. 
 
This region is 1.48 Mb in size taking into account all genes in the analysis window and 
0.53 Mb taking into account the first to last gene with a significant TCS. This region also 
contained genes (QPRT, MAZ, PRRT2, MVP, ASPHD1, TMEM219, TAOK2, INO80E) 
previously shown to be involved in estrogen-mediated repression by DNA looping in 
breast cancer (Hsu et al., 2010). Interestingly this region does not conform to the LRES 
phenotype described by previous studies. This region appears to be aberrantly 
upregulated in breast cancer (Figure 3.14: top panel, middle) and shows segregation by 
heat map analysis of expression data into the two main subgroups of breast cancer. Also, 
this region contains ZNF proteins and it has been shown that CBX, a component of 
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heterochromatin that is associated with repression (through binding H3K9me2/3), can 
coat regions of up to 4Mb that harbour KRAB-ZNF genes (Vogel et al., 2006). 
 
The mechanism by which this region is misregulated in breast cancer is investigated and 


















An RER on chromosome 16p11.2 shows 








Rather than single genes, large regions of coordinately misexpressed genes, termed Long 
Range Epigenetic Silencing (LRES) regions, have emerged as an exciting new 
phenomena in the cancer literature and have been attributed to a cocktail of chromatin 
remodelling and DNA methylation changes (Coolen et al., 2010; Dallosso et al., 2012, 
2009; Frigola et al., 2006; Hsu et al., 2010; Javierre et al., 2011; Novak et al., 2008, 2006; 
Park et al., 2011; Stransky et al., 2006; Vallot et al., 2010). These studies have relied 
heavily on using expression datasets to identify regions of coordinately misregulated 
genes and have investigated epigenetic changes at these target loci to identify the possible 
cause of the misregulation. The LRES status of a tumour has been implicated in the 
aggressiveness of tumours and therefore also has implications for patient prognoses 
(Dallosso et al., 2009; Vallot et al., 2010).  
 
 In the previous chapter I identified large domains of co-ordinately misregulated  genes in 
breast cancer and established that, as well as LRES, there is another phenomenon 
occurring which involves long-range activation of expression compared to normal 
tissues, rather than gene silencing. I therefore denoted domains from my analysis as 
regions of epigenetic regulation (RER) rather than LRES. Given that there is no 
consensus from previous studies as to the cause of coordinated  misregulation of long 
stretches of the genome,  I hypothesized that changes in chromatin structural organization 
itself may be causative of gene expression changes for such large regions, as has been 
seen for some developmentally regulated gene clusters (Eskeland et al., 2010).  
 
In this chapter I describe experiments which set out to investigate chromatin compaction 
and decompaction as a mechanism of altered gene expression for large misregulated 
domains (RER’s). Additionally I investigated the influence of the nuclear environment by 
investigating the localisation of a RER with respect to the nuclear periphery, which is 







Fluorescence in situ hybridisation (FISH) is a molecular cytogenetic technique which has 
been used by the Bickmore lab (and others) to detect whole chromosomes as well specific 
DNA loci in the nucleus. FISH can be used to measure the compaction of chromatin over 
a specified genomic region (Section 1.2.4.2)(Sachs et al., 1995). Chromatin compaction 
has been well studied using this method during differentiation of embryonic stem cells, 
(Chambeyron and Bickmore, 2004), in the developing embryo (Chambeyron et al., 2005; 
Morey et al., 2007), comparing wildtype and mutant cells (Ragnhild Eskeland et al., 
2010) and also for the study of multiple loci in the same cells (Gilbert et al., 2004). Data 
from 2D FISH analysis of fixed cells has been shown to recapitulate the chromatin 
compaction observed with 3D FISH though distances are typically larger (Ragnhild 
Eskeland et al., 2010; Morey et al., 2007). Therefore in this chapter all cell-line based 
analyses are based on 2D FISH data which are more swiftly imaged, processed and 




4.2.1: Selection of RER domain on chromosome 16p11.2 to 
investigate changes in chromatin organisation 
	  
As described in chapter 3, a computational approach was used to identify regions of 
epigenetic regulation (RER) in breast cancer. I identified 45 RER’s in breast tumours  
(Table 3.1) with a view towards studying the mechanism of RER biology and how this 
relates to transcription. In order to study this phenomenon in vitro, I carried out an 
identical analysis in breast cancer cell lines which revealed 71 RER’s (Table 3.2). To 
ensure that the region I selected to study in vitro was a true domain of RER that also 
occurred in tumours I compared both the tumour and cell line analysis to produce a list of 
26 potential target RER’s (Table 3.3) that could be studied easily by in vitro analysis of 
cell lines and that are not just cell line artefacts. Comparison of gene expression data for 
breast tumour and normal tissues revealed 8 LRES regions and 9 aberrantly activated 
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RERs in tumours. As the published literature focused on LRES regions I decided to focus 
on up-regulated RER’s.  
 
One of these candidate up-regulated regions (RER no.16 in Table 3.3) contained the 
genes (SPN, QPRT, ZG16, KIF22, MAZ, PRRT2, MVP, SEZ6L2, ASPHD1, KCTD13, 
TMEM219, TAOK2, INO80E, DOC2A) that have been reported to undergo ER-mediated 
looping in breast tumour cells in association with LRES (Hsu et al., 2010). This 1.38 Mb 
RER domain on chromosome 16p11.2 which overall I found had aberrantly activated 
gene expression in tumours compared to normal breast (Figure 4.1A) was therefore 
selected for further study.  
 
This RER was also selected because heat map analysis by z scores of gene expression for 
all genes in the RER (not just those with a significant transcriptional correlation score) 
revealed a differential gene expression pattern between the two broad categories of breast 
cancer subtypes - luminal-type/estrogen-receptor positive (ER+ve) and basal-
type/estrogen-receptor negative (ER-ve) - as shown by unsupervised hierarchical cluster 





Figure 4.1: Gene Expression at an RER on chromosome 16p11.2 in breast tumours and 
tumour subtypes. (A) Mean centred z scores were calculated for all genes in the region. Box 
plot of the distribution of median z scores for all sample compared between normal tissue and 
tumours. (B) Unsupervised cluster analysis of breast cell lines from Neve et al (2006).The heat 
map is vertically clustered using Euclidean clustering (shown as dendogram) to indicate the 
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similarity of sample (z) scores with each other. Based on subtype information from Neve et al 
each sample is identified by a color-coded matrix below the dendrogram: basal (red), luminal 
(blue) The legend shows z-scores where red/green indicate an increase/decrease in gene 
expression relative to the universal mean for each gene. The values were mean centred and the 




4.2.2: Investigating chromatin compaction of RER domain 
 
	  
Chromatin compaction was assayed by measuring the physical distance between pairs of 
fosmid probes that flanked the locus of interest. Fosmid probes were selected using the 
fosmid end pairs track of the UCSC genome browser (http://genome.ucsc.edu/). Fosmids 
flanking each locus were labelled and detected as described in Methods (Chapter 2). The 
interprobe separations between the “green” and “red” hybridisation signals was 
determined by in-house scripts. Distances converted from pixels to microns were always 
squared (d2) as previous work in the Bickmore lab has shown that in FISH experiments d2 
is proportional genomic distance. Mean d2 was used to estimate the level of chromatin 
compaction in all comparisons between cell lines. FISH can be used to measure 
chromatin compaction at genomic distances of <1Mb, as chromatin follows a random-
walk giant-loop mathematical model, with loops above 1.5Mb  as discussed in section 
4.2.7 (Sachs et al, 1995; van den Engh et al, 1992).  
 
As the RER domain being investigated is large (1.38 Mb) it was subdivided into four sub-
regions of similar size (locus 1: 382 Kb, locus 2: 414.2 Kb, locus 3: 445.2 Kb and locus 
4: 418.5 Kb) to accurately assess chromatin compaction across the region (Figure 4.2). 
Significant differences in chromatin compaction were assessed using the Wilcox test with 
a cut off of p<0.05. This non-parametric test was chosen as it does not rely on the data 
belonging to a particular distribution but can make a pair-wise assessment between the 
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Figure 4.2: RER on chromosome 16p11.2 from Breast Tumour and Cell Line Analysis. 
UCSC human genome browser window showing; Top - ideogram of chromosome 16 with the 
region (p11.2) containing the RER domain highlighted. Below – expanded view of the RER. The 
top track shows the extent of the RER identified from the analysis of 356 breast tumours or 48 
breast cancer cell lines. The FISH probes browser track (red and green) represents the location 
of fosmids used as probes for analysis of the region by FISH. At the bottom, the locations of all 




As the RER I had selected showed good segregation into subtypes by heat map analysis 
of the gene expression signature (Figure 4.1B) I selected a breast cancer cell line that was 
luminal ER+ve (MCF7) and another that was basal-type ER-ve (MDAMB231) according 
to Neve et al (2006) for initial analyses.  These two cell lines also fell into separate 
clusters by unsupervised Euclidean analysis (Figure 4.1B). Unnormalised inter-probe 
distances (d2) showed a significant difference (Wilcox test p<0.05) for locus 2 and 4 with 
MCF7 cells being less compact at these loci than in MDAMB231 cells. It appeared that 
locus 3 also followed this trend though the data was not statistically significant.  Locus 1 
on the other hand appears to have the same level of chromatin compaction in both cell 
lines.  
 
The observed inter-probe distances were normalised to the radius squared (d2/r2) as 
previous work as well as my own showed considerable differences in the nuclear area 
between cell types and preparation of slides which could skew distances when comparing 
them. When normalised in this way, locus 2 remained consistent in having significantly 
more decompact chromatin in MCF7 cells compared with MDAMB231 cells (Figure 
4.3). Though locus 4 appears from the boxplots to also show this pattern the effect is not 
significant. Locus 3 has the exact same distribution of normalised inter-probe distances 
between cell lines. Locus 1 appears to be more decompact in MDAMB231 cells than in 
MCF7 cells, an affect that would perhaps be expected taking into account the proposed 
ER-mediated looping of genes in the region to form a compact structure (Hsu et al., 
2010), however this effect is not significant in either normalised or unnormalised FISH 














Figure 4.3: FISH analysis of compaction for RER on chromosome 16p11.2. (A) Top - the 
location of the RER identified from the analysis of 356 breast tumours and 48 breast cancer cell 
lines with the location of FISH probes. Below - boxplots show the distribution of normalised 
interprobe distances in MCF7 and MDAMB231 cells. Shaded boxes show the median and 
interquartile range of data; circles represent outliers.  n= 45-60 nuclei. (B) Representative FISH 
images of MCF7 and MDAMB231 nuclei hybridised with probes W12-1754H9 (green) and W12-




4.2.3: Further delineation of the RER domain and subtype 
specific changes in chromatin compaction 
 
In order to further investigate the locus 2 region of the 16p RER, where I detected 
different chromatin compaction between MCF7 and MDAMB231 cells, I revisited the 
heat map analyses of gene expression data selecting only for the genes in the locus 2 
region. Unsupervised hierarchical clustering of locus 2 using expression data from the 48 
breast cell lines (Neve et al., 2006) was sufficient to segregate the z scores into two main 
branches that corresponded to the two main sub-classes of breast cancer: luminal-type 
ER+ve and basal-type ER-ve cancer (Figure 4.4).  From this heat map it is clear that the 
two selected cell lines, MCF7 and MDAMB231, were consistently repressed/activated 
relative to one an other across the entire locus.  
Figure 4.4: Unsupervised cluster analysis of Locus 2 in the 16p11.2 RER. The heat map is 
vertically clustered using Euclidean clustering (shown as dendogram) to indicate the similarity of 
sample scores with each other. Based on subtype information from Neve et al., 2006 each 
sample is identified by a color-coded matrix below the dendrogram: basal (red), luminal (blue) 
The legend shows z-scores where red/green indicate an increase/decrease in gene expression 
relative to the universal mean for each gene. The values were mean centred and the colours 
scaled from the max (+4) & min (-4) standard deviations. This enables relative comparison of 





I therefore returned to the computational analysis described in chapter 3 to determine 
whether this region on chromosome 16p11.2 could be further delineated using a smaller 
window size. Varying the number of neighbours in the analysis from n=1-10 where 2n+1 
is the total window size I was able to identify all the possible genes that showed 
correlated gene expression patterns with the other genes in the window. I then plotted a 
heat map of all genes with a significant transcription correlation score when decreasing 
the window size (Figure 4.5). This analysis shows that the high scoring genes cluster into 
groups across the RER on chromosome 16p11.2, one of which is mostly in locus 2 
extending into locus 1 and the other of which lies in locus 3.  
	  
	  
Figure 4.5: Heat map representation of 16p11.2 RER with varying window size. Only genes 
in the region with significant transcription correlation scores (TCS) are coloured black on the heat 
map at each of the sliding window sizes (x axis). Genes across the region (y axis) are named on 
the right of the heat map. Adjacent to gene names are the FISH probes demarking the 4 loci that 
were examined. This figure is based on the breast cancer cell line derived TCS’s and map of 






To determine the entire region of transcriptional correlation for these two clusters of 
significant TCS genes, I  delineated the regions as described in Chapter 3 – by  taking all 
the genes in the analysis window for all significant TCS genes, discarding regions that 
only had one significant TCS and therefore producing  a list of raw regions for each 
window size. The resulting regions at 16p11.2 are shown in Figure 4.6 for all window 
sizes, alongside the location of the refined tumour and cell line derived RERs (as 
described in chapter 3).  
 
This segment of chromosome 16p11.2 does appear to be a valid RER at different sliding 
window sizes. Between n=5-10 this remains as one large RER domain that then splits 
into two smaller RERs at n=2-4.   One of these small RER domains (left) covers 
completely (and infact spans out of) locus 2 whereas the other smaller RER (right) is 
mostly but not entirely contained in locus 3 (Figure 4.6). It is therefore not unexpected 
that of the 4 loci examined by FISH it was locus 2 where the difference in chromatin 
compaction was seen and not the other loci.  
 
Having confirmed that locus 2 in the RER was subject to coordinate misregulation at 
smaller window sizes I then went on to confirm the compaction results seen at this locus 
in other breast cancer cell lines. I used the heat map analysis of expression data for locus 
2 to select another ER+ve (LY2) and another ER-ve (MDAMB468) cell line (Figure 4.4.: 
Yellow box, black arrows). These two cell lines also showed a coordinate and consistent 
expression phenotype of relative activation in ER+ve cells and repression  in  ER-ve cells 









Figure 4.6: RER analysis at 16p11.2 with decreasing the sliding window size. Ideogram at 
the top represents chromosome 16 with a red box encompassing the region (p11.2) highlighted 
below containing the RER domain. The browser tracks represents the location of the RER 
identified from the analysis of 356 breast tumours (top) or 48 breast cancer cell lines (below). The 
position of fosmids (blue) used as probes for analysis of the region by FISH are indicated. Below 
this are browser tracks (black) representing regions derived from the cell line data when varying 
the number of neighbours in the sliding analysis window, from n=1-10 (where 2n+1 = total 
window size), before refinement of the region.  
	  
 
The normalised inter-probe FISH distances recapitulated my previous findings of a 
significantly more decompact chromatin architecture in ER+ve (MCF7, LY2) versus ER-
ve breast cancer cells (MDAMB231, MDAMB468) (Figure 4.7). The significance of 
these differences were assessed using the Wilcox test and are summarised in Table 4.1. 
Interestingly there was also a significant difference in chromatin compaction between 
LY2 and MCF7 cells with LY2 appearing to be more decompact at this locus (Figure 4.7; 
Table 4.1). This may be due to differences in the nuclear size between the cell lines.  
 
	  
Table 4.1: Summary Table of all Wilcox test p-values for cell line analysis of normalised 
interprobe distances for locus 2 in the RER on chromosome 16p11.2  
 
Cell lines tested Wilcox test p-value 
HMLE MCF7 0.001 
HMLE LY2 0.000 
HMLE MDAMB361 0.029 
HMLE MDAMB231 0.196 
HMLE MDAMB468 0.071 
MCF7 LY2 0.022 
MCF7 MDAMB361 0.127 
MCF7 MDAMB231 0.026 
MCF7 MDAMB468 0.043 
LY2 MDAMB361 0.000 
LY2 MDAMB231 0.000 
LY2 MDAMB468 0.000 
MDAMB361 MDAMB231 0.358 
MDAMB361 MDAMB468 0.716 






                 
 
 
Figure 4.7: Chromatin compaction at locus 2 correlates with breast cancer subtype. (A) As 
viewed in the UCSC browser with scale and location on chromosome 16p11.2. The top browser 
track represents the location of the RER identified from the analysis of 356 breast tumours. The 
bottom browser track represents the location of the RER identified from the analysis of 48 breast 
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cancer cell lines. The FISH probes browser track (red and green) represents the location of 
fosmids used as probes for analysis of the region by FISH, dividing the region into 4 loci. n = 45-
60 interphase nuclei. and normalised to nuclear area. The distribution of these normalised 
interprobe distances in two luminal-type ER+ve cell lines (MCF7, LY2) and two basal-type ER-ve 
cell lines (MDAMB231,MDAMB468) are represented as  boxplots below the tracks described. (B) 
Representative FISH images of nuclei hybridised with probes W12-1754H9 (green) and W12-
906G10 (red). DNA is stained with DAPI (blue). Scale bars = 5µm. 
 
 
The ER+ve cell lines generally had a significant larger nuclear size compared with the 
ER-ve cell lines (Figure 4.8; Table 4.2). MCF7 cells from these preparations had much 
larger nuclear area than all other cell lines tested though these cells did not have the 
largest normalised inter-probe distances at this locus.  Interestingly it was the LY2 cells 
that had the largest normalised inter-probe distances at locus 2 even though they were not 
the cells with the largest nuclear area they were significantly larger than MDAMB231 
they were not larger than MDAMB468 cells. There was also a significant difference 
between the nuclear area between MDAMB231 and MDAMB468 cells though there was 
no significant change in the level of chromatin compaction at this locus. This data would 
indicate therefore that the difference in nuclear size between cell lines does not explain 
the changes in chromatin compaction seen between the ER+ve and ER-ve cell lines.  
 
Additionally, the two ER+ve cell lines were mostly aneuploidy with three chromosome 
16’s in MCF7 cells and five in LY2 cells (Figure 4.7B). The precise relationship between 
ploidy and nuclear area is unknown and therefore the variable ploidy seen in these cell 
lines could account for the changes seen in chromatin compaction between the two 
subtypes. To eliminate this possibility I selected a negative control region to study by 
FISH, at which I would not expect to see chromatin compaction differences between 







Figure 4.8: Nuclear area in breast cancer cell lines. Box plots of the nuclear area (µm2) 
distribution across all nuclei tested in the four breast cancer cell lines as determined from DAPI 






Table 4.2: Summary Table of all Wilcox test p-values for cell line analysis of nuclear area using 
FISH data for locus 2 analysis on chromosome 16p11.2  
 
Cell lines tested Wilcox p-value  
MCF7 LY2 0.000 
MCF7 MDAMB231 0.000 
MCF7 MDAMB468 0.000 
LY2 MDAMB231 0.043 
LY2 MDAMB468 0.110 






4.2.4: Selection of a negative control region 
 
 
To ensure that there are no systematic variations in the chromatin compaction between 
the cell lines used in the above analysis of the RER on chromosome 16p11.2 it was 
necessary to investigate a control locus. Previously in the Bickmore lab the β-globin 
locus on chromosome 11 has been used as a FISH control region as these genes are 
expressed in a tissue specific manner in erythroid cells. The β-globin locus is also 
surrounded by olfactory receptor genes which were generally thought to be expressed 
exclusively in the olfactory sensory neurons, although recent expression profiling has 
shown that they are expressed in a wide variety of human tissues (Flegel et al., 2013).  I 
used a pair of probes 533 kb apart that span the β-globin locus  to examine the two 
luminal-type ER+ve cell lines (MCF7, LY2) and the two basal-type ER-ve cell lines 




Figure 4.9: A FISH control locus on chromosome 11p15.4 encompassing the β-globin and 
olfactory receptor loci. As viewed in the UCSC browser. Ideogram at the top represents 
chromosome 11 with a red box encompassing the region (p15.4) highlighted below containing the 
control domain. The  FISH probes browser track (red:	   W12-528M6; green:W12-2033J5) 
represents the location of fosmids used as probes for analysis of the region by FISH. Below the 





There was no significant difference between the distribution of normalised inter-probe 
distances for this region between LY2, MDAMB231 and MDAMB468 cell lines (Figure 
4.10; Table 4.3). However the region appears to be more compact in MCF7 cells than in 
all other cell lines analysed (Figure 4.10; Table 4.3). This is not what I would have 
expected if there was a systematic change in the chromatin compaction between the cell 
lines tested for locus 2 on chromosome 16p11.2 – I would have expected a mirror of the 
results shown in Figure 4.7 and Table 4.1.  
 
 
Table 4.3: Summary Table of all Wilcox test p-values for cell line analysis of normalised 
interprobe distances the control region on chromosome 11 
 
 
Cell lines tested Wilcox test p-value 
MCF7 LY2 0.023 
MCF7 MDAMB231 0.056 
MCF7 MDAMB468 0.010 
LY2 MDAMB231 0.665 
LY2 MDAMB468 0.790 




LY2 and MDAMB231 cells both have three copies of chromosome 11 whereas the 
MCF7 and MDAMB468 cells have two (Figure 4.10B). This difference in ploidy appears 
to have no bearing on the chromatin compaction status of the control locus as although 
both MCF7 and MDAMB468 have normal ploidy for this chromosomes there is a 
significant difference in the chromatin compaction with a more decompact structure for 
the MDAM468 cells akin to that seen for the cell lines LY2, MDAMB231 (Figure 4.10A, 







Figure 4.10: Chromatin compaction at control region on chromosome 11p15.4.  (A) As 
viewed in the UCSC browser with scale and location on chromosome 11. The probes browser 
track (red and green) represents the location of fosmids used as probes for analysis of the region 
by FISH. For this control locus the interprobe distance was assayed in 45-60 interphase nuclei 
and normalised to nuclear area. The distribution of these normalised interprobe distances in two 
luminal-type ER+ve cell lines (MCF7, LY2) and two basal-type ER-ve cell lines 
(MDAMB231,MDAMB468) are represented as  boxplots. (B) Representative images of FISH 
nuclei for all cell lines hybridised with probes W12-2033J5 (green) and W12-528M6 (red). DNA is 





I then set out to identify a control region that was as similar to the region of subtype 
specific compaction change (locus 2) as possible, and located on the same chromosome 
(16). The control region identified was 1.4 Mb upstream of the start of locus 2 and was 





Figure 4.11: UCSC genome browser tracks showing the location of control FISH probes in 
relation to the RER on chromosome 16p11.2. Ideogram at the top represents chromosome 16 
with a red box encompassing the region (p11.2) highlighted below containing the RER domain. 
The top browser track represents the location of the RER identified from the analysis of 356 
breast tumours. The bottom browser track represents the location of the RER identified from the 
analysis of 48 breast cancer cell lines. The control FISH probes browser track (red and green) 
shows the start and end point of the control region selected. The RER FISH probes track below 
(red and green) represents the location of fosmids used as probes for analysis of the RER region 
by FISH. Below this are browser tracks (black) representing regions derived from the cell line 
data when varying the number of neighbours in the sliding analysis window, from n=1-10 (where 







Figure 4.12 shows all genes within the 380 bp region selected as a FISH control domain 
on chromosome 16p11.2. 
 
 
Figure 4.12: Control locus on chromosome 16p11.2. The FISH probes browser track (red: 
WI2-3081O2; green:WI2-2889N9) represents the location of fosmids used as probes for analysis 
of the region by FISH. Below the browser track are all genes within the coordinates for the red 
box as determined by UCSC.  
 
FISH using this control locus in the two ER+ve (MCF7, LY2) and ER-ve (MDAMB231, 
MDAMB468) breast cancer cell lines show that the differences in nuclear area and ploidy 
between these cell lines was not responsible for the changes seen in chromatin 
compaction seen in the 16p locus 2 RER (Figure 4.13, Table 4.4). As for the region 
encompassing the β-globin locus, the chromatin at this second control region was most 
compact in the MCF7 cells when compared to all other cell lines. No other significant 
differences in chromatin compaction were seen between the other cell lines.  
 
Table 4.4: Summary Table of all Wilcox test p-values for cell line analysis of normalised 
interprobe distances for the control locus located adjacent to the RER on chromosome 16p11.2  
 
Cell lines tested Wilcox test p-value 
MCF7 LY2 0.000 
MCF7 MDAMB231 0.026 
MCF7 MDAMB468 0.001 
LY2 MDAMB231 0.252 
LY2 MDAMB468 0.914 
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          B 
 
 
Figure 4.13: Chromatin compaction at control region on chromosome 16p11.2. The 
interprobe distance was assayed in 50-60 interphase nuclei and normalised to nuclear area. The 
distribution of these normalised interprobe distances in two luminal-type ER+ve cell lines (MCF7, 
LY2) and two basal-type ER-ve cell lines (MDAMB231,MDAMB468) are represented as  boxplots. 
(B) Representative images of FISH nuclei for all cell lines hybridised with probes WI2-2889N9 






4.2.5: Chromatin compaction in a normal breast cell line 
	  
I had established that the changes in chromatin compaction at locus 2 of the RER on 
chromosome 16p11.2 in breast cancer cell lines are related to tumour subtype. I detected 
a relative chromatin decompaction in ER+ve cell lines at this locus compared with ER-ve 
cell lines and this is correlated with gene expression signature. To show that altered 
chromatin compaction was indeed related to coregulated gene expression I selected, from 
the heat map analysis of expression z scores for locus 2, a cell line where there was not a 
coordinate expression pattern across the entire locus (an “intermediate expression 
phenotype”).  
 
Figure 4.14: Selecting a cell line with an intermediate gene signature in 16p11.2 RER. 
Unsupervised cluster analysis of locus 2 for 48 breast cell lines from Neve et al., 2006. The heat 
map is vertically clustered using Euclidean clustering (shown as dendogram) to indicate the 
similarity of sample scores with each other. Based on subtype information from Neve et al., 2006 
each sample is identified by a color-coded matrix below the dendrogram: basal (red), luminal 
(blue) The legend shows z-scores where red/green indicate an increase/decrease in gene 
expression relative to the universal mean for each gene. The values were mean centred and the 
colours scaled from the max (+4) & min (-4) standard deviations. This enables relative 





Consistent with its gene expression profile, the normalised inter-probe distances 
established by FISH in the MDAMB361 cell line indicated a chromatin compction level 
intermediate to that in ER+ve (MCF7, LY2) and ER-ve (MDAMB231,MDAMB468) 
cells (Figure 4.15). The distribution of inter-probe distances for MDAMB361 cells was 
not significantly different to that of any of the other breast cancer cell lines except LY2 
which was the most decompact cell line overall as well as when compared to the other 
ER+ve cell line MCF7 (Table 4.1).  
 
Given that gene expression in the 16p11.2 RER is thought to be aberrantly upregulated in 
tumours compared to normal breast tissue  (Figure 4.1A) I next wanted to examine the 
chromatin compaction status at locus 2 of a normal breast cell line. To do this, I carried 
out FISH on fixed preparations of a non-transformed immortalized human mammary 
epithelial cell line HMLE obtained from Elad Katz (Breakthrough Breast Cancer) and 
developed in the Weinberg lab (Elenbaas et al., 2001; Rangarajan et al., 2004); (Ma et al., 
2010). Analysis of normalised inter-probe distances showed that locus 2 is more compact 
in chromatin structure in HMLE cells than in all ER+ve cell lines tested (MCF7, LY2, 
MDAMB361), but not compared to ER-ve cell lines (MDAMB231, MDAMB468) 
(Figure 4.15; Table 4.1). This was not an altogether surprising finding given that the 
largest incidence of tumours tend to be ER+ve  and that the analysis of tumour expression 








Figure 4.15: Chromatin compaction at locus 2 correlates with breast cancer subtype. (A) 
As viewed in the UCSC browser with scale and location on chromosome 16p11.2. The top 
browser track represents the location of the RER identified from the analysis of 356 breast 
tumours. The bottom browser track represents the location of the RER identified from the analysis 
of 48 breast cancer cell lines. The FISH probes browser track (red and green) represents the 
location of fosmids used as probes for analysis of the region by FISH, dividing the region into 4 
loci. For Locus 2 the interprobe distance was assayed in 45-60 interphase nuclei and normalised 
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to nuclear area. The distribution of these normalised interprobe distances in three luminal-type 
ER+ve cell lines (MCF7, LY2, MDAMB361), two basal-type ER-ve cell lines 
(MDAMB231,MDAMB468) and a normal breast cell line (HMLE)  are represented as boxplots 
below the tracks described. (B) Representative images of FISH nuclei for all cell lines hybridised 
with probes W12- 1754H9(green) and W12-906G10 (red). DNA is stained with DAPI (blue). Scale 
bars = 5µm. 
 
 
4.2.6: Confirmation of chromatin compaction status in tumour 
tissue sections 
 
Having confirmed, for a candidate RER, changes in chromatin compaction that correlated 
with changes in gene expression in vitro I then wanted to examine this ex vivo. To do so I 
obtained breast tumour tissue sections and normal breast tissue by collaboration with 
Jeremy Thomas (Consultant Pathologist at Edinburgh Breast Unit).  Usage of tumour 
material was approved by the Lothian Research Ethics Committee (08/S1101/41) and 
obtained under the auspices of Experimental Cancer Medicine Centre programme 
(Edinburgh). 
 
3D FISH analysis using probes for locus 2 (RER on chromosome 16p11.2) on tissue 
sections from an ER+ve tumour, an ER-ve tumour and normal breast tissue confirmed 
previous findings from cell-line based work. The chromatin at this locus was at its most 
compact in the normal tissue with the most significant decompaction observed in ER+ve 
tissue (Figure 4.16; Table 4.5). Moreover there was no significant difference in chromatin 
compaction between normal tissue and ER-ve tumour at this locus (Table 4.5). There was 
however, as expected from the cell line data, a significant difference in the chromatin 
compaction between ER+ve and ER-ve tumours for this locus contained in the RER on 
chromosome 16p11.2 (Figure 4.16; Table 4.5).   
 
Table 4.5: Summary Table of all Wilcox test p-values for breast tumour and normal tissue 
analysis of normalised interprobe distances for the RER (locus 2) located  on chromosome 
16p11.2 
Tissues tested Wilcox test p-value 
Normal ER+ve 0.000 
Normal ER-ve 0.240 
ER+ve ER-ve 0.004 
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Figure 4.16: Chromatin compaction at locus 2 of RER correlates with breast cancer 
subtype in tumour tissues by 3D FISH. (A). The squared interprobe distances for 250-300 pairs 
of FISH probes was assayed in normal breast tissue, an ER+ve type tumour tissue and an ER-ve 
type tumour tissue. The distribution of these interprobe distances are represented as  boxplots.  
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(B) Representative snapshot images of tissue sections used for FISH analysis with probes W12-




4.2.7: Data for chromatin compaction follows a random-walk 
model  
	  
A random walk model of the behaviour of higher order chromatin has been identified 
using FISH data with pairs of probes at different genomic intervals along the linear DNA 
molecule (van den Engh et al., 1992). With probe separations of 100kb to 1.5 Mb there is 
a linear relationship between the mean inter-probe distances (squared) and the genomic 
distance that fits a “random walk” model with the chromatin behaving like a flexible 
polymer (van den Engh et al., 1992). This model was also suggested by further work 
using probes for 150kb to 190Mb intervals on chromosomes 4, 5 and 19 and modelling of 
the large-scale chromatin geometry (Sachs et al., 1995; Yokota et al., 1995). This analysis 
produced a “random walk/giant loop” model of large-scale chromatin organisation 
whereby at megabase intervals the chromatin is organised in loop structures which are 
fixed on a flexible backbone that shows random walk behaviour (Sachs et al., 1995).  
 
In this model interprobe distance conform to a Rayleigh distribution and are characterised 
by a standard deviation/mean ratio of ~0.52 and a median/mean ratio of ~0.94. Similar 
data distributions have been seen in the Bickmore lab for many regions of the mouse and 
human genomes in a wide variety of cell types and in tissue sections (Chambeyron and 
Bickmore 2004, Gilbert et al., 2004, Williamson et al., 2012). In this chapter the 
distribution of observed distances for each of the cell lines I tested also fitted this 
distribution, with the exception of the MCF7 (locus 1) and HMLE (locus 2) cell lines 
(Table 4.6). Therefore, with these exceptions, at the genomic distances tested in this 
chapter the chromatin fibre between two probes follows a random walk model. The 
deviation from this random walk model by the MCF7 and HMLE cells suggests an 








In normal breast and tumour tissue samples the observed distances by FISH also 
conformed to a Rayleigh distribution for each of the cell lines tested (Table 4.7) thereby 
indicating that the ex vivo 3D FISH analyses also followed the random walk model of 
chromatin behaviour. This was also true of the normal breast tissue tested by 3D FISH 
unlike the normal breast epithelial cell line (HMLE).  
 
 






4.2.8: RER localisation with regard to the nuclear periphery 
	  
As discussed in chapter 1 (sections 1.2.4.4. and 1.3.4) the spatial organisation of 
chromosomes in the nucleus influences gene expression, with the nuclear periphery 
associated with transcriptional repression. Differences in the radial position of genes in 
the nucleus have been reported that can reliably detect cancerous tissues (Meaburn et al., 
2009). I therefore set out to determine whether or not there were differences in the radial 
positioning of the RER on chromosome 16p11.2.  To quantify radial positioning, I 
compared the relative proportion of hybridization signals from the RER on chromosome 
16p11.2 across five shells of equal area eroded from the centre (shell 1) through to the 
periphery (shell 5) in 40-60 nuclei from each cell line (Figure 4.17).  
 
Chromosome 16 is normally located in the centremost erosion shells of nucleus (S Boyle 
et al., 2001) therefore it was not unexpected to find that most of the hybridisation signals 
were located in shells 1-2 (Figure 4.17).  Given that the ER+ve cell lines (MCF7, LY2) 
show a higher expression signature and more decompact chromatin structure at this RER 
compared to ER-ve cell lines (MDAMB231, MDAMB468), I examined whether the 
ER+ve cell lines had more hybrisation signals in the centremost erosion shells of the 
nucleus. Indeed whilst this appears to be the case for the centremost erosion shell 1, 
overall the difference in the distribution of hybridisation signals across erosion shells was  
only significant between ER+ve MCF7 cells and the ER-ve MDAMB231 cells (Table 
4.8, Figure 4.17).  
	  
Table 4.8 Summary of statistics testing changes in the radial positioning of 16p11.2  
	  
Cell lines tested Fisher exact test (p-value) 
MCF7 MDAMB231 0.015 
MCF7 MDAMB468 0.289 
MCF7 LY2 0.238 
LY2 MDAMB231 0.261 
LY2 MDAMB468 0.708 










Figure 4.17: Eroding the nucleus into shells of equal nuclear area to determine the 
localisation of RER on chromosome 16p11.2 Shown are the percentage of FISH probe signals 
for this region that occurred in each of five shells of equal area with increasing shell number 







In the previous chapter I identified at least 26 regions in the breast cancer genome that 
show aberrant coordinate gene expression potentially due to epigenetic regulation. These 
were consistent between breast cancer cell line and tumour datasets and were denoted 
Regions of Epigenetic Regulation (RERs). The most interesting part of this analysis was 
that these RERs were not all subject to the LRES phenomena described in previous 
studies, rather they showed a variety of expression phenotypes that included aberrantly 
“activated” and “repressed” expression when comparing breast tumours to normal tissue.  
 
In this chapter I selected a RER on chromosome 16p11.2 to investigate the mechanism of 
dysregulation that appeared in analyses from both tumour and cell line data and that was 
also differentially expressed between different subtypes of breast cancer. Given that 
previous reports have shown multiple epigenetic changes in LRES domains I 
hypothesized that an alteration in the higher order chromatin organisation may have a 
role to play in misregulating such large regions of the genome in cancer.  The selected 
RER domain also contained genes  (SPN, QPRT, ZG16, KIF22, MAZ, PRRT2, MVP, 
SEZ6L2, ASPHD1, KCTD13, TMEM219, TAOK2, INO80E, DOC2A) in a region 
previously shown to be involved in estrogen-mediated repression by DNA looping in 
breast cancer (Hsu et al., 2010) which also made it an interesting candidate for 
investigating chromatin structure. This region is aberrantly upregulated in breast cancer.  
 
 
Having refined the domain of RER by dividing it into 4 loci for FISH and using smaller 
sliding windows for computational analyses, I investigated chromatin decompaction as a 
mechanism of the aberrant activation of gene expression at this RER on chromosome 
16p11.2 (denoted  locus 2). Previous work in the Bickmore lab has shown by FISH that 
gene-rich transcriptionally active loci are in a decondensed chromatin structure in the 
nucleus which is thought to be a permissive environment for transcription to take place 
by allowing access to the genome (Gilbert et al., 2004). My findings in this chapter also 
showed that where the chromatin for locus 2 was decompacted in ER+ve breast cancer 
cell lines and tumour tissue, transcription was activated compared to normal and ER-ve 
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cell lines and tissue. Control FISH loci were used to confirm that the changes observed 
were not systemic.  
 
Whereas, these findings are consistent with what is expected from previous studies that 
link active gene expression and chromatin decompaction, it is not what would have been 
expected based on data from (Hsu et al., 2010). Hsu et al describe a “large repressive 
zone” in breast cancer cells that is encompassed by my original RER on chromosome 
16p11.2 (specifically FISH locus 1) and that involves 14 gene promoters in a DNA loop 
structure thought to act as a physical repressive barrier to transcription (Figure 4.19A, 
green boxes). It was suggested that in normal cells this is a transient estrogen mediated 
structure but is a permanent feature of cancer cells (Hsu et al., 2010). I would therefore 
have expected the ER+ve subtype of breast cancer cells to be significantly more compact 
at loci 1. However, this was not the case and the region as a whole was also not repressed 
in tumours relative to normal tissue  (Figure 4.19B: p-value = 1.403e-09). Heat map 
analysis of the cell line expression data shows that there is not an obvious subtype-
specific coordinated expression pattern at locus 1 taken by itself (Figure 4.19C). Looking 
at the cell lines used for FISH this is particularly true of the MCF7 cell line. Therefore it 
is not surprising that upon refinement of the region using smaller window sizes this locus 
was lost as part of the 16p11.2 RER.  
 
I also observed a re-localisation of the 16p11.2 region more toward the nuclear centre in 
ER+ve MCF7 cells compared with ER-ve MDAMB231 cells. This was not however a 
significant effect when comparing ER+ve LY2 and ER-ve MDAMB468 cell lines. It’s 
possible that this is due to the highly rearranged nature of chromosomes in the cancer cell 
lines, especially for the LY2 cell line, which would likely effect  positioning.  
 
Overall, the data in this chapter suggest that this refined RER domain of 16p11.2 is 
aberrantly upregulated in breast cancer due to an overall decompaction of chromatin of 
the locus and possibly its repositioning towards the centre of the nucleus - perhaps to 
hubs containing transcriptional machinery required for active gene expression 
(Sutherland and Bickmore, 2009). In chapter 5 I further investigate the mechanism 





Figure 4.19: Assessing locus 1 of the RER on chromosome 16p11.2. (A) As viewed in the 
UCSC browser. Ideogram at the top represents chromosome 16 with a red box encompassing 
the region (p11.2) highlighted below containing RER domain in tumours and cell lines (red) and 
locus 21 FISH probes below (blue). At bottom are all genes within the coordinates for the red box 
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as determined by UCSC. Boxed in green are the 14 genes involved in DNA looping by Hsu et al 
2010.  (B) Analysis of gene expression changes in tumours relative to normal tissue. Mean 
centred z scores were calculated for all genes in the region. The median z score for each sample 
was used to to plot the distribution of these scores as boxplots and enabling relative comparison 
of scores between samples. (C) Unsupervised cluster analysis of locus 1 for 48 breast cell lines 
from Neve et al., 2006. The heat map is vertically clustered using Euclidean clustering (shown as 
dendogram) to indicate the similarity of sample scores with each other. Based on subtype 
information from Neve et al., 2006 each sample is identified by a color-coded matrix below the 
dendrogram: basal (red), luminal (blue) The legend shows z-scores where red/green indicate an 
increase/decrease in gene expression relative to the universal mean for each gene. The values 
were mean centred and the colours scaled from the max (+3.81) & min (-3.81) standard 


















Changes in chromatin compaction at locus 2 













In the previous chapter I began investigating a proposed RER domain at 16p11.2. This 
RER was of particular interest as it was aberrantly upregulated in breast tumours and 
showed a differential expression phenotype across ER+ve and ER-ve tumour subtypes.  
The RER was further refined by division into four sub-regions which were assayed by 
FISH to assess chromatin compaction. At sub-region 2 chromatin decompaction was 
observed that correlated with breast cancer subtype and gene expression signature. 
Further computational work based on efforts described in chapter 3 showed that the RER 
domain could be further delineated into a much smaller RER domain that correlated with 
FISH locus 2.  
 
Previous studies looking for large regions of coordinated gene misregulation in cancer 
have observed changes in DNA methylation and histone modifications present at 
particular genes, though these are not uniformally distributed through the regions. Based 
upon this premise I set out to investigate alterations in chromatin architecture as a 
plausible explanation for the misregulation of large regions of contiguous genes. In this 
part of the thesis I investigate the hypothesis that the alteration in chromatin packing at 






5.2.1: Sub-region 2 of the 16p11.2 RER contains genes bound by 
ERα  
 
The changes in chromatin architecture described in Chapter 4 showed subtype specificity 
in relation to the ER status of the cell lines and tumours. As described in the Introduction 
to this thesis (Section 1.2.4.6.) the estrogen receptor has been reported to have a role in 
chromatin organisation. I therefore wanted to see what ER binding sites there were in 
locus 2 of the 16p11.2 where I had observed the subtype specific chromatin organisation 
changes. Using the ChIA-PET visualisation browser (http://cms1.gis.a-star.edu.sggure) I 
was able to identify a number of ER binding sites in the locus that overlapped with 
H3K4me3, RNA polymerase II and FoxA1 binding in estrogen induced MCF7 cells 
(Figure 5.1) (Fullwood et al., 2009). Moreover from the ChIA-PET ERα data the region 
was not enriched in complex or duplex intra-chromosomal interactions in response to 
estrogen treatment (Figure 5.1 – browser track 5). 
 
By extrapolating from their complex intra-chromosomal associations assayed by ChIA-
PET, Fullwood et al (2009) postulate that there are estrogen-mediated chromatin loop 
structures, that allow interacting ‘anchor’ genes to be actively transcribed in close 
proximity to one another. This is conceptually similar to the transcription factory model. 
Contrary to this, Hsu et al (2010) showed that estrogen-mediated cross-linked 
associations bring together multiple gene promoters linked to their transcriptional 
repression. However as discussed at the end of Chapter 4 this analysis  was not supported 
by my own findings for this reported domain (FISH locus 1).  
 
From the ChIA-PET data it was evident that locus 2 of the 16p11.2 RER domain was 
largely devoid of the complex estrogen-induced intra-chromosomal interactions in ER+ve 
MCF7 cells (Figure 5.1) that are described in Fullwood et al (2009). This is in keeping 
with my observation that ER+ve cell lines and tumours are more decompact at this locus 
than those that are ER-ve, since presumably complex interactions and looping within the 
locus should result in a chromatin conformation that appears more compact in ER+ve 
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cells/tumours by FISH (Fullwood et al 2009).  To confirm this, and to discover the 
impact of the ER with regard to compaction at locus 2, I decided to investigate the 




Figure 5.1: Locus 2 of RER 16p11.2 in estrogen-induced MCF7 cells. Screenshot taken from 
the ChIA-PET visualation browser: http://cms1.gis.a-star.edu.sg (Fullwood et al 2009) using hg18 
coordinates for FISH locus 2.  ChIA-PET browser tracks:  1, H3K4me3 ChIP-Seq; 2, RNAPII 
ChIP-Seq; 3, ERα (orange) and FoxA1 ChIP-chip (green) (Lupien et al., 2008); 4, ERα ChIA-PET 





5.2.2: The affect of estrogen on chromatin compaction 
	  
Having concluded that there were ER binding sites in locus 2 of RER 16p11.2 (Figure 
5.1) I wanted to test my hypothesis that the changes in higher order chromatin 
architecture were mediated by estrogen and the ER. To do this I cultured the ER+ve 
breast cancer cell line MCF7, and ER-ve cell line MDAMB231, in phenol-free media 
with fetal calf serum that had been stripped of all endogenous hormones (see Methods). 
After three consecutive days in this media under “starvation” conditions I treated the cells 
with 100nM of 17β-estradiol (hereby referred to as estrogen) for 24 hours. These 
conditions have been shown in time-course experiments to activate high level expression 
of estrogen-regulated genes in MCF7 cells (Karp et al., 2007; Tynan et al., 2004).   
 
Cells were then fixed to make preparations for FISH, from normal media (N), starved 
media (S) and starved media with the reintroduced estrogen (E) and  chromatin 
compaction was assayed by measuring the physical distance between probes (W12-
1754H9 and W12-906G10) flanking locus 2 of RER 16p11.2 (Figure 4.2). Inter-probe 
distances from 50-60 images were converted from pixels to microns and were then were 
squared (d2). The mean d2 was used to estimate the level of chromatin compaction under 
the different conditions. The observed inter-probe distances were also normalised to the 
radius squared (d2/r2) to account for differences in the nuclear area between samples. As 
before, significant changes in chromatin compaction were assessed using the Wilcox test 
with a cut off of p<0.05 (summarised in Table 5.1).  
 
Analysis of the data for ER+ve MCF7 cells showed that upon hormone deprivation the 
chromatin at locus 2 compacts significantly and that this effect can be rescued by addition 
of estrogen to the starved media (Figure 5.2 and Table 5.1). This is consistent with the 
idea that the decompact chromatin status at locus 2 for ER+ve cells is mediated by 
estrogen itself.  
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Table 5.1: Summary of statistics for detecting significance of estrogen-mediated changes  
Cell lines tested Locus tested Wilcox test p-value 
MCF7 (Normal) MCF7 (Starved) locus 2 RER  0.002 
MCF7 (Normal) MCF7 (Starved + Estrogen) locus 2 RER 0.520 
MCF7 (Starved) MCF7 (Starved + Estrogen) locus 2 RER 0.003 
MCF7 (Normal) MCF7 (Starved) control  0.000 
MCF7 (Normal) MCF7 (Starved + Estrogen) control  0.000 
MCF7 (Starved) MCF7 (Starved + Estrogen) control  0.944 
MDAMB231 (Normal) MDAMB231 (Starved) locus 2 RER  0.406 
MDAMB231 (Normal) MDAMB231 (Starved + Estrogen) locus 2 RER 0.766 
MDAMB231 (Starved) MDAMB231 (Starved + Estrogen) locus 2 RER 0.324 
MDAMB231 (Normal) MDAMB231 (Starved) control  0.540 
MDAMB231 (Normal) MDAMB231 (Starved + Estrogen) control  0.477 





Figure 5.2: Effect of estrogen on chromatin compaction at locus 2 in MCF7 cells. (A) Box 
plots to show the distribution of FISH interprobe distances (d) normalised to nuclear area (d2/r2) in 
normal media, hormone-deprived media (3 days) and hormone deprived media (3 days) +100nM 
estrogen (24h). N= 50-60 nuclei (B) Representative images (for each culture condition) of FISH 
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nuclei hybridised with probes W12-1754H9 (green) and W12-906G10 (red). DNA is stained with 
DAPI (blue). Scale bars = 5µm. 
 
	  
To ensure there were no systemic changes in gross chromatin compaction across the 
genome upon these culture conditions I used the FISH control region on chromosome 
16p11.2 adjacent to the RER domain as designed in the previous chapter (Figure 5.3 and 
Table 5.1). Under normal culture conditions the MCF7 cells were at their most compact. 
Upon hormone deprivation there was a significant decompaction of the control locus that 
remained decompact after the reintroduction of estrogen to the cells. This latter result 
suggests that at this control locus estrogen itself does not have an effect on chromatin 
compaction levels though charcoal-stripping of the serum, which removes hormones and 




Figure 5.3: Effect of estrogen on chromatin compaction at control locus on 16p11.2 in 
MCF7 cells. (A) The interprobe distance (d) was assayed in 50-60 interphase nuclei and 
normalised to nuclear area (d2/r2). The distribution of these normalised interprobe distances in 
normal media, hormone-deprived media (3 days) and hormone derprived media (3 days) +100nM 
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estrogen (24h) are shown as boxplots. (B) Representative images (for each culture condition) of 
FISH nuclei hybridised with probes W12-1754H9 (green) and W12-906G10 (red). DNA is stained 
with DAPI (blue). Scale bars = 5µm. 
 
	  
To show that the changes in chromatin compaction at locus 2 were mediated by estrogen 
acting through the estrogen receptor, FISH was used to examine chromatin compaction 
during hormone deprivation and subsequent estrogen addition, in the ER-ve cell line 
MDAMB231.  This showed that chromatin at locus 2 shows no significant change in 
chromatin compaction after hormone deprivation and after the reintroduction of estrogen 




Figure 5.4: Effect of estrogen on chromatin compaction at locus 2 in MDAMB231 cells (A) 
The interprobe distance (d) was assayed in 50-60 interphase nuclei and normalised to nuclear 
area (d2/r2). The distribution of these normalised interprobe distances in normal media, hormone-
deprived media (3 days) and hormone derprived media (3 days) +100nM estrogen (24h) are 
shown as boxplots. (B) Representative images (for each culture condition) of FISH nuclei 
hybridised with probes W12-1754H9 (green) and W12-906G10 (red). DNA is stained with DAPI 




As for MCF7 cells, the control locus designed adjacent to the RER on chromosome 
16p11.2 was assayed for each of the three culture conditions in MDAMB231 cells. This 
locus showed no change in the level of chromatin packing between each of the conditions 
(Figure 5.5 and Table 5.1).  Therefore I conclude that the changes in chromatin 





Figure 5.5: Effect of estrogen on chromatin compaction at control locus on 16p11.2 in 
MDAMB231 cells. (A) The interprobe distance (d) was assayed in 50-60 interphase nuclei and 
normalised to nuclear area (d2/r2). The distribution of these normalised interprobe distances in 
normal media, hormone-deprived media (3 days) and hormone derprived media (3 days) +100nM 
estrogen (24h) are shown as boxplots. (B) Representative images (for each culture condition) of 
FISH nuclei hybridised with probes W12-1754H9 (green) and W12-906G10 (red). DNA is stained 




As discussed in the previous results chapter the behaviour of higher order chromatin 
follows a “random walk/giant loop”  model where at megabase intervals the chromatin is 
organised in loop structures which are fixed on a flexible backbone that shows random 
walk behaviour (Sachs et al., 1995).  In this chapter the distribution of observed distances 
for each FISH analysis conformed to a Rayleigh distribution (i.e. the standard 
deviation/mean ~0.52 and the median/mean ~0.94) (Table 5.2). Therefore at the genomic 
distances tested in this chapter the chromatin fibre between two probes follows the 
random walk model in the nucleus expected as described by previous reports (Sachs et 
al.,1995;Yokota et al., 1995).  
 
 







5.2.3: An ER-dependent re-localisation of locus 2 in the nucleus 
	  
In the previous chapter I found that the 16p11.2 region was more central in the nucleus in 
ER+ve MCF7 cells than ER-ve  MDAMB231 cells. Given that association with the 
centre and periphery of the nucleus has been associated with transcriptional activation 
and silencing I was interested to see if there would be a difference in the nuclear 
localisation of 16p11.2 that was influenced by estrogen. I therefore analysed the FISH 
data to determine whether or not there were differences in the radial positioning of locus 
2 under the different culture conditions.  
	  
The nuclear position of locus 2 was quantified from the relative proportion of 
hybridization signals across five shells of equal area eroded from the centre (shell 1) 
through to the periphery (shell 5) for each cell line and for each culture condition. This 
data showed that in MCF7 cells the largest proportion of hybridisation signals were 
centrally located (shell 1) but that this reduced dramatically upon hormone deprivation 
and could be rescued by the reintroduction of estrogen to the hormone deprived media 
(Figure 5.6). These changes in the distribution of locus 2 over shells 1-5 upon hormone 
deprivation and subsequent treatment with estrogen were all statistically significant 
(Fisher’s test p<0.05, Table 5.3).  This shows that there is a re-localisation of locus 2, 
representing the p11.2 domain of chromosome 16, that is mediated by estrogen whereby 
in its absence it moves away from the centre of the nucleus and in its presence moves 
towards the centre.  
	  
Table 5.3: The significance of changes in the distribution of hybridisation signals in MCF7 cells 
under different culture conditions( N – normal culture conditions, S-starvation conditions, E – 




test  (p-value) 
N S 0.004 
N E 0.684 









Figure 5.6: Nuclear erosion of MCF7 cells shows an ER-mediated re-localisation of locus 2.   
Shown are the percentage of FISH probe signals for this region that occurred in each of five 
shells of equal area with increasing shell number indicating shells away from the centre of the 





Given the absence of any affect of estrogen withdrawal and re-addition on chromatin 
compaction in ER-ve MDAMB231 cells (Figure  5.5), I would not have expected to see a 
change in radial positioning of the locus in these cells either (Figure 5.7). There appeared 
to some subtle, but not statistically significant (Table 5.4) effect in these nuclei that are 
quite distinct from that seen in the ER+ve MCF7 cells  
	  
Table 5.4: The significance of changes in the distribution of hybridisation signals in MDAMB231 
cells under different culture conditions ( N – normal culture conditions, S-starvation conditions, E 





test  (p-value) 
N S 0.904 
N E 0.086 
S E 0.065 
	  
	  
Figure 5.7: Nuclear erosion of MDAMB231 cells shows an ER-mediated re-localisation of 
locus 2.  Shown are the percentage of FISH probe signals for this region that occurred in each of 
five shells of equal area with increasing shell number indicating shells away from the centre of the 





5.2.3: Changes in nuclear area upon hormone deprivation and 
stimulation by estrogen  
	  
I also observed gross changes in the nuclear area of MCF7 and MDAMB231 cells under 
the different culture conditions (Figure 5.8 and Table 5.5). Although the nuclear area for 
the ER+ve cell line MCF7 was larger than the ER-ve MDAMB231 cells  there were also 
differences when depriving both cell types of hormones and when reintroducing estrogen 
to the cells. Interestingly in both cases there was a significant reduction in the overall 
nuclear size (as assessed by DAPI staining) upon hormone deprivation and reintroduction 
of estrogen to the media by comparison to cells growing in their normal media. Moreover 
for MDAMB231 cells there was also a significant reduction in the nuclear size between 
hormone deprived cells and those that were hormone deprived and then treated with 
estrogen. This effect was not significant in the MCF7 cells. It is likely that these changes 
in nuclear area were due to cell cycle changes upon hormone deprivation and that adding 
estrogen back in the ER+ve MCF7 cells was sufficient to allow cell cycle progression 
(Prall et al., 1997).  
	  
 
Table 5.5: Summary table of all Wilcox test p-values for cell line analysis of nuclear area using 
FISH data 
 
Cell lines tested Wilcox test p-value 
MCF7 (Normal) MCF7 (Starved) 0.014 
MCF7 (Normal) MCF7 (Starved + Estrogen) 0.000 
MCF7 (Starved) MCF7 (Starved + Estrogen) 0.275 
MDAMB231 (Normal) MDAMB231 (Starved) 0.010 
MDAMB231 (Normal) MDAMB231 (Starved + Estrogen) 0.000 










Figure 5.8: Nuclear area differences for MCF7 and MDAMB231 cells. The nuclear area (µm2) 
distribution across all nuclei examined by FISH as determined by quantification of DAPI staining 
for  (A) ER+ve MCF7 cells and (B) ER-ve MDAMB231 cells, under different culture conditions. 









In the previous chapter I was able to pinpoint a sub-region of coordinated misexpression 
of genes on 16p11.2 that correlates with chromatin packing.  There was also a marked 
difference in the localisation of the domain in the nucleus that was subtype specific and 
thought to place the RER in an environment that was conducive to active gene 
expression. The re-localisation of 16p11.2 towards the centre of the nucleus, coupled 
with its chromatin decompaction was highly correlated with the estrogen receptor status 
of the cells examined. This suggested that there are mechanisms in place at this locus that 
require the estrogen receptor to mediate the aberrant expression patterns both with regard 
to subtype and normal breast.    
 
I investigated the role of the estrogen receptor with regard to the sub-RER that was 
aberrantly activated in ER+ve cell lines/tumours compared with ER-ve and normal cell 
lines/tissue. The estrogen receptor has been previously associated with large-scale 
changes in chromatin organisation through both extensive decondensation (Nye et al., 
2002) and complex intrachromosomal interactions (Fullwood et al., 2009). I found that 
starving ER+ve cells of hormone resulted in a compaction of the locus that could be 
reversed by adding estrogen to the medium. This was not the case in the ER-ve cells 
tested. This effect was not seen at the control locus adjacent to the RER domain on 
chromosome 16p11.2. Furthermore these changes were associated with a re-localisation 
away from the nuclear centre in the absence of estrogen which was reversible in ER+ve 
cells by reintroducing estrogen to the system.  
 
Chromatin decondensation and nuclear repositioning of loci that are being actively 
transcribed has been shown previously for the HoxB gene cluster in the developing 
embryo (Chambeyron et al., 2005). Therefore it is possible that in ER+ve cells the active 
gene expression signature is reliant on estrogen signalling to decompact locus 2 and 
reposition it to a hub of enriched in factors for active transcription. Certainly this region 
did not appear to be one of Fullwood et al’s (2009) regions of estrogen induced complex 
looping domains to active transcription hubs nor Hsu et al’s (2010) looped domains of 




The nuclear area in the estrogen deprivation and treatment experiments was also grossly 
effected. There was an overall reduction in the size of the nucleus in both the ER+ve 
MCF7 cells and the ER-ve MDAMB231 cells after culturing in hormone deprived media. 
This would be expected given that the hormones are needed for the growth and 
propogation of cells in culture. This is in keeping with published data that inhibition of 
estrogen induces G1 phase arrest in the cell cycle and that subsequent treatment with 
estrogen allows re-entry of these cells into S phase after 12 hours (Prall et al., 1997). This 
would help explain why the nuclear area was not significantly reduced in ER+ve MCF7 
cells after estrogen addition (24 hours) compared to ER-ve cells, if indeed this is a cell 
cycle effect. This could be tested by Fluorescence Activated Cell Sorting (FACS) 
analysis of cell populations under each of the culture conditions tested to see if there is a 














Comparing RER domains in breast cancer to 












In Chapter 3 I identified domains of copy-number-independent coordinate misregulation 
of gene expression in breast cancer. I went on to show that the aberrant activation of one 
of these domains on chromosome 16p11.2 was correlated with an overall decompaction 
of the chromatin at this locus and that this effect was tumour subtype specific (Chapter 
4). Moreover the changes in chromatin compaction between ER+ve and ER-ve cell lines 
was estrogen dependent (Chapter 5).  
 
During my PhD, as part of a collaboration with Marie Annick Buendia (INSERM U785, 
Centre Hepato-Biliaire, Hôpital Paul Brousse, Villejuif, France) who was interested in 
investigating epigenetic changes in hepatoblastoma I was asked to identify RER domains 
in this tumour subtype. I was able to use the methods described in Chapter 3 to identify 
RER domains in hepatoblastoma tissues using published expression and CGH array data 
from the Buendia lab. This chapter briefly summarises the findings from this 
collaboration.  
 
To identify whether there were “universal” RER domains that were not cancer type 
specific, I have cross referenced my findings for regions of epigenetic regulation in breast 
cancer with those I derived for hepatoblastoma. To this end I also revisit the LRES 








6.2.1. RER in Hepatoblastoma 
 
Hepatoblastomas are childhood cancers that are thought to originate from liver precursor 
cells. Wnt signaling and c-myc function are thought to be important in this malignancy 
(Cairo et al., 2012). Using aCGH and expression data for 25 liver hepatoblastomas and 4 
normal tissues  I used the computational approach described in chapter 3 to identify RER 
domains in the liver hepatoblastoma samples (Cairo et al., 2008).  
Overall, 3.9% of the genes showed a significant correlation in expression (TCS) with 
their neighbours that was copy-number independent. DNA copy number profiles for the 
25 tumour samples and TCS maps for all chromosomes are shown in Appendix XI with 
examples in Figure 6.1. The genes with significant TCS were grouped into 68 regions 
with more than 1 significant TCS gene and containing overall 329 genes above the 
threshold set by transforming the data into z-scores and setting a significance cut off of 
p<0.05 (as described previously for breast cancer). A full list of the 68 RER domains 





   A 
   
   B 
 
Figure 6.1: Copy number profiles  & Transcription Correlation Maps (TCM’s) in 
Hepatoblastoma. (A) The log2 (sample:ref) ratios of the clones were plotted against 
chromosomal position. Regions of loss (green), gain (red), and no change (black) as determined 
by CGHcall (van de Wiel et al., 2007) (B) Transcriptome Correlation Maps generated for 
chromosomes 4 & 6 using data for 25 hepatocoma samples. Dashed line represents the 






Mean centred z scores were calculated for all genes in the region and a comparison of 
overall gene expression in the RERs to that of normal tissue showed that hepatoblastoma, 
like breast cancer, does not conform to the simple LRES phenotype of misregulation of 
large genomic domains. Overall I found that of the 68 RER domains, just 17 of them 
were significantly downregulated in tumours relative to normal tissue and 14 were 
significantly upregulated. Moreover there were 37 RER domains where the overall gene 
expression for the region was not significantly different between normal and tumour 
tissue.  Examples of aberrantly up/down-regulated regions are shown in Figure 6.2 and 
highlighted red/green respectively in Table 6.1 with Wilcox p-values shown for all 68 
regions.   
A     “Activated” gene expression 
 
B    “Repressed” gene expression 
 
Figure 6.2: Analysis of gene expression changes in tumours relative to normal tissue. 
Boxplots showing the distribution of median z score between samples. (A) Regions 16, 17 and 22 
- three examples of regions that were relatively upregulated in tumours. (B) regions  41, 50 and 
68, are three examples of regions that were relatively downregulated in tumours.  
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Table 6.1. Summary of 68 RER domains in hepatoblastoma. Significant up/down-regulated 
RERs were obtained by comparing tumour expression to normal liver tissue samples (Wilcox 
p<0.05). RERs highlighted in yellow show overlap with the 26 RERs identified from breast cancer 







Significant TCS genes 
Hepatoblastoma 
V Normal Liver 
1 1p36.23 - 1p36.21 7.97 PGD,DFFA,TNFRSF8,PRAMEF10 No.sig.change 
2 1p36.13 - 1p36.12 3.44 PAX7,RNF186 No.sig.change 
3 1p34.2 - 1p34.1 2.69 CDC20,DPH2,B4GALT2,RNF220, TMEM53 Downregulated 
4 1p32.3 - 1p32.1 7.24 DIO1,HSPB11,DHCR24,GOT2L1, PRKAA2 No.sig.change 
5 1p12 - 1q21.2 27.81 ADAM30,ITGA10,CD160 No.sig.change 
6 1q21.3 1.65 CRNN,C1orf46 No.sig.change 
7 1q21.3 - 1q22 1.27 RAG1AP1,SCAMP3,CLK2,YY1AP1,DAP3 Downregulated 
8 1q23.1 - 1q23.2 2.57 CD5L,KIRREL,CD1D,CD1A,CD1C No.sig.change 
9 1q24.2 - 1q25.1 4.66 FMO4,C1orf105 No.sig.change 
10 1q25.1 - 1q25.3 6.02 RALGPS2,ABL2 Downregulated 








13 2p23.3 - 2p23.2 4.26 DTNB,KCNK3,CAD,PPM1G No.sig.change 
14 2q31.1 - 2q32.2 13.75 UBE2E3,SSFA2 No.sig.change 




16 2q37.1 - 2q37.2 3.32 NEU2,SAG Upregulated 
17 3q27.1 - 3q27.3 2.53 PSMD2,POLR2H Upregulated 
18 4p16.3 - 4p16.2 3.27 TETRAN,NOP14 Upregulated 




20 6p22.2 - 6p21.33 5.45 
HIST1H1A,HIST1H4A,HIST1H2AB, HIST1H2BB, 
HIST1H3C,HIST1H1C,  HIST1H1T,HIST1H2BC, 




HIST1H2AL, HIST1H1B, HIST1H2BO,OR2B2, 
ZNF192, ZKSCAN3,ZSCAN12,OR2W1, 
OR2J3,OR2N1P,OR12D3, OR12D2, OR11A1, 
OR2H1,HCG9,RNF39 
No.sig.change 
21 6p21.33 1.04 NCR3,C6orf25,C6orf27 Upregulated 
22 6p21.2 - 6p21.1 4.08 APOBEC2,TREM2,TREML2 Upregulated 
23 6p12.2 - 6q13 19.73 RP3-334F4.2,HCRTR2, RP11-278J20.1, KHDRBS2 Upregulated 
24 6q14.2 - 6q21 22.21 HTR1E,GABRR2,FHL5,GPR63,POU3F2 No.sig.change 
25 6q23.2 - 6q24.1 9.41 ALDH8A1,MAP3K5 No.sig.change 
26 6q25.3 - 6q27 7.41 RP11-72O9.4, T,RP3-497J21.1 Upregulated 
27 7q21.3 - 7q22.1 4.85 SLC25A13,ACN9 Upregulated 





29 8q11.21 - 8q12.1 7.30 TCEA1,LYPLA1 No.sig.change 
30 8q22.1 - 8q22.3 5.55 COX6C,ZNF706 No.sig.change 
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31 8q24.22 - 8q24.3 12.00 AC115836.1,LY6D,ZNF696,PUF60,CYC1,DGAT1 No.sig.change 
32 9p22.1 - 9p21.1 13.48 IFNB1,IFNA5,IFNA2,IFNA8,C9orf53 Upregulated 
33 9q33.3 - 9q34.11 1.89 DPM2,PTGES2,COQ4,URM1,ODF2 No.sig.change 
34 10q11.22 - 10q21.3 17.76 SLC18A3,A1CF,CISD1 Downregulated 
35 10q22.3 - 10q23.31 9.12 LRIT1,RGR,MMRN2 Downregulated 
36 10q24.31 - 10q24.32 2.13 LBX1,POLL,FGF8 No.sig.change 
37 11p15.4 2.82 OR52A1, HBE1 Upregulated 
38 11p15.1 - 11p13 13.22 LGR4,KCNA4,ELP4,PAX6 Upregulated 
39 11q12.2 - 11q12.3 1.36 SCGB1D1,SCGB2A1,SCGB1A1,MTA2 Upregulated 
40 11q13.1 - 11q13.2 0.57 BANF1,SF3B2,RAB1B No.sig.change 
41 12p13.32 - 12p13.31 2.75 FGF23,FGF6,AKAP3,GALNT8 Downregulated 
42 12p13.31 - 12p13.2 2.75 KLRB1,CD69,KLRF1,CLEC2B,CLEC7A, KLRK1 No.sig.change 
43 12q13.11 - 12q13.12 2.14 WNT10B, TROAP No.sig.change 




45 12q13.13 0.92 HOXC13,HOXC11 No.sig.change 
46 14q13.3 - 14q21.3 13.76 FKBP3,RPS29 No.sig.change 
47 14q32.33 0.86 IGHA1,IGHG1 No.sig.change 
48 15q15.3 - 15q21.2 6.53 SEMA6D,SLC12A1 Downregulated 
49 16p13.3 1.55 DECR2,RAB40C,RHOT2,TPSG1,TPSD1 No.sig.change 
50 16q22.1 - 16q22.2 3.13 TERF2,AARS,ST3GAL2 Downregulated 




52 17q11.2 1.50 TMEM199,SARM1,SLC13A2,FOXN1, UNC119 No.sig.change 





54 17q21.31 2.96 RUNDC3A,GJC1,C1QL1 Downregulated 








57 19p13.3 1.75 FUT5,RFX2,ACSBG2 Downregulated 
58 19p13.2 1.35 CDC37,DNM2 No.sig.change 
59 19p13.12 - 19p13.11 2.04 OR7C2,SLC1A6,OR10H2 No.sig.change 
60 19p13.11 1.89 RAB3A,PGPEP1,TMEM59L,COPE, ARMC6 No.sig.change 








63 19q13.42 1.41 AC006293.3,NCR1,TNNT1,SYT5 Downregulated 
64 19q13.43 0.72 ZNF606,ZNF329 No.sig.change 
65 20q13.33 1.47 COL9A3,C20orf11,ARFGAP1,EEF1A2, PTK6 Downregulated 
66 22q11.21 0.95 SLC25A1,CLTCL1 No.sig.change 
67 22q11.21 - 22q11.23 2.65 IGLV6-57,PRAME  Downregulated 







To understand the function of the genes occurring in RER domains, I performed Gene 
Ontology (GO) analysis using the GO web-based program Gorilla (Eden et al., 2009, 
2007). GO term analysis by biological function showed enrichment for receptor activity 
in the RER domains and most significantly olfactory receptor activity (summarised in 
Table 6.2).  
The olfactory receptor (OR) genes comprise a large family of genes organised in clusters 
and distributed across all but a few chromosomes (Rouquier et al., 1998). As well as 
being expressed in sensory neurons they are also expressed in other tissues where their 
function is largely unknown (Flegel et al., 2013). Their altered expression has been 
reported in both prostate and breast cancer where they impact tumour progression 
(Muranen et al., 2011; Neuhaus et al., 2009).  
Ephirin receptor activity was also highly enriched by GO term analysis which was not 
surprising given that as a member of the receptor tyrosine kinase family it has been 
associated with a wide range of tumour types with multi-faceted roles in tumorigenesis.   
GO term analysis by biological process showed significant enrichment for epidermal and 
tissue development as well as factors that affect chromatin organisation like nucleosome 










Table 6.2. GO term analysis by biological function 
 
GO Term Description P-value FDR q-value Enrichment 
GO:0004984 olfactory receptor activity 1.26E-09 3.84E-06 3.72 
GO:0005198 structural molecule activity 4.60E-05 7.00E-02 1.5 
GO:0004872 receptor activity 8.20E-04 8.32E-01 1.28 
GO:0004888 transmembrane signaling receptor activity 8.22E-04 6.26E-01 1.33 
GO:0005003 ephrin receptor activity 8.66E-04 5.27E-01 3.99 
 
 
Table 6.3. GO term analysis by biological process 
 
GO Term Description P-value FDR q-value Enrichment 
GO:0008544 epidermis development 2.18E-08 2.04E-04 2.55 
GO:0006334 nucleosome assembly 3.84E-06 1.80E-02 2.5 
GO:0034728 nucleosome organization 2.39E-05 7.47E-02 2.25 
GO:0009888 tissue development 2.87E-05 6.73E-02 1.54 
GO:0065004 protein-DNA complex assembly 3.93E-05 7.37E-02 2.24 
GO:0071824 protein-DNA complex subunit organization 8.87E-05 1.39E-01 2.11 
GO:0050907 detection of chemical stimulus involved in 
sensory perception 
1.89E-04 2.53E-01 2.76 
GO:0006705 mineralocorticoid biosynthetic process 2.34E-04 2.74E-01 5.32 
GO:0008212 mineralocorticoid metabolic process 2.34E-04 2.44E-01 5.32 
GO:0006575 
cellular modified amino acid metabolic 
process 5.69E-04 5.34E-01 1.69 
GO:0031424 keratinization 8.02E-04 6.84E-01 3.27 
GO:0006704 glucocorticoid biosynthetic process 8.66E-04 6.77E-01 3.99 
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6.2.2. Comparing Breast Cancer & Hepatoblastoma RER’s 
 
The hepatoblastoma RER domains were compared to those identified for breast cancer 
and are visualised as a circular map in Figure 6.3. Although ten of RER domains (shaded 
yellow in Table 6.1) in hepatoblastoma overlapped all/in part with the 26 RER’s I found 
for the breast cancer cell line and tumour tissue data, only two of these regions showed a 
significant (Wilcox test p<0.05) aberrant change in gene expression when compared to 
normal liver tissue. These were the 3.13 Mb RER on chromosome 16q22.1-22.1 and the 
2.64 Mb RER on chromosome 22q11.21-q11.23.  These two domains were both 
aberrantly repressed in hepatoblastoma and breast tumours (Table 6.1).  
 
Figure 6.3: Circular map of RER domains identified for breast and liver cancer. Shown are 
the RER domains on each chromosome derived from analysis of aCGH and expression array 
data for breast (outer circle, red) and liver (inner circle, blue) tumour data. RER domains for 
breast are based upon the 26 overlapping domains obtained from comparison of cell line and 





6.2.3. Comparison of RER domains to LRES domains in 
published studies   
 
I also compared the RER data for breast cancer with other published studies that have set 
out to systematically identify LRES domains in cancer. Hsu et al (2010) identified 11 
domains of LRES that were estrogen-mediated in breast cancer however only one of 
these domains was a significant RER domain from my analysis of breast cancer cell lines 
and tumours. This was the RER on chromosome 16p11.2 that contained the 14 gene 
region falling into the RER domain (locus 1) that I investigated during my PhD. Given 
that Hsu et al were looking specifically for domains silenced in response to estrogen 
signalling and thereby used different criteria and methodology to mine, this finding is not 
surprising.   
 
Comparison of the 26 overlapping RER domains common to both my breast tumour 
tissue and cell line analysis with the 28 LRES regions in bladder carcinoma described by 
Stransky et al (2006) showed no common regions. However on comparison of the 45 
breast tumour and 71 breast cancer cell line RER’s showed 10 RER domains that appear 
as LRES domains in bladder carcinoma (Table 6.2). This included the 3-2 domain on 
3p22.3 that was followed up in that study and found to be associated with increased 
histone methylation (H3K9me3 and H3K27me3) and histone hypoacetylation, without 





Table 6.2: Summary of comparison between LRES domains in bladder carcinoma with RER 







Significant TCS genes in bladder 
carcinoma (after recalculation) 















MAP7, MAP3K5, PEX7, IFNGR1, HEBP2, 




LRP10, ACIN1, PABPN1, EFS, AP1G2, 
DHRS2,PCK2, WDR23, PSME1 1,260 
24 - 




WIZ, CYP4F3, CYP4F12, CYP4F11, CHERP, 
SIN3B, MYO9B,FLJ22709, NR2F6, FCHO1, 
B3GNT3, INSL3, SLC5A5, PIK3R2 
2,732 - 58 
6-5 6q16.1 KIAA0776, C6orf111, ASCC3, PREP 8,755 6 - 
1-4 1p34.1 
ATP6V0B, PRNPIP, (RPS15A), (UROD), 
(PRDX1), (AKR1A1) 




WDR50, COX11 3,701 36 - 
3-2 3p22.3 PLCD1, ACAA1, MYD88 277 - 8 
3-5 3p21.31 
IMPDH2, GPX1, RHOA, AMT, UBE1L, 
MST1R 
1,288 3 - 
 
 
Comparison of my 26 RER domains with the 47 LRES regions in prostate cancer 
described  by Coolen et al (2010) showed two common regions: one 3.2 Mb domain on 
chromosome 8q22.3-23.1 and the other a 1.06 Mb domain on chromosome 10q26.13 
(Table 6.3, highlighted yellow). Further comparison of the 45 breast tumour  and 71 
breast cancer cell line RER’s showed a further 11 RER domains that appeared as LRES 





Table 6.3: Summary of comparison between LRES domains in prostate cancer with RER 


















RALB, INHBB, GLI2, TFCP2L1, 
RNU4ATAC, CLASP1 
1.4  2 - 
11 3p14.3 
SLMAP, (FLNB), (DNASE1L3), (ABHD6), 
(RPP14), (PXK), (PDHB), (KCTD6), 
(ACOX2), (FAM107A) 
0.83 3 - 
18 6p12.1–p11.2 
(HCRTR2), (GFRAL), (HMGCLL1), 
(BMP5), (COL21A1), (DST), (BEND6), 
(KIAA1506), (ZNF451), BAG2, RAB23, 
PRIM2 
2.48 6 - 
19 6q14.3–q15 
CYB5R4, MRAP2, KIAA1009, TBX18, 
NT5E, SNX14, SYNCRIP, SNORD50A, 
SNORD50B, SNHG5, HTR1E, CGA, 
ZNF292, GJB7, C6orf162, C6orf165, 
SLC35A1, RARS2, ORC3L, NCRNA00120, 
AKIRIN2, SPACA1, CNR1, RNGTT 
5.11 6 - 
20 6q21 
PDSS2, SOBP, SCML4, SEC63, OSTM1, 
NR2E1, SNX3 
1.11 6 - 
26 8q22.3–q23.1 
DPYS, LRP12, ZFPM2, OXR1, ABRA, 
ANGPT1 
3.2 12 26 
31 10q26.13 
FGFR2, ATE1, NSMCE4A, TACC2, 
BTBD16, PLEKHA1, ARMS2, HTRA1 
1.06 17 32 
34 12q21.2 
ZDHHC17, CSRP2, E2F7, NAV3, SYT1, 
PAWR, PPP1R12A 
3.17 20 - 
36 16q12.2–q13 
(MMP2), (LPCAT2), (CAPNS2), (SLC6A2), 
(CES4), (CES1), (CES7), (GNAO1), 
AMFR, NUDT21, OGFOD1, BBS2, MT4, 
MT3, MT2A, MT1L, MT1E, MT1M, MT1A, 
MT1DP, MT1B, MT1F, MT1G, MT1H, 
MT1IP, MT1X 
1.21 30 - 
37 16q23.3–q24.1 
MBTPS1, HSDL1, LRRC50, TAF1C, 
ADAD2, KCNG4, WFDC1, ATP2C2, 
KIAA1609, COTL1, KLHL36, (USP10), 
(CRISPLD2), (ZDHHC7), (KIAA0513) 
1.04 30 - 
39 18p11.22–p11.21 
RAB31, TXNDC2, VAPA,APCDD1, NAPG, 
FAM38B, GNAL, CHMP1B, MPPE1 
2.20 39 - 
41 22q12.3 
C22orf28, BPIL2, FBXO7, TIMP3, SYN3, 
LARGE 
1.53 43 - 
42 22q13.1 
APOBEC3C, APOBEC3D, APOBEC3F, 
APOBEC3G, APOBEC3H, CBX7, PDGFB, 
SNORD83B, SNORD83A, RNU86, 
SNORD43, RPL3, SYNGR1 





One of the first LRES domains identified was the HoxA gene cluster on chromosome 
7p15.2 (Novak et al., 2006). Subsequently this LRES domain was also identified as a 
differentially methylated region (DMR) in breast cancer (Novak et al., 2008). Therefore I 
would have expected the HoxA gene cluster to appear as an RER domain in my analysis, 
but this was not the case. Further analysis showed that in my breast cancer cell line 
analysis a number of genes at this locus had high TCS but they did not meet the threshold 
of significance to denote it a RER domain (Figure 6.4). The datasets I had for breast 
tumour analysis however did not include many of the genes at this locus and those that 
were present did not have high TCSs. Upon investigation of the other DMR domains 
described  in (Novak et al., 2008) I found that the RER containing the histone gene 
cluster was also a DMR hypermethylated in breast cancer (Table 6.4). However, in my 
analysis, the genes in this cluster were not significantly up or down-regulated relative to 
normal tissue. Co-ordinate regulation of histone gene clusters is to be expected given that 
they are generally replication-dependent reaching high levels during rapid S phase 
(Marzluff et al., 2008).  I also found one hypermethylated and one hypomethylated DMR 
that corresponded with cell line RER domains identified by my analysis (Table 6.4).  
 
Table 6.4: Summary of comparison between DMR domains in prostate cancer with RER domains 
in breast cancer cell lines and tumours 









Hypermethylated     6p22.2 
HIST1H2BE, HIST1H4D, HIST1H3D, HIST1H2AD, 
BC056264, HIST1H2BF, HIST1H4E, BC082232, 
HIST1H2BG, HIST1H2AE, HIST1H3E, HIST1H1D, 
HIST1H4F, HIST1H4G, HIST1H3F, HIST1H2BH, 
HIST1H3G, HIST1H2BI 
91 5 15 
Hypermethylated    6p21.32 RXRB, X66424, SLC39A7, HSD17B8, RING1  260 - 17 
Hypomethylated   19q13.42 
 KIR2DL1, KIR2DL3, KIR2DL4, KIR2DS2, 
KIR2DS4, KIR3DL1, KIR3DL2, KIR3DL3, 
KIR3DP1, L76664, L76668, LILRB4 




The protocadherin family cluster (PCDH) has been reported to be subject to LRES by 
hypermethylation in a number of tumour types including breast (Dallosso et al., 2012, 2009; 
Novak et al., 2008). I therefore investigated this cluster of genes on chromosome 5q31.3 in 
my transcriptional correlation data. As with the HoxA gene cluster I found that in both the 
cell line and tumour data the TCS genes did not meet my significance threshold (Figure 6.5). 
Also, as before, the tumour data contained very few of the protocadherin cluster genes and 
those that were present did not have high TCS values.  
 
Figure 6.4: Transcription Correlation Scores (TCS) at the locus containing the HoxA gene 
cluster on chr7p15.2. Customised UCSC browser tracks with TCS in bedgraph format for breast 
cancer cell line (orange) and tumour data (blue). The horizontal line represented the TCS 





Figure 6.5: Transcription Correlation Scores (TCS) at the locus containing the 
protocadherin gene cluster on chr5q31.3. Customised UCSC browser tracks with TCS in 
bedgraph format for breast cancer cell line (orange) and tumour data (blue) Horizontal line 
represents the TCS significance threshold. UCSC genes in their chromosomal positon are shown 






Previously in this thesis I devised a method to identify regions of coordinate 
misregulation of gene expression that were copy number independent. This was to find 
regions that were potentially epigenetically regulated (RER domains) through changes in 
higher order chromatin architecture. Having validated this approach in breast cancer cell 
lines and tumours, it was possible to use this system to identify RER domains in other 
types of cancer or disease for which copy number and expression data are available.  
 
In this chapter I described work carried out as collaboration with Marie Annick Buendia 
for hepatoblastoma. From this analysis I found a large number of genomic regions that 
were subject to RER.  Interestingly the RER domains were very different to those I 
identified for breast cancer and where there was commonality those regions showed no 
significant change in gene expression between normal and tumour tissues. The two 
common regions between breast and liver that showed a significant difference in gene 
expression between normal and tumour tissue were both aberrantly downregulated. This 
concurs with the most frequently reported type of region of epigenetic regulation (RER) 
in the literature to date – the long range epigenetically silenced (LRES)  phenotype.  
 
GO term analysis of hepatoblastoma RER genes alluded significantly to both receptor 
activity and nucleosome organisation/assembly. This was particularly interesting as there 
was high enrichment for olfactory receptor (OR) activity and though these genes are 
abundantly expressed in a number of tissues little is known about their function (Flegel et 
al., 2013; Muranen et al., 2011; Neuhaus et al., 2009). Moreover chromatin organisation 
of the OR genes has been shown to govern their expression in olfactory neurons whereby 
they form heterochromatic foci which they can be actively transcribed outside of 
(Clowney et al., 2012). Therefore they also appear to have a role to play in nuclear 
organisation of genetic material which is suggestive of the mechanism of aberrant 






The main focus of my PhD was to investigate RER in breast cancer. Overall I found very 
few RER domains that corresponded to liver hepatoblastoma RER domains. In 
comparison to other types of cancer in published literature (i.e. prostate and bladder 
cancer) where similar computational methods have been used to systematically identify 
LRES, I found that few of these studies showed overlap with the RER domains from my 
analysis. This indicates that most of RER is cancer-specific in nature though there are 
some regions which overlap. Investigation of breast cancer studies also showed that some 
but not all of reported LRES regions were RER domains also and upon investigation this 
was mainly due to a depletion of those genes in the data used for analysis or that they 



























Misregulation of gene expression is a common event in cancer with a number of long-
range events documented. Such studies have uncovered large chromosomal domains of 
repression in association with a cocktail of DNA methylation changes, gain of repressive 
histone marks and loss of active histone marks. This phenomena was denoted as Long 
Range Epigenetic Silencing (LRES) and these studies are described in more detail in the 
Introduction (Section 1.3.5) to this thesis. At the start of my PhD the most interesting 
aspect of these LRES studies, in my opinion, was that (1) there does not seem to be any 
consensus as to the cause of misregulation of such large genomic regions with a number 
of lower level epigenetic changes reported and that (2) these studies all focussed on a 
deregulation of  large domains by epigenetic repressive mechanism(s).  My main 
hypothesis was that for such large regions of the genome to be co-ordinately misregulated 
there could be higher order epigenetic changes occurring involving the chromatin 
architecture itself that are having an effect on gene expression in these regions. Therefore 
the main aim of this project was to identify regions of potential epigenetic regulation in 
the breast cancer genome, which could be used to investigate this hypothesis and provide 
insight into the mechanism of LRES.  
 
The main findings of my PhD have been that: 
(1) In breast cancer there are large domains containing clusters of genes that are co-
ordinately regulated.  
(2) These domains show coordinate expression patterns that are independent of copy 
number aberrations, which could otherwise have accounted for these patterns. 
(3) These RER domains can be found to overlap in breast tumour tissue and cell line 
datasets but there are also a number of regions that are tumour tissue or cell line 
specific. 
(4)  As demonstrated for breast cancer and liver hepatoblastoma, there are RERs that 
are subject to long range epigenetic activation (LREA), not just the LRES 
phenotype, and others that showed no significant change in gene expression when 
compared to normal tissue.   
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(5) Some of the breast cancer RERs showed gene expression signatures that were 
subtype-specific and were able to distinguish luminal/ER+ve from basal/ER-ve 
samples.  
(6) The subtype-specific gene expression patterns correlated with changes in 
chromatin architecture and organisation. 
(7) The changes in gene expression between normal breast tissue and tumour tissue 
correlated with changes in chromatin architecture and organisation  
(8) The changes in chromatin architecture and organisation included: different levels 
of chromatin compaction and the nuclear localisation of the RER on 16p11.2 
(9) The changes in chromatin architecture/organisation are estrogen-dependent  
(10)  Long range changes in gene expression by RER are mostly cancer specific with 
little overlap between cancer types 
 
 
7.1: Computational biology as a tool for identifying RER 
 
	  
As discussed in section 1.1.2.5 a number of large scale molecular profiling studies using 
transcriptome data has allowed the classification of breast cancers into distinct groups 
based on their gene signature which is predictive of clinical outcome (Blows et al., 2010; 
Lu et al., 2012; Prat et al., 2010; Sørlie et al., 2001; Sorlie et al., 2003). In contrast, 
epigenetic profiling of cancers is less well established. From 2006 to 2013 a number of 
studies emerged which systematically identified long range epigenetic domains using 
expression datasets for bladder (Stransky et al., 2006), prostate (Coolen et al., 2010) and 
breast cancer genomes(Bert et al., 2013; Hsu et al., 2010)(Hsu et al., 2010; Stransky et 
al., 2006)(Hsu et al., 2010; Stransky et al., 2006). Furthermore domains subject to LRES 
in cancer have been associated with different disease pathways correlated with 
aggressiveness of tumours (Dallosso et al., 2012; Vallot et al., 2010).  
 
The Radvanyi lab showed that chromosomal domains containing co-expressed genes 
could be identified using transcriptome data with positional information to visualise 
transcriptional correlation of neighbouring genes as maps (Reyal et al., 2005). These 
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algorithms were utilised in bladder carcinoma to identify LRES domains by categorising 
the co-regulated gene clusters into those that were copy number dependent and those that 
were copy number independent (Stransky et al., 2006). Although this method identifies 
regions of transcription bias that are not attributable to genomic effects it does not 
automatically mean they are subject to LRES. Indeed this method would identify all 
possible Regions of Epigenetic Regulation (RERs). It was testing of one such region that 
was silenced in correlation with changes to the epigenetic landscape that led to the 
classification of these domains as LRES in bladder carcinoma. Indeed the group later 
went onto show that infact Multiple Regional Epigenetic Silencing (MRES) occurred at 
several of these domains where they were epigenetically repressed in association with an 
aggressive pathway of bladder carcinoma progression (Vallot et al., 2010). Neither study 
however described regions that were subject to long range epigenetic activation or that 
were co-ordinately regulated between normal and cancer samples  (no change), though 
they would have been identified by this method. 
 
On the other hand a systematic approach to identify LRES in prostate cancer did look 
specifically for regions of the genome, within a specified genome size window, that 
contained genes with low expression levels (Coolen et al., 2010). This approach is 
exclusive to identifying LRES domains and the study suggested that these changes were 
attributed once again to changes in the epigenetic landscape where in some cases the 
domain had hypermethylated DNA, in others a gain of repressive marks and loss of 
active histone marks, but also domains that were a combination of all three. Interestingly 
the Clark lab also recently published a study describing long range epigenetically 
activated regions (LREA) in prostate cancer which were identified by the same method 
with the exception that they were looking for windows of high gene expression in the 
transcriptome data (Bert et al., 2012)(Bert et al., 2012)(Bert et al., 2013). As before, 
investigations into the epigenetic mechanism behind LREA pointed towards chromatin 
remodelling but also strongly towards DNA hypermethylation at CpG islands or "CpG-
island borders" but not at promoters.  
 
The final method I wish to discuss was utilised on estrogen-induced breast cancer cells to 
provide a map of LRES events in association with this hormone (Hsu et al., 2010). By 
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integrated analysis of transcriptome, methylome, and ERa binding datasets 11 large 
domains were identified which were repressed in response to estrogen signalling. Again, 
as with the studies on bladder (Stransky et al., 2006) and prostate cancer (Bert et al., 
2013; Coolen et al., 2010), this analysis focussed on long range epigenetic repression. A 
number of other studies also used genome-wide methylome data to identify LRES 
regions in cancer  (Dallosso et al., 2012, 2009; Devaney et al., 2011; Frigola et al., 2006; 
Park et al., 2011).  
 
For my project I was interested in systematically identifying all regions of epigenetic 
regulation in breast cancer using publicly available datasets. I felt the most 
comprehensive way to do this was using a method akin to the Radvanyi labs 
identification of regions of transcriptome bias (Reyal et al., 2005) that are copy number 
independent (Stransky et al., 2006). This was because I believe this method was the only 
one that would identify all regions of possible epigenetic regulation – as transcriptome 
bias could mean that the genes have a co-ordinate up- or down- regulated gene expression 
pattern. As I was only interested in copy-number independent regions of transcriptome 
bias, in my methods I first removed all genes that were affected by a copy number 
aberration in those effected samples.  Therefore using the sliding window approach 
described in Chapter 3 I was then able to assign significance to how well a gene was 
expressed compared to its neighbours. This method was successfully employed to 
identify 45 RERs in breast tumours and 71 RERs in cell lines. Using a cell line model I 
was able to test the mechanism of RER at one such region that overlapped between the 
tumour and cell line analyses. Later in my PhD this computational approach was also 
applied to hepatoblastoma as part of a collaboration with the Buendia lab where I 




7.2: Regions of Epigenetic Regulation 
 
Clusters of co-ordinately regulated genes are not uncommon in the genome and 
frequently housekeeping genes are organised in this way. Examples of co-ordinately 
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regulated clusters include the Hox, α/β-globin, MHC, histone and olfactory gene clusters 
(Sproul et al., 2005). For the simultaneous regulation of multiple genes changes in the 
chromatin architecture have been implicated. For example the looping of gene clusters to 
distal control regions containing regulatory elements has been shown for the β-globin 
locus, HoxD gene cluster and also the MHC clusters (as reviewed in Sproul et al 2005). 
Changes in the large scale chromatin architecture have also been shown to regulate 
contiguous genes (e.g. at the HoxB locus) by opening up domains through chromatin 
decondensation and nuclear reorganisation through looping out of chromosome territories 
(Chambeyron and Bickmore, 2004). It is thought that chromatin decondensation at such 
regions and their looping out of their chromosome territories puts them in an environment 
and state that is permissive to access to transcriptional machinery. 
 
A number of studies have reported that there are large domains (often spanning 
megabases) that are co-ordinately misregulated in cancers (Bert et al., 2013; Coolen et 
al., 2010; Dallosso et al., 2012, 2009; Frigola et al., 2006; Hsu et al., 2010; Novak et al., 
2006; Stransky et al., 2006). Chromatin structure and organisation within the nucleus 
would be a good candidate mechanism for regulating multiple neighbouring genes 
simultaneously.  However studies of long-range regulation in cancer have mainly 
focussed on lower level changes in the epigenetic landscape, namely DNA methylation 
and histone modifications. One exception to this was for the 14 gene cluster on 
chromosome 16p11.2 which was reported to be silenced in breast cancer cells in response 
to estrogen signalling (Hsu et al., 2010). The authors concluded that the region was 
repressed by gain of the polycomb repressive mark H3K27me3 and DNA 
hypermethylation at CpG island promoters, but that this repression was reinforced by an 
“inflexible DNA scaffold” bringing together the 14 gene promoters by DNA looping. 
 
Although this was the first study to show that alterations in chromatin structure itself 
could contribute to LRES in cancer, I had a number of misgivings about this report. The 
idea of chromatin forming a permanent loop structure is incompatible with the 
observations that chromatin is dynamic and continually undergoing changes (Müller et 
al., 2010).  However Hsu et al were describing ER mediated events at this locus in cancer 
cells and not in normal cells where they suggest the loop structure is more dynamic. 
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Nevertheless the 16p11.2 region described by that study was also part of a RER domain 
identified by my own work and, by FISH, I found no significant difference in the level of 
compaction between ER positive and ER negative cell lines. Furthermore, this subregion 
(as well as the entire RER domain), showed activated gene expression in tumours 
compared to normal tissue in my analysis, rather than the repression as described by Hsu 
et al (2010). By cell line analysis I also showed that this region was relatively activated in 
ER+ve cell lines compared with ER-ve cell lines using data from Neve et al (2006) 
(Chapter 4: Figure 4.19). Hsu et al show that this region is repressed in ER+ve cell lines 
compared to ER-ve cell lines also using the same publically available dataset from Neve 
et al (2006). Confounded, I manually checked the expression data for genes that are 
described by Neve et al (2006) as upregulated in luminal/ER+ve cell lines (e.g. GATA3, 
SPDEF) compared to basal/ER-ve cell lines, and also conversely those that are 
upregulated in basal/ER-ve cell lines compared with luminal/ER+ve cell lines (e.g. 
CD44. MSN), and confirmed that they were behaving as expected in the data I processed 
from Neve et al (2006). After confirming that my data matched that described by Neve et 
al (2006) I can only conclude that there has been a technical error in assigning colour to 
the heat map of gene expression for the 16p11.2 region described as looping in Figure 3B 
of Hsu et al., (2010). This would however nullify the model of ER mediated looping as a 
mechanism reinforcing repression of gene expression at this locus. It would however 
agree with the model of ERα –bound intrachromosomal interactions bringing together 
genes for transcription in active hubs (Fullwood et al., 2009).   
 
This RER domain at 16p11.2 identified by my analysis was one amongst many regions in 
breast cancer that served as the first examples of long range epigenetic activation (LREA) 
during my PhD. LREA was also identified in my analysis of hepatoblastoma tissue data 
and very recently has also been reported in prostate cancer  (Bert et al 2013).  
Interestingly, many of my RER domains identified were cancer type specific with little 
overlap between them. Given that I was seeking clusters of genes that were co-ordinately 
regulated it was not altogether surprising that the RER domains I identified were in gene 





7.3: Chromatin organisation at RER 16p11.2  
 
The RER on chromosome 16p11.2 was used as a candidate for investigating the 
mechanism of long range control in breast cancer. Apart from the fact that this RER has 
previously been implicated in LRES in breast cancer cells (Hsu et al., 2010), this was also 
a good candidate after it appeared in both breast tumour and cell line investigations with 
significant overlap. Moreover this region was interesting as it was an example of long 
range activation, which at the time was an unreported phenomena, and it showed a 
subtype specific gene expression signature.   
 
Chromatin decompaction, as assayed by FISH in this study, has been correlated with 
transcriptional activation of genes in a number of studies (Chambeyron and Bickmore, 
2004; Ragnhild Eskeland et al., 2010; Williamson et al., 2012). By dividing the RER into 
four subregions it was possible to further refine the RER borders by chromatin 
compaction analysis combined with computational analysis of transcriptional correlation 
at smaller window sizes (Chapter 4). Investigation of chromatin compaction at the refined 
locus (sub-region 2) showed it was relatively decompacted in breast cancer cells and 
tissues compared to normal breast and that there was also a distinct subtype specific 
difference with ER+ve cell lines/tumours being the most decompacted overall.  
 
Furthermore comparison of the nuclear localisation of this RER domain showed that it 
was located significantly more towards the centre of the nucleus in the ER+ve MCF7 cell 
line compared with the ER-ve MDAMB231 cell line. (This was not however a significant 
effect for LY2 or MDAMB468). Chromosome 16 on which this RER is located is 
generally located towards the centre of the nucleus in normal cells (Shelagh Boyle et al., 
2001). It is possible that the higher  frequency of  16p11.2 localisation with the centre of 
the nucleus by MCF7 cells compared with MDAMB231 cells was due to the movement 
of the RER by looping out of its chromosome territory, possibly to a hub of active 
transcription. The looping out of a chromosome territory coupled with decondensation of 




7.4: The role of the ER for RER 16p11.2  
 
Having identified a subtype-specific gene expression signature at locus 2 of the RER on 
16p11.2 and having shown that it correlated with changes in chromatin organisation I 
hypothesized that these changes were regulated by the estrogen receptor (ER).  
 
ER+ve tumours, which grow in the presence of estrogen, account for a large proportion 
of all breast cancers. As discussed in section 1.2.4.6 estrogen action is mediated by the 
estrogen receptor where ligand binding results in a sequence of events culminating in an 
upregulation in the expression of estrogen-regulated genes. Blocking estrogen-action 
using anti-estrogens like Tamoxifen, or estrogen-synthesis with aromatase inhibitors, has 
been the dominant strategy to treating ER+ve tumours. The exact mechanism by which 
the estrogen receptor regulates the expression of these genes is unclear but it is thought to 
involve the recruitment of coregulators, transcription factors and changes to the 
epigenetic landscape. Moreover ER binding in the breast cancer genome has been shown 
to alter higher order chromatin architecture allowing ER-bound loci to interact (Carroll et 
al., 2005; Fullwood et al., 2009; Hsu et al., 2010; Nye et al., 2002).  
 
Investigation of higher order chromatin structure in estrogen-responsive MCF7 cells 
showed that the level of compaction at these cells was estrogen dependent. In estrogen 
deprived conditions the locus compacted – an effect that could be reversed by 
reintroduction of estrogen (Chapter 5). This effect was not apparent in the ER-ve cell line 
MDAMB231. Given that the level of compaction was found to correlate with the gene 
expression signature at this locus in breast cancer cell lines and tumours (Chapter 6) these 
results were a good indication that the estrogen activation of the ER leads to increased 
chromatin “openness” that allows activation of transcription.  
 
Furthermore, estrogen was found to effect the nuclear localisation of the refined 16p11.2 
RER in ER+ve MCF7 cells (Chapter 5). The proportion of FISH signals in the innermost 
erosion shell was significantly reduced upon estrogen-starvation but increased again after 
reintroducing estrogen to the media. By contrast in ER-ve MDAMB231 no significant 
change was seen in the localisation of the RER under any of these conditions. These 
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results indicated that overall estrogen activation of the ER leads to repositioning of this 
RER domain possibly into an environment that is enriched in transcription factors. Its 
possible that the decompaction of the locus coupled with looping out of its chromatin 
territory (as with HoxB (Chambeyron and Bickmore, 2004; Chambeyron et al., 2005)) in 
response to estrogen stimulation of the ER is sufficient for aberrant upregulation of these 
genes in ER+ ve breast cancer. Indeed large-scale decondensation of chromatin in 
response to ER binding has been previously reported (Nye et al., 2002) though it’s 
precise functional link is currently unknown. During my PhD it certainly appeared that 
the decondensation of chromatin (as assayed by FISH compaction studies) at locus 2 in 
concert with its repositioning after estrogen stimulation was enough to allow active 
transcription, however these two mechanisms have also been shown to function distinctly 
of one another to activate gene transcription (Morey et al., 2007). Therefore its possible 
that whilst the decompaction observed in ER+ve cell lines and tumours and indeed upon 
estrogen stimulation in MCF7 cells facilitates active transcription taking place, that other 
mechanisms are also required to induce transcription. This could include looping out of a 
chromosome territory to an active transcription hub and the recruitment of protein 
complexes associated with active transcription.  
 
In a recent study, estrogen-induced decondensation of chromatin and transcriptional 
activity was associated with citrullination of histone H3R26 at ER target genes in MCF7 
cells (Zhang et al., 2012). Citrullination is catalysed by PAD2 and this enzyme is thought 
to interact with ERα upon estrogen stimulation creating an open chromatin structure that 
is permissive of transcription. As discussed in the introduction to this thesis (see section 
1.2.3 and 1.3.2) a number of other histone modifications have been associated with 
altered packing of chromatin, notably hyperacetylation of histones and trimethylation of 
H3K27me3.  Therefore its possible that whilst changes higher order chromatin 
organisation are key to RER domain formation the repression/activation at such domains 
is orchestrated by a whole host of transcription factor binding and recruitment of histone 
modifying enzymes which all work together on a template whose accessibility is 





7.5: The future of RER 16p11.2 
	  
In terms of immediate future work it will be important to determine the expression status 
of 16p11.2 genes upon hormone deprivation and induction by estrogen. This is important 
to understand why the genes in the RER are misregulated in breast cancer. Whilst in this 
thesis I have demonstrated that the changes in chromatin compaction and nuclear 
positioning of this locus are estrogen-mediated, it will be crucial to determine whether the 
estrogen-mediated decompaction and repositioning of the RER on 16p11.2 in ER+ve 
cells also leads to their upregulation and relative repression under starvation conditions. 
To further characterise the topology of the region, taking into account the ERα-binding 
sites present (Fig 5.1: Fullwood et al 2009), it will be interesting to further tile the region 
with additional FISH probes. This would tell me exactly how different parts of the region 
are behaving in response to estrogen deprivation and reintroduction.   To ask whether the 
changes in nuclear area upon hormone deprivation that were observed in ER+ve and ER-
ve cells it will be important to FACS analyse the cells for changes in cell cycle under 
these culture conditions. I also think this study would benefit from testing other RER 
domains, including those that did not show a ER status specific subtype signature, as it 
will be important to determine their mechanism of long range misregulation – perhaps 
also changes to chromatin organisation but mediated by other factors e.g. by chromatin 
regulatory complexes.   
	  
	  
7.6: Concluding remarks  
	  
Altered chromatin architecture and nuclear morphology as assessed subjectively by light 
microscopy is used as a crude measure to diagnose breast tumours from biopsies. This 
does not however reflect our current molecular understanding of chromatin organisation 
within the nucleus. During my PhD, I have shown that there are changes to the packing of 
chromatin and also the relative nuclear position of genes that are misregulated in different 
types of breast cancer. Furthermore I have shown that such changes in chromatin 
organisation are mediated by estrogen in ER+ve breast cancer. This is the first step 
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towards understanding how chromatin re-organisation in the nucleus is linked to breast 
tumour biology. Further work needs to be done to characterise these changes during 
disease progression as well as during their response to endocrine therapies – in the hope 
that such findings will lead to improved methods of diagnosis and a better understanding 
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Legends for appendices on data CD 
 
Appendix I 
DNA Copy Number Profiles for 48 Breast Cancer Cell Lines  
The log2 (sample:ref) ratios of the clones were plotted against chromosomal position. 
Regions of loss (green), gain (red), and no change (black) as determined by CGHcall (van 
de Wiel et al., 2007). 
 
Appendix II 
DNA Copy Number Profiles in 356 Breast Tumours 
The log2 (sample:ref) ratios of the clones were plotted against chromosomal position. 
Regions of loss (green), gain (red), and no change (black) as determined by CGHcall (van 
de Wiel et al., 2007). 
 
Appendix III 
Breast tumour TCS Maps for all chromosomes 
Transcriptome correlation maps generated by plotting all TCS values against 
chromosome position in megabases (Mb) using data for 356 tumours (Jönsson et al., 
2010). The dotted line represents the significance threshold. Genes above this line are 




Analysis of gene expression changes in tumours relative to normal tissue 
for 45 RER domains derived from breast tumour analysis.  
Mean centred z scores were calculated for all genes in the region. The median z score for 
each sample was used to plot the distribution of these scores as boxplots and to compare 
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scores between samples. Significant changes in expression were determined by the 
Wilcox test (p<0.05). 
 
Appendix V 
Breast cancer cell line TCS Maps for all chromosomes 
Transcriptome correlation maps generated by plotting all TCS values against 
chromosome position in megabases (Mb) using data for 48 cell lines (Neve et al., 2006). 
The dotted line represents the significance threshold. Genes above this line are 




26 overlapping RER domains between breast tumour and cell lines  
The BioMart function at Ensembl.org was used to extract the Ensembl Ids and Associated 
Gene Names for all genes within the coordinates for the 26 overlapping RER domains.  
 
Appendix VII 
Analysis of gene expression changes in tumours relative to normal tissue 
for 26 overlapping RER domains between tumour and cell line analysis.  
Mean centred z scores were calculated for all genes in the region. The median z score for 
each sample was used to plot the distribution of these scores as boxplots and to compare 
scores between samples. Significant changes in expression were determined by the 
Wilcox test (p<0.05). 
 
Appendix VIII 
Unsupervised cluster analysis of genes in breast cancer RER domains 
Heat maps of the 45 tumour data derived RER domains. Each tumour is identified by 
a color-coded matrix below the dendrogram: basal (red), luminal (blue), ERBB2 (purple), 
normal-like (green). Red/green indicate an increase/decrease in gene expression relative 
to the universal mean for each gene.  The values were mean centred and the colours 
scaled from the max (+) & min (-) standard deviations for each heat map.  
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Heat maps of the 71 cell line data derived RER domains. Each cell line is identified 
by a color-coded matrix below the dendrogram: basal (red), and luminal (blue). 
Red/green indicate an increase/decrease in gene expression relative to the universal mean 
for each gene.  The values were mean centred and the colours scaled from the max (+) & 
min (-) standard deviations for each heat map.  
 
Appendix IX 
GOrilla Gene Ontology analysis of breast cancer RER genes 
Top GO terms for 26 overlapping RER domains in breast cancer  
 
Appendix X 
Comparing the localisations of breast cancer RER domains with 
RIDGEs/antiRIDGEs  
Table 1: The number of RER domains overlapping with Regions of Increased Gene 
Expresion (RIDGEs) in randomly generated regions (expected) and in RER domains 
(observed). Fisher’s exact test (p=0.395) showed there was no significant correlation 
between RER domains and RIDGE’s above what would be expected by chance.  
Table 2: The number of RER domains overlapping with anti-RIDGEs in randomly 
generated regions (expected) and in RER domains (observed). Fisher’s exact test (p=0.1) 
showed there was no significant correlation between RER domains and anti-RIDGE’s 
above what would be expected by chance. 
 
Appendix XI 
Identifying copy number independent regions of transcriptome bias in 
liver heaptoblastoma 
Copy number profiles for 25 hepatoblastoma samples: The log2 (sample:ref) ratios of 
the clones were plotted against chromosomal position. Regions of loss (green), gain (red), 
and no change (black) as determined by CGHcall (van de Wiel et al., 2007). 
Heptoblastoma TCS Maps for all chromosomes: Transcriptome correlation maps 
generated by plotting all TCS values against chromosome position in megabases (Mb) 
using data for 25tumours. The dotted line represents the significance threshold. Genes 
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above this line are considered to have expression profiles that are considerably correlated 
with their neighbours. 
 
